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Portal hypertension is a clinical syndrome defined by a portal venous pressure 
gradient exceeding 5 mm Hg. It is initiated by increased outflow resistance, and can 
occur at a presinusoidal (intra- or extrahepatic), sinusoidal, or postsinusoidal level. As 
the condition progresses, there is a rise in portal blood flow, a combination that mains 
and worsens the portal hypertension. 
Cirrhosis is the most common cause of portal hypertension in the Western world. 
There are more rare intrahepatic causes of portal hypertension, such as cystic fibrosis 
liver disease. Extra hepatic portal venous obstruction is found mainly at children, and 
it can also be caused by myeloproliferative diseases. 
In cirrhosis, the principal site of increased resistance to outflow of portal venous blood 
is within the liver itself. Mesenteric arterial vasodilation is hallmark of cirrhosis and 
contributes to both increased portal venous inflow and a systemic hyperdinamic 
circulatory state. Arterial vasodilatation is regulated by a complex interplay of various 
vasodilator molecules and factors that influence the production of those vasodilator 
molecules. 
Portal hypertension is associated with severe complications, including ascites, hepatic 
encephalopathy, hypersplenism, bleeding from gastro-esophageal varices. Despite the 
progress achieved over last decades, the 6-week mortality associated with variceal 
bleeding is still in the order of 10-20%. Endoscopic assessment of esophageal varices 
and the state of esophageal and stomach mucosa at the esophagogastroduodenoscopy, 
presents high importance for the assessment of risk of their development. However, 
invasiveness as well as discomfort that are tolerated by patients during the given 
procedure, lead to the rejection from it and therefore they can’t be subjected to 
examination in a number of cases. Beside that, the research might be impossible to 
carry out in case if the state of patient is grave. The investigation of hepatic venous 
pressure gradient, that reflects the portal hypertension intensity best of all, haven`t 
been realized in the clinical practice up to now. Considering the above mentioned 
disadvantages of main methods, the development of additional prognostic criteria of 




Current methods of treatments in portal hypertension include farmacologic therapy by 
vasoactive drugs, endoscopic therapy, portosystemic shunt surgery and transjugular 
intrahepatic portosystemic shunts (TIPS). Expansion in the knowledge of 
pathophysiology of portal hypertension is need as this might provide new and useful 
strategies for the future. The described problems above associated mainly with portal 
hypertension are presented in this book. 
 
Dmitry V. Garbuzenko 
Department of Surgical Diseases and Urology, 
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Yale University School of Medicine,  
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1. Introduction 
Portal hypertension, defined as an increase in pressure within the portal vein, is a detrimental 
complication in liver diseases. The increased intrahepatic resistance as a consequence of 
cirrhosis is the primary cause of portal hypertension (Figure 1). Once it is developed, portal 
hypertension influences extrahepatic vascular beds in the splanchnic and systemic circulation. 
Two major consequences of portal hypertension in this regard are excessive arterial 
vasodilation/hypocontractility and the formation of portosystemic collateral vessels. Both 
excessive arterial vasodilation and portosystemic collateral vessel formation help to increase 
the blood flow through the portal vein and worsen portal hypertension. This facilitates the 
development of the abnormal hemodynamic condition, called the hyperdynamic circulatory 
syndrome, and ultimately leads to variceal bleeding and ascites (Bosch 2000; Bosch 2007; 
Groszmann 1993; Iwakiri 2011; Iwakiri & Groszmann 2006). 
 
Fig. 1. Overview of portal hypertension. 
This chapter summarizes current knowledge of molecules and factors that play critical roles 
in the development and maintenance of excessive arterial vasodilation and portosystemic 
collateral vessels in the splanchnic and systemic circulation in cirrhosis and portal 
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hypertension. The chapter concludes with a brief discussion about the future directions of 
this area of study. 
2. Key molecules and factors – Excessive arterial 
vasodilation/hypocontractility 
This section addresses molecules and factors that are involved in the development and 
maintenance of excessive arterial vasodilation/hypocontractility in cirrhosis and portal 
hypertension. 
2.1 Key molecules  
The molecules discussed here include nitric oxide (NO), carbon monoxide (CO), 
prostacyclin (PGI2), endocannabinoids, Endothelium-derived hyperpolarizing factor 
(EDHF), adrenomedullin, tumor necrotic factor alpha (TNF), bradykinin and urotensin II. 
In addition to these vasodilatory molecules, decreased response to vasoconstrictors, such as 
neuropeptide Y, also contributes to hypocontractility of mesenteric arterial beds (i.e., arteries 
of the splanchnic circulation). 
2.1.1 Nitric oxide 
Nitric oxide (NO) is the most potent vasodilatory molecule in vessels and contributes to 
excessive arterial vasodilation in the splanchnic and systemic circulation in portal 
hypertension perhaps to the most significant degree. NO, synthesized by endothelial NO 
synthase (eNOS) in the endothelium, defuses into smooth muscle cells and activates 
guanylate cyclase (GC) to produce cyclic guanosine monophosphate (cGMP) (Arnold, et al. 
1977; Furchgott & Zawadzki 1980; Ignarro, et al. 1987), facilitating vessel relaxation. 
In portal hypertension, elevated eNOS activity causes overproduction of NO and the 
resultant excessive arterial vasodilation in the splanchnic and systemic circulation. As for 
the other two NOS isoforms, neuronal NOS (nNOS) and inducible NOS (iNOS), a couple of 
studies suggest that nNOS, which resides in the nerve terminus and smooth muscle cells of 
the vasculature, also contributes to excessive arterial vasodilation in portal hypertension, 
although its effect is small (Jurzik, et al. 2005; Kwon 2004). In contrast to eNOS and nNOS, 
which are constitutively expressed, iNOS is generally expressed in the presence of 
endotoxin and inflammatory cytokines and generates a large amount of NO. Interestingly, 
however, despite the presence of bacterial translocation and endotoxin in cirrhosis, iNOS 
has not been detected in arteries of the splanchnic and systemic circulation in cirrhosis and 
portal hypertension (Fernandez, et al. 1995; Heinemann & Stauber 1995; Iwakiri, et al. 2002; 
Morales-Ruiz, et al. 1996; Sogni, et al. 1997; Weigert, et al. 1995; Wiest, et al. 1999). This 
paradox remains to be elucidated. Accordingly, eNOS would be the most important among 
the three isoforms of NOS for excessive vasodilation observed in arteries of the splanchnic 
and systemic circulation in portal hypertension (Iwakiri 2011; Iwakiri & Groszmann 2006; 
Wiest & Groszmann 1999). 
eNOS is regulated by complex protein-protein interactions, posttranslational modifications 
and cofactors (Sessa 2004). A summary of mechanisms that activate eNOS is shown in 
Figure 2. Below presented are several proteins that have been reported to increase eNOS 
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activity in the superior mesenteric artery (i.e., an artery of the splanchnic circulation) of 
portal hypertensive rats. 
2.1.1.1 Heat shock protein 90 (Hsp90)  
This figure shows a general idea of eNOS regulation, not limited to portal hypertension. 
Caveolin-1 inhibits eNOS activity, while eNOS is activated through interactions with heat 
shock protein 90 (Hsp90), tetrahydrobiopterin (BH4), guanosine triphosphate (GPT) and 
calcium calmodulin (CaM). Additionally, eNOS is phosphorylated and activated by Akt, 
also known as protein kinase B. VEGF; vascular endothelial growth factor, TNF; tumor 
necrosis factor alpha. 
 
Fig. 2. Endothelial nitric oxide synthase (eNOS) is regulated by complex protein-protein 
interactions and posttranslational modifications. 
A molecular chaperone, Hsp90, acts as a mediator of a signaling cascade leading to eNOS 
activation (Garcia-Cardena, et al. 1998). In the superior mesenteric artery isolated from 
portal hypertensive rats, an Hsp90 inhibitor, geldanamycin (GA), partially attenuated 
excessive vasodilation (Shah, et al. 1999). This observation suggests that Hsp90, at least in 
part, plays a role in elevated activation of eNOS, which causes overproduction of NO in the 
superior mesenteric artery in portal hypertensive rats. 
2.1.1.2 Tetrahydrobiopterin (BH4) 
eNOS requires BH4 for its activity (Cosentino & Katusic 1995; Mayer & Werner 1995). 
Cirrhosis increases circulating endotoxin, which elevates activity of guanosine triphosphate 
(GPT)-cyclohydrolase I, an enzyme that generates BH4. One study shows that increased 
levels of BH4, as a result of cirrhosis, enhance eNOS activity in the superior mesenteric 
artery (Wiest, et al. 2003). Thus, an increase in BH4 production in the superior mesenteric 
artery of cirrhotic rats is thought to be one of the mechanisms by which eNOS contributes to 
excessive arterial vasodilation. 
2.1.1.3 Akt/protein kinase B 
Akt, a serine/threonine kinase, can directly phosphorylate eNOS on Serine1177 (human) or 
Serine1179 (bovine) and activates eNOS, leading to NO production (Dimmeler, et al. 1999; 
Fulton, et al. 1999). We have shown that portal hypertension increases eNOS 
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phosphorylation by Akt in the superior mesenteric artery and that wortmannin, an inhibitor 
of the phosphatidylinositol-3-OH-kinase (PI3K)/Akt pathway, decreases NO production 
and excessive vasodilation in the superior mesenteric artery isolated from portal 
hypertensive rats (Iwakiri, et al. 2002). These observations suggest that Akt-dependent 
phosphorylation and activation of eNOS play a role in excessive NO production and the 
resulting vasodilation in the superior mesenteric artery of portal hypertensive rats. 
Since eNOS is the major NOS that generates NO in arteries of the splanchnic and systemic 
circulation, understanding the mechanisms by which eNOS is activated in these arteries is 
essential and allows us to develop critical strategies to block excessive arterial vasodilation 
and the subsequent development of the hyperdynamic circulatory syndrome. 
2.1.2 Carbon monoxide (CO) 
CO is an end product of the heme oxygenase (HO) pathway and a potent vasodilatory 
molecule that functions in a similar mechanism to NO (Figure 3). It activates sGC in vascular 
smooth muscle cells and regulates the blood flow and resistance in several vascular beds 
(Naik & Walker 2003). HO has two isoforms, HO-1 and HO-2. HO-1, also known as heat 
shock protein 32, is an inducible isoform. HO-2, a ubiquitously expressed constitutive 
isoform, is also found in blood vessels (Ishizuka, et al. 1997; Zakhary, et al. 1996). In 
pathological conditions, HO activity increases markedly due to the up-regulation of HO-1 
(Cruse & Lewis 1988). Several experimental and clinical studies have shown a possible 
relationship between HO pathway and several complications of cirrhosis and portal 
hypertension, such as cardiac dysfunction (Liu, et al. 2001), renal dysfunction (Miyazono, et 
al. 2002), hepatopulmonary syndrome (Carter, et al. 2002), spontaneous bacterial peritonitis 
(De las Heras, et al. 2003) and viral hepatitis (Tarquini, et al. 2009). 
Increased portal pressure alone contributes to the activation of HO pathway in mesenteric 
arteries and other organs (Angermayr, et al. 2006; Fernandez & Bonkovsky 1999). In a study 
using rats with partial portal vein ligation, a surgical model that induces portal 
hypertension, HO-1 was up-regulated in the superior mesenteric arterial beds (Angermayr, 
et al. 2006). When rats with partial portal vein ligation were given an HO inhibitor, tin(Sn)-
mesoporphyrin IX, intraperitoneally immediately after surgery for the following 7 days, a 
significant reduction in portal pressure was observed in the HO inhibitor-treated group 
compared to the placebo group. However, the HO inhibition did not affect the formation of 
portosystemic collaterals in portal hypertensive rats (Angermayr, et al. 2006). 
Like those surgically induced portal hypertensive rats, rats with cirrhosis exhibit enhanced 
HO pathway to mediate excessive vasodilation in arteries of the splanchnic and systemic 
circulation (Chen, et al. 2004; Tarquini, et al. 2009). Rats with bile duct ligation (a surgical 
model of biliary cirrhosis) showed an increase in HO-1 expression in both the superior 
mesenteric artery and the aorta, compared to sham-operated rats. In contrast, HO-2 
expression did not differ between the two groups of rats. Importantly, aortic HO activities as 
well as blood CO levels were positively related to the degree of the hyperdynamic 
circulatory syndrome assessed by mean arterial pressure, cardiac input and peripheral 
vascular resistance. Acute administration of an HO inhibitor, zinc protoporphyrin (ZnPP), 
ameliorated the hyperdynamic circulatory syndrome in cirrhotic rats with 4 weeks after bile 
duct ligation (Chen, et al. 2004; Tarquini, et al. 2009). 
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Fig. 3. Hemeoxygenase (OH) pathway in the arterial splanchnic and systemic circulation in 
cirrhosis and portal hypertension. HO-1 is an inducible isoform, while HO-2 is a constitutive 
isoform. Both nitric oxide (NO) and carbon monoxide (CO) activate soluble guanylate 
cyclase (sGC) in smooth muscle cells and facilitate vasodilation. 
In contrast to other studies, a study by Sacerdoti et al. (Sacerdoti, et al. 2004) reported that 
HO-2, not the inducible HO-1, was up-regulated in mesenteric arteries of cirrhotic rats. In 
their study, cirrhotic rats were generated by giving carbon tetrachloride (CCl4) in gavage for 
8 to 10 weeks. Consistent with other studies, however, administration of an HO inhibitor, 
tin(Sn)-mesoporphyrin IX, ameliorated excessive arterial vasodilation in cirrhotic rats. 
Collectively, these observations may suggest that different experimental models of cirrhosis 
and portal hypertension cause different effects on HO pathway in the aorta and mesenteric 
arteries, thus resulting in up-regulation of different types of HO isoforms. 
Studies with cirrhotic patients also showed an increase in plasma CO levels (De las Heras, et 
al. 2003; Tarquini, et al. 2009). Spontaneous bacterial peritonitis further accelerated blood CO 
levels in cirrhotic patients (De las Heras, et al. 2003). Furthermore, Tarquini et al. (Tarquini, et 
al. 2009) documented that plasma CO levels as well as HO expression and activity in 
polymorphonuclear cells were significantly increased in patients with viral hepatitis and the 
hyperdynamic circulatory syndrome. Importantly, plasma CO levels were directly correlated 
with the severity of the hyperdynamic circulatory syndrome. Collectively, these clinical 
studies with cirrhotic patients also suggest that enhanced circulating CO levels are associated 
with the development of the hyperdynamic circulatory syndrome. 
2.1.3 Prostacyclin (PGI2) 
PGI2 is generated by the activity of cyclooxygenase (COX) in endothelial cells and facilitates 
smooth muscle relaxation by stimulating adenylate cyclase to produce cyclic adenosine 
monophosphate (Claesson, et al. 1977) (Figure 4). There are two isoforms of COX. COX-1 is a 
constitutively expressed form, and COX-2 is an inducible form (Smith, et al. 2000; Smith, et 
al. 1996). 
PGI2 is an important mediator in the development of experimental and clinical portal 
hypertension (Hou, et al. 1998; Ohta, et al. 1995; Skill, et al. 2008). Increased COX-1 
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Fig. 3. Hemeoxygenase (OH) pathway in the arterial splanchnic and systemic circulation in 
cirrhosis and portal hypertension. HO-1 is an inducible isoform, while HO-2 is a constitutive 
isoform. Both nitric oxide (NO) and carbon monoxide (CO) activate soluble guanylate 
cyclase (sGC) in smooth muscle cells and facilitate vasodilation. 
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PGI2 is an important mediator in the development of experimental and clinical portal 
hypertension (Hou, et al. 1998; Ohta, et al. 1995; Skill, et al. 2008). Increased COX-1 
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expression contributed to increased arterial vasodilation in the splanchnic circulation in 
portal hypertensive rats (Hou, et al. 1998). COX-2, however, was not detected in the superior 
mesenteric artery of those rats. These observations suggested that COX-1, not COX-2, would 
be responsible for the increased vasodilation in the superior mesenteric artery of portal 
hypertensive rats. However, inhibiting COX-1 only neither decreased PGI2 levels nor 
ameliorated the hyperdynaic circulatory syndrome in portal hypertensive mice (Skill, et al. 
2008). A study using both COX-1-/- and COX-2-/- mice in combination of selective COX-2 
(NS398) and COX-1 (SC560) inhibitors, respectively, showed that blockade of both COX-1 
and COX-2 ameliorated the hyperdynamic circulatory syndrome in portal hypertensive 
mice. Therefore, it is suggested that both COX-1 and COX-2 need to be suppressed to reduce 
PGI2 production and to ameliorate the hyperdynamic circulatory syndrome (Skill, et al. 
2008). Similar to experimental portal hypertension, circulating PGI2 levels are also elevated 
in cirrhotic patients (Ohta, et al. 1995). 
 
Fig. 4. Cyclooxygenase (COX) pathway in the arterial splanchnic and systemic circulation in 
cirrhosis and portal hypertension. COX-1 is a constitutive form, while COX-2 is inducible 
form. Both COX-1 and COX-2 seem to play a role in production of prostacyclin (PGI2), 
which activates adenylate cyclase (AC) in smooth muscle cells to produce cyclic adenosine 
monophosphate (cAMP), thereby leading to vasodilation. 
2.1.4 Endocannabinoids 
Endocannabinoid is a collective term used for a group of endogenous lipid ligands, 
including anandamide (arachidonyl ethanolamide) (Wagner, et al. 1997). Endocannabinoids 
bind to their receptors, CB1 receptors, and cause hypotension (Figure 5). The bacterial 
endotoxin lipopolysaccharide (LPS) elicits production of endocannabinoids (Varga, et al. 
1998) and thus develops hypotension. 
Cirrhotic patients are generally endotoxemia, which is characterized by elevated 
endotoxin/LPS levels in the blood. Thus, it is not surprising that circulating anandamide 
levels are elevated in cirrhotic patients (Caraceni, et al. 2010; Fernandez-Rodriguez, et al. 
2004). Cirrhotic rats also exhibit endotoxemia. Thus, antibiotic treatment to suppress 
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endotoxemia decreased hepatic endocannabinoid levels and ameliorated the hyperdynamic 
circulatory syndrome in those rats (Lin, et al. 2011). 
 
Fig. 5. Anandamide produced by circulating monocytes causes hypotension in cirrhotic rats 
and patients. Anandamide (arachidonyl ethanolamide) is an endogenous lipid ligand that 
belongs to endocannabinoids (Wagner, et al. 1997) and generated from arachidonic acid 
(AA). The bacterial endotoxin lipopolysaccharide (LPS) elicits production of anandamide in 
monocytes and endothelial cells (Varga, et al. 1998). Anandamide binds to CB1 receptors 
located on endothelial cells and smooth muscle cells and causes hypotension. 
Monocytes and platelets are the two major sources of endocannabinoids in endotoxemia 
(Batkai, et al. 2001; Ros, et al. 2002; Varga, et al. 1998). When monocytes and platelets were 
pre-exposed to LPS and then injected to normal rat recipients, hypotension was developed 
(Varga, et al. 1998). Hypotension was however prevented by pretreatment of recipient rats 
with a CB1 receptor antagonist, SR141716A. Thus, endotoxemia elicits production of 
endocannabinoids in monocytes and platelets, leading to hypotension. 
Anandamide levels were also elevated 2- to 3-fold and 16-fold in monocytes isolated from 
cirrhotic rats and patients, respectively, compared to their corresponding controls (Batkai, et 
al. 2001). Transplantation of monocytes isolated from cirrhotic rats or patients via 
intravenous injection, but not those monocytes from control rats, to normal recipient rats 
gradually caused the development of hypotension. In contrast, when normal recipient rats 
were pretreated with a CB1 receptor antagonist, SR141716A, the monocytes from the same 
cirrhotic rats or patients did not cause hypotension in those rats. Besides elevated 
anandamide levels, CB1 receptor levels were 3 times higher in hepatic arterial endothelial 
cells isolated from cirrhotic human livers than in those isolated from normal human livers. 
Importantly again, blocking CB1 receptor by SR141716A ameliorated arterial hypotension 
and the hyperdynamic circulatory syndrome in cirrhotic rats. Collectively, these results 
suggest that CB1 receptor can be a therapeutic target to ameliorate the hyperdynamic 
circulatory syndrome in cirrhosis and portal hypertension. 
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2.1.5 Endothelium-Derived Hyperpolarizing Factor (EDHF) 
Endothelium-derived hyperpolarizing factor (EDHF) is also an important vasodilatory 
molecule that regulates vascular tone (Cohen 2005; Feletou & Vanhoutte 2006; Feletou & 
Vanhoutte 2007; Griffith 2004). It is associated with hyperpolarization of vascular smooth 
muscle cells and facilitates vasodilation. The term EDHF might be confusing, since it implies 
a single molecule (Feletou & Vanhoutte 2006). Currently, it is not still fully characterized 
what molecule EDHF is. However, accumulating evidence suggests that HDHF could be 
multiple molecules, including PGI2 (Feletou & Vanhoutte 2006), NO (Cohen, et al. 1997; 
Plane, et al. 1998), epoxyeicosatrienoic acids (EETs) (Fleming 2004; Gauthier, et al. 2004; Li & 
Campbell 1997; Oltman, et al. 1998; Quilley & McGiff 2000; Widmann, et al. 1998), 
lipoxygenase [12-(s)-hydroxyeicosatetraenoic acid (12-S-HETE)] (Barlow, et al. 2000; Faraci, 
et al. 2001; Gauthier, et al. 2004; Pfister, et al. 1998; Zhang, et al. 2005; Zink, et al. 2001), 
hydrogen peroxide (H2O2) (Beny & von der Weid 1991; Chaytor, et al. 2003; Ellis, et al. 2003; 
Gluais, et al. 2005; Matoba, et al. 2002; Matoba, et al. 2003; Matoba, et al. 2000; Morikawa, et 
al. 2003; Shimokawa & Matoba 2004), potassium ions (K+), C-type natriuretic paptides 
(Banks, et al. 1996; Wei, et al. 1994) and hydrogen sulfide (Mustafa, et al. 2011). It has also 
been suggested that EDHF function may be mediated through direct coupling between 
endothelial and smooth muscle cells at myoendothelial gap junctions composed of 
connexins (Cohen 2005; Feletou & Vanhoutte 2007; Griffith 2004) (Figure 6). 
Most recently, a study by Mustafa et al. (Mustafa, et al. 2011) suggested that H2S could be an 
EDHF. H2S is synthesized endogenously from L-cystathionine--lyase (CSE) and 
cystathionine--synthase (Hosoki, et al. 1997; Stipanuk & Beck 1982). The H2S-mediated 
vasodilation occurs through the opening of ATP-sensitive potassium channel (KATP channel) 
and is independent of the activation of cGMP pathway (Zhao, et al. 2001). In the superior 
mesenteric artery of mice lacking CSE, hyperpolarization is virtually abolished. Most 
interestingly, H2S covalently modifies (i.e., S-sulfhydrating) KATP channel and leads to 
relaxation of vessels. 
EDHF seems to be more important in smaller arteries and arterioles than in larger arteries. 
This tendency has been recognized in a number of vascular beds, including mesenteric and 
cerebral arteries and arteries in ear and stomach (Tomioka, et al. 1999; Urakami-Harasawa, 
et al. 1997; You, et al. 1999). 
It has not been established whether EDHF is involved in vasodilation and hypocontractility 
of arteries of the splanchnic and systemic circulation in cirrhosis and portal hypertension. 
Barriere et al. (Barriere & Lebrec 2000) reported that EDHF contributed to hypocontractility 
in the superior mesenteric artery isolated from cirrhotic rats when NO and PGI2 production 
were inhibited. This hypocontractility was abolished when the vessels were further treated 
with inhibitors of small conductance Ca2+-activated K+ channel (SK channel), such as 
apamin and charybdotoxin, suggesting that EDHF blunts contractile response in cirrhotic 
rats (Barriere & Lebrec 2000). In contrast, a study by Dal-Ros et al. (Dal-Ros, et al. 2010) 
showed that the contribution of EDHF to vasodilation in mesenteric arteries was even 
smaller in cirrhotic rats than in normal rats. It was speculated that decreased expression of 
connexins (Cx), such as Cx37, Cx40, and Cx43, as well as Ca2+-activated K+ channel 
contributed to this smaller contribution of EDHF to vasodilation in the superior mesenteric  
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Fig. 6. Overview of endothelium-derived hyperpolarizing factor (EDHF) in the superior 
mesenteric artery. Shear stress generated by an increase in portal pressure increases 
endothelial Ca2+ concentration and produces hyperpolarization by activating ion channels, 
such as small conductance calcium-activated potassium channel (SK3) and intermediate 
conductance calcium-activated potassium channel (IK1). Hydrogen sulfide (H2S) is formed 
in vascular endothelial cells from cysteine by L-cystathionine-gamma-lyase (CSE). H2S 
causes hyperpolarization through activation of SK3, IK1 and ATP-sensitive potassium 
channel (KATP). Connexins (Cx) 37 and 40 are predominant gap junction proteins in 
endothelial cells and contribute to EDHF-mediated response. Connexin 43 (Cx43) is also 
present at the gap junction, but it does not play a major role in this context. Potassium ion 
(K+) activates Na+/K+-ATPase pump, preventing the effects of any substantial rise of 
potassium during endothelium-dependent hyperpolarization. Bradykinin, through its G-
protein coupled receptor (B2R), activates the metabolism of arachidonic acid (AA) via 
cytochrome P450 monooxygenase (P450). Bradykinin also activates phospholipase C (PLC) 
that stimulates inositol trisphosphate (IP3) to increase cytosolic Ca2+ concentration. 
Epoxyeicosatrienoic acids (EETs) cause hyperpolarization/relaxation, acting through the 
voltage-gated potassium channel (BKCa) and gap junction. 
artery of cirrhotic rats (Dal-Ros, et al. 2010). However, Bolognesi et al. (Bolognesi, et al. 2011) 
presented that mesenteric arteries isolated from cirrhotic rats exhibited elevated Cx40 and 
Cx43 expression, which increased sensitivity to epoxyeicosatrienoic acids (EETs) in those 
arteries and contributed to enhanced vasodilation. 
2.1.6 Tumor necrosis factor  
A proinflammatory cytokine, tumor necrosis factor  (TNF), is produced by mononuclear 
cells upon activation by bacterial endotoxins. In cirrhosis and portal hypertension, therefore, 
TNF levels are elevated (Lopez-Talavera, et al. 1995; Mookerjee, et al. 2003). Inhibition of 
TNF action by an anti-TNF antibody resulted in a significant reduction in hepatic venous 
pressure gradient (HVPG) of patients with alcoholic hepatitis (Mookerjee, et al. 2003). 
Similarly, inhibition of TNF synthesis by thalidomide also prevented the development of 
the hyperdynamic circulatory syndrome in portal hypertensive rats (Lopez-Talavera, et al. 
1996). The mechanism of TNF action in cirrhosis and portal hypertension is not fully 
understood. 
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TNF stimulates NOS activity by increasing BH4 production through stimulation of 
expression and activity of guanosine triphosphate-cyclohydrolase I, a key enzyme for the 
regulation of BH4 biosynthesis in endothelial cells (Katusic, et al. 1998; Rosenkranz-Weiss, et 
al. 1994). Enhanced BH4 production directly increases eNOS-derived NO production 
(Katusic, et al. 1998; Rosenkranz-Weiss, et al. 1994; Wever, et al. 1997). In biliary cirrhotic 
rats, it was demonstrated that TNF, through the activation of iNOS in the aorta and lung, 
plays a role in the development of the hyperdynamic circulatory syndrome and the 
hepatopulmonary syndrome (Sztrymf, et al. 2004). 
2.1.7 Adrenomedullin 
Adrenomedullin is an endogenous vasodilatory peptide consisting of 52 amino acid 
residues in human and 50 amino acid residues in the rat (Kitamura, et al. 1993; Kitamura, et 
al. 1993; Nuki, et al. 1993). The major producers of circulating adrenomedullin are vascular 
smooth muscle cells (Sugo, et al. 1994) and endothelial cells (Sugo, et al. 1995). 
Adrenomedullin binds to and induces its signaling through the G-protein-coupled 
calcitonin receptor-like receptor/receptor activity-modifying protein (RAMP)2 and 3, which 
are expressed in multiple tissues, including blood vessels, kidney, lung, atrium, 
gastrointestinal tract, spleen, endocrine glands, brain and heart. Receptor RAMP2 is 
essential for angiogenesis and vascular integrity (Ichikawa-Shindo, et al. 2008). 
Adrenomedullin expression is up-regulated by hypoxia (Nagata, et al. 1999; Wang, et al. 
1995) and inflammation (Sugo, et al. 1995; Ueda, et al. 1999), both of which are associated 
with neovascularization. 
The vasodilatory action of adrenomedullin was considered in the beginning to be solely due 
to elevated cAMP production, i.e., endothelium-independent vasodilation. However, 
endothelial denudation substantially reduced its vasodilatory action in rodent aortic rings 
(Hirata, et al. 1995; Nishimatsu, et al. 2001). Furthermore, this adrenomedullin-induced 
endothelium-dependent vasodilation was exerted mostly through activation of the 
phosphatidylinositol 3-kinase (PI3-K)/Akt pathway (Nishimatsu, et al. 2001). It has been 
well established that this pathway is involved in various important actions in endothelial 
cells, such as activation of eNOS. While one study demonstrated in a mouse model of 
ischemia that adrenomedullin-induced collateral vessel formation in ischemic tissues was 
eNOS-dependent (Abe, et al. 2003), no study has so far shown that adrenomedullin activates 
eNOS through Akt activation. 
Several studies have reported that in liver cirrhotic patients, circulating adrenomedullin 
levels are elevated and are associated with increased levels of plasma nitrite (a stable NO 
metabolite) and plasma volume expansion (Guevara, et al. 1998; Kojima, et al. 1998; Tahan, 
et al. 2003). Furthermore, the increased circulating adrenomedullin levels in those patients 
are inversely related to peripheral resistance (Guevara, et al. 1998). These observations 
indicate that adrenomedullin may promote excessive vasodilation and the hyperdynamic 
circulatory syndrome in cirrhotic patients. It is not surprising, therefore, that administration 
of an anti-adrenomedullin antibody prevented the occurrence of the hyperdynamic 
circulatory syndrome in the early sepsis (Wang, et al. 1998) and ameliorated blunted 
contractile response to phenylephrine in the aorta isolated from cirrhotic rats (Kojima, et al. 
2004). 
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Portal hypertension alone, regardless of the presence of cirrhosis, increases adrenomedullin 
production. One clinical study showed that adrenomedullin and NO levels are elevated not 
only in patients with cirrhotic portal hypertension, but also in those patients with non-
cirrhotic portal hypertension (Tahan, et al. 2003). How an increase in portal pressure 
influences production of adrenomedullin is an interesting and important question to be 
investigated. 
 
Fig. 7. Adrenomedullin causes vasodilation and hypotension. Adrenomedullin (AM) binds 
to and induces its signaling through the G-protein-coupled calcitonin receptor-like receptor 
(CRLR)/receptor activity-modifying protein (RAMP)2 and 3. The vascular action of 
adrenomedullin was at first considered to be solely due to elevated cAMP production by 
activation of adenylate cyclase (AC) in endothelial cells, thereby causing endothelium-
independent vasodilation. Adrenomedullin-induced endothelium-dependent vasodialation 
is exerted mostly through activation of the phosphatidylinositol 3-kinase (PI3-K)/Akt 
pathway, which activates eNOS to produce NO. NO then diffuses into smooth muscle cells 
to activate soluble guanylate cyclase (sGC) and produce cyclic GMP (cGMP), leading to 
vasodilation. 
2.1.8 Bradykinin 
Bradykinin is a nine amino acid peptide and known to facilitate vasodilation (Antonio & 
Rocha 1962). Bradykinin leads to endothelium-dependent hyperpolarization through 
activation of phospholipase C (PLC), which could raise Ca2+ concentration and also 
stimulate production of EETs (Feletou & Vanhoutte 2006) (Figure 6). Bradykinin reduces 
sensitivity to glypressin (a long lasting vasopressin analogue) in both portal hypertensive 
and cirrhotic rats (Chen, et al. 2009; Chu, et al. 2000), thereby advancing vasodilation. 
2.1.9 Urotensin II 
Urotensin II is a cyclic peptide and has a structural similarity to somatostatin. It can function 
both as a vasoconstrictor and a vasodilator depending on vascular beds (Coulouarn, et al. 
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1998). In the systemic vessels including the aorta and coronary artery, urotensin II serves as 
the strongest vasoconstrictor known (Ames, et al. 1999; Douglas, et al. 2000). In rat 
mesenteric arteries, however, urotensin II causes vasodilation (Bottrill, et al. 2000). In biliary 
cirrhotic rats, plasma urotensin II levels were increased, and 
hypocontractility/vasodilatation was advanced in mesenteric arteries. An urotensin II 
receptor antagonist, palosuran, improved this hypocontractility/vasodilatation, by 
increasing RhoA/Rho-kinase expression and Rho-kinase activity (thereby more contraction) 
and decreasing nitrite/nitrate levels (Trebicka, et al. 2008). These observations may suggest 
that elevated levels of urotensin II also lead to hypocontractility/excessive vasodilation in 
the mesenteric arteries of patients with cirrhosis and portal hypertension. Thus, blocking the 
urotensin II-mediated signaling pathway may be an effective way to treat those patients. 
2.1.10 Neuropeptide Y 
Neuropeptide Y is a sympathetic neurotransmitter and known to cause -adrenergic 
vasoconstriction (Tatemoto 1982; Tatemoto, et al. 1982). RhoA/Rho-kinase modulates 
various cellular functions such as cell contractility through phosphorylation of myosin light 
chain (Uehata, et al. 1997; Wang, et al. 2009). It was suggested that impaired RhoA/Rho-
kinase signaling was responsible for excessive vasodilation and vascular hypocontractility 
in biliary cirrhotic rats (Hennenberg, et al. 2006). Acute administration of neuropeptide Y 
improved arterial contractility in the mesenteric arteries of cirrhotic rats by restoring 
impaired RhoA/Rho-kinase signaling (Moleda, et al. 2011). These observations may suggest 
that neuropeptide Y can be used for the treatment of hypocontractility/excessive 
vasodilation of the arterial splanchnic circulation in cirrhosis and portal hypertension. 
2.2 Key factors 
An increase in portal pressure alone can induce excessive arterial vasodilation and 
hypocontractility in the splanchnic and systemic circulation. In addition, chronic liver 
cirrhosis and portal hypertension are known to cause arterial wall thinning in these 
circulations. This arterial wall thinning is a critical factor that maintains excessive arterial 
vasodilation and hypocontractility and facilitates the development of the hyperdynamic 
circulatory syndrome in advanced portal hypertension. 
2.2.1 Portal pressure 
Using rats with partial portal vein ligation (Abraldes, et al. 2006; Fernandez, et al. 2005; 
Fernandez, et al. 2004; iwakiri 2011), which enables induction of different degrees of portal 
hypertension in animals (Iwakiri & Groszmann 2006), Abraldes et al. (Abraldes, et al. 2006) 
showed that portal pressure is detected at different vascular beds depending on the stage of 
portal hypertension. A small increase in portal pressure is first detected by the intestinal 
microcirculation. Then, further increased portal pressure is sensed by the arterial splanchnic 
circulation (e.g., the mesenteric arteries), finally followed by the arterial systemic circulation 
(e.g., the aorta). Thus, the intestinal microcirculation functions as a “sensing organ” to portal 
pressure. It is postulated that mechanical forces generated as a result of increased portal 
pressure, presumably cyclic strains and shear stress, activate eNOS and thus lead to NO 
production (Abraldes, et al. 2006; Iwakiri, et al. 2002; Tsai, et al. 2003). 
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When mild portal hypertension is generated in rats using partial portal vein ligation, an 
increase in portal pressure is too small to cause splanchnic arterial vasodilation. However, 
the level of vascular endothelial growth factor (VEGF) is significantly elevated in the 
intestinal microcirculation, followed by increased eNOS levels (Abraldes, et al. 2006). This 
model of mild portal hypertension may likely correspond to the portal pressure changes 
observed in early-stage cirrhosis, in which the progression of portal hypertension is 
generally slow. When portal pressure is further increased to a certain level, vasodilation 
develops in the arterial splanchnic circulation. Once vasodilation is established in the 
intestinal microcirculation and the arterial splanchnic circulation, arterial systemic 
circulatory abnormalities seem to follow (iwakiri 2011). 
Like the above study using rats with partial portal vein ligation, portal pressure modulates 
intestinal VEGF and eNOS levels during the development of cirrhosis in rats (Huang, et al. 
2011). We have shown that there is a significant positive correlation between portal pressure 
and intestinal VEGF levels (r2 = 0.4, p<0.005). While plasma VEGF levels were significantly 
elevated in cirrhotic rats with portal hypertension (63.7 pg/ml, p<0.01) compared to controls 
(8.5 pg/ml), no correlation was observed between portal hypertension and plasma VEGF 
levels. 
2.2.2 Arterial wall thinning 
Endothelial NO plays a critical part in regulating the structure of the vessel wall (Rudic, et 
al. 1998). Studies using cirrhotic rats with ascites documented the occurrence of arterial wall 
thinning. Those rats exhibited decreased thickness of the vascular walls of the thoracic aorta, 
abdominal aorta, mesenteric arteries and renal artery (Fernandez-Varo, et al. 2007; 
Fernandez-Varo, et al. 2003). Administration of a NOS inhibitor significantly ameliorated 
wall thickness and attenuated the hyperdynamic circulatory syndrome, by increasing 
arterial pressure and peripheral resistance (Fernandez-Varo, et al. 2003). Since NO is 
predominantly derived from endothelial cells in these arteries, these observations suggest 
that increased eNOS-derived NO, at least in part, is responsible for this profound arterial 
wall thinning. Therefore, understanding the mechanisms of arterial wall thinning is 
important for the development of useful therapies for patients with portal hypertension. 
3. Key molecules and factors – Portosystemic collateral vessel formation 
In addition to excessive arterial vasodilation/hypocontractility in the splanchnic and 
systemic circulation, the formation of portosystemic collateral vessels is also thought to 
exacerbate portal hypertension (Bosch 2007; Iwakiri & Groszmann 2006). The portosystemic 
collateral vessel formation is probably an adaptive response to increased portal pressure, 
which, by releasing the pressure, may transiently help to delay the progression of portal 
hypertension. However, these collateral vessels eventually contribute to an increase in the 
blood flow through the portal vein and advance portal hypertension (Langer & Shah 2006). 
In addition, the formation of these vessels can also lead to detrimental complications. Since 
the vessels are fragile, they tend to rupture easily, causing esophageal and gastric variceal 
bleeding. Furthermore, since these vessels have the portal blood bypass the liver, toxic 
substances carried by it, such as drugs, bacterial toxins and toxic metabolites, returns to the 
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systemic circulation and can cause portal-systemic encephalopathy and sepsis (Bosch 2007; 
Iwakiri & Groszmann 2006). The enlargement of pre-existing vessels as well as angiogenesis 
facilitate the development of these collateral vessels (Langer & Shah 2006; Sumanovski, et al. 
1999). Studies have shown that vascular endothelial growth factor (VEGF) and placental 
growth factor (PIGF) play critical roles in the development of portosystemic collateral 
vessels in cirrhosis and portal hypertension. 
3.1 Vascular Endothelial Growth Factor (VEGF) 
The process of angiogenesis is regulated by growth factors exhibiting vasodilatory activity, 
such as VEGF. How are these angiogenic growth factors elevated in cirrhosis and portal 
hypertension? One mechanism may be initiated by an increase in portal pressure. As 
described previously, studies using portal hypertensive rats showed that a sudden increase 
in portal pressure is signaled to the intestinal microcirculation and induces intestinal VEGF 
expression (Abraldes, et al. 2006; Fernandez, et al. 2005). This sudden increase in portal 
pressure may create local mechanical forces, such as cyclic strains and shear stress, which 
may trigger VEGF induction. 
It has been documented that administration of anti-angiogenic agents, such as blockers of 
VEGF receptor-2 (SU5416, anti-VEGFR2 monoclonal antibody) (Fernandez, et al. 2005; 
Fernandez, et al. 2004) and inhibitors of receptor tyrosine kinases (Sorafenib and Sunitinib)  
(Mejias, et al. 2009; Tugues, et al. 2007), reduces the formation of portosystemic collateral 
vessels and decreases portal pressure. 
3.2 Placental growth factor 
In addition to VEGF, placental growth factor (PlGF), another member of the VEGF family, 
has also been found to be increased in the intestinal microcirculation of portal hypertensive 
mice (Van Steenkiste, et al. 2009). In portal hypertensive mice lacking PlGF or given an anti-
PlGF monoclonal antibody, both portal pressure and portosystemic collateral vessel 
formation were decreased. Collectively, these VEGF and PIGF studies suggest that blocking 
angiogenic activities, thereby decreasing the formation of portosystemic collateral vessels, 
has potential for the treatment of portal hypertension. 
4. Summary 
There are two major factors that contribute to excessive arterial vasodilation/hypocontractility 
in arteries of the splanchnic and systemic circulation in portal hypertension. One is an intrinsic 
factor and the other is a structural factor. The intrinsic factor includes vasodilatory molecules 
such as NO, CO, PGI2, endocannabinoids, EDHF, adrenomedullin, TNF, bradykinin and 
urotensin II. Decreased response to vasoconstrictors, such as neuropeptide Y, also facilitates 
hypocontractility of mesenteric arterial beds in cirrhosis and portal hypertension. The 
structural factor includes thinning of arterial wall (Fernandez-Varo, et al. 2007; Fernandez-
Varo, et al. 2003). NO plays a critical role for arterial wall thinning in cirrhotic rats. However, 
its mechanism is not clear. In addition to excessive arterial vasodilatation/hypocontractility in 
the splanchnic and systemic circulation, the development of portosystemic collateral vessels is 
also regarded as the major factor that worsens portal hypertension (Bosch 2007; Iwakiri & 
Groszmann 2006). 
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4.1 Future direction 
Both experimental and clinical studies of cirrhosis and portal hypertension have 
documented that a wide variety of molecules are involved in excessive arterial 
vasodilation/hypocontractility in the splanchnic and systemic circulation. This 
accumulation of knowledge allows us to further investigate molecular and cellular 
mechanisms in which these molecules exert excessive arterial vasodilation/ 
hypocontractility in cirrhosis and portal hypertension. In particular, it is interesting and 
important to address how changes in portal pressure, along with these molecules, influence 
the function and structure of vasculatures in the splanchnic and systemic circulation. 
Furthermore, it is not fully elucidated how these molecules are excessively induced in portal 
hypertension. Another important investigation would be to elucidate paracrine and 
autocrine regulations of vascular cells (e.g., endothelial cells, smooth muscle cells and 
fibroblasts) by these molecules. While the roles of these molecules in the vasculature per se 
have been described, few studies have investigated cell specific regulations and cell-cell 
communications exerted by these molecules. 
Among those molecules introduced in this chapter, there are at least two molecules that are 
particularly anticipated for further investigation in the context of excessive arterial 
vasodilation and portosystemic collateral vessel formation in portal hypertension. One is 
hydrogen sulfide (H2S). An increasing body of evidence suggests that H2S is a crucial 
vasodilatory molecule in the superior mesenteric artery. However, it is not known whether 
H2S is also involved in excessive arterial vasodilation in the splanchnic circulation in portal 
hypertension. Another molecule of interest is adrenomedullin. Studies using mice lacking 
adrenomedullin or its receptors indicated that adrenomedullin plays a critical role in the 
regulation of blood vessel integrity, including vascular stability and permeability (Caron & 
Smithies 2001; Fritz-Six, et al. 2008; Ichikawa-Shindo, et al. 2008; Shindo, et al. 2001). Given 
that increased vascular permeability and decreased vessel integrity are typical of vessels in 
cirrhosis and portal hypertension, this aspect of adrenomedullin should be explored in 
cirrhosis and portal hypertension. 
5. Conclusion 
To date, there are only limited options for the treatment of portal hypertension, despite the 
fact that portal hypertension leads to the most lethal complications of liver diseases such as 
gastro-oesophageal varices and ascites. Facing this situation, there is a strong need for 
studies of the vascular abnormalities associated with cirrhosis and portal hypertension 
(Shah 2009). These studies will have potential to lead us to develop novel targets for the 
treatment of portal hypertension. 
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Varo, et al. 2003). NO plays a critical role for arterial wall thinning in cirrhotic rats. However, 
its mechanism is not clear. In addition to excessive arterial vasodilatation/hypocontractility in 
the splanchnic and systemic circulation, the development of portosystemic collateral vessels is 
also regarded as the major factor that worsens portal hypertension (Bosch 2007; Iwakiri & 
Groszmann 2006). 
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4.1 Future direction 
Both experimental and clinical studies of cirrhosis and portal hypertension have 
documented that a wide variety of molecules are involved in excessive arterial 
vasodilation/hypocontractility in the splanchnic and systemic circulation. This 
accumulation of knowledge allows us to further investigate molecular and cellular 
mechanisms in which these molecules exert excessive arterial vasodilation/ 
hypocontractility in cirrhosis and portal hypertension. In particular, it is interesting and 
important to address how changes in portal pressure, along with these molecules, influence 
the function and structure of vasculatures in the splanchnic and systemic circulation. 
Furthermore, it is not fully elucidated how these molecules are excessively induced in portal 
hypertension. Another important investigation would be to elucidate paracrine and 
autocrine regulations of vascular cells (e.g., endothelial cells, smooth muscle cells and 
fibroblasts) by these molecules. While the roles of these molecules in the vasculature per se 
have been described, few studies have investigated cell specific regulations and cell-cell 
communications exerted by these molecules. 
Among those molecules introduced in this chapter, there are at least two molecules that are 
particularly anticipated for further investigation in the context of excessive arterial 
vasodilation and portosystemic collateral vessel formation in portal hypertension. One is 
hydrogen sulfide (H2S). An increasing body of evidence suggests that H2S is a crucial 
vasodilatory molecule in the superior mesenteric artery. However, it is not known whether 
H2S is also involved in excessive arterial vasodilation in the splanchnic circulation in portal 
hypertension. Another molecule of interest is adrenomedullin. Studies using mice lacking 
adrenomedullin or its receptors indicated that adrenomedullin plays a critical role in the 
regulation of blood vessel integrity, including vascular stability and permeability (Caron & 
Smithies 2001; Fritz-Six, et al. 2008; Ichikawa-Shindo, et al. 2008; Shindo, et al. 2001). Given 
that increased vascular permeability and decreased vessel integrity are typical of vessels in 
cirrhosis and portal hypertension, this aspect of adrenomedullin should be explored in 
cirrhosis and portal hypertension. 
5. Conclusion 
To date, there are only limited options for the treatment of portal hypertension, despite the 
fact that portal hypertension leads to the most lethal complications of liver diseases such as 
gastro-oesophageal varices and ascites. Facing this situation, there is a strong need for 
studies of the vascular abnormalities associated with cirrhosis and portal hypertension 
(Shah 2009). These studies will have potential to lead us to develop novel targets for the 
treatment of portal hypertension. 
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Cystic fibrosis (CF) is the most common fatal autosomal recessive disorder in the white 
population with a frequency of 1 in 2500 live births. Inherited defects in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene result in abnormal regulation of salt 
and water movement across membranes. The overall feature of CF is that secretions are 
dehydrated due to water deprivation of luminal surfaces. This is true for the sino-
pulmonary tract, biliary tree and for reproductive tubes (vas deferens and fallopian tubes). 
Lung involvement is the main cause of morbidity and mortality, but this abnormal gene 
results in a multisystem disease affecting the liver, pancreas, sinuses, bones and 
reproductive system. Since its recognition in 1938 when life expectancy was 6 months 
(Davis, 2006), advances in medicine and a multidisciplinary team approach to patient care 
have increased the life expectancy of this condition such that children born today could 
expect to reach their 50s (Dodge et al., 2007; UK CF Trust 2009; USCF foundation 2009). The 
changing course of the disease has resulted in increasing relevance of other organ systems 
such as the liver. 
2. Epidemiology of CF Liver Disease 
The incidence of CF liver disease (CFLD) varies significantly among previous studies 
ranging from 5-30%. This is probably due to variations in definition.  
On the whole, CFLD can be classified into 3 stages: 
1. Biochemical – manifested by impaired liver enzymes 
2. Structural – as increased bile content in the liver tissues or fatty infiltration visualised 
on liver ultrasound studies 
3. Decompensated liver disease – which includes portal hypertension, hypoalbuminaemia, 
ascites and impaired coagulation. 
The authors of this chapter propose to call ‘clinically significant disease’ as hepatic 
abnormalities that necessitate treatment by pharmacological and non-pharmacological 
methods. 
In one study by Nash et al (2008), 30% of CF patients were found to be affected by clinically 
significant CFLD. Clinically significant disease in this study was defined as biochemical 
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abnormalities manifesting with raised liver enzymes and ultrasonographic evidence of 
structural changes, but not necessarily liver cirrhosis.  
Post mortem analysis suggested that focal abnormalities in the liver tissues are commoner 
than was previously thought occurring in 25-50% of CF patients (Gaskin et al., 1988; Nagel 
et al., 1989). 
The prevalence of CFLD changes with age. Unlike most CF-related complications, CFLD 
appears to decrease with age. The reason for this is not clear. In one study by Scott-Jupp et al 
(1991) on 1100 CF patients in the South and West of England, the prevalence of CFLD - as 
judged by the presence of an enlarged liver or spleen (or both) - was 4.2%. The age-related 
prevalence rose to a peak in adolescence, and then fell in patients over 20 years old. The 
authors concluded that the decrease in prevalence was not due to drop-out of those who 
died of CFLD as the proportion of fall in incidence was much greater than the expected 
mortality rate from CFLD.  
Other studies have also found increasing prevalence with age through childhood to mid-
adolescence with no significant increase thereafter (Colombo, 2007). 
The prognosis of patients with a well-established CFLD also varies. Herrmann et al (2011) 
reported that 7.9% of patients over the age of 40 have portal hypertension. But with a 7 year 
median follow up, only 28% went on to develop ascites or variceal bleeding, and liver 
failure was a late event. Median survival after a first variceal bleed is 8.4 years. This  favours 
well when compared to the general cirrhotic population where 1 year survival is only 34%. 
Hence in the absence of other markers of decompensated liver disease, bleeding may not 
necessarily be a marker of poor prognosis (Colombo, 2007). 
Older studies suggested a much more benign course, but it is now the 3rd most common 
cause of death after ventilatory failure and organ transplant complications. It is therefore an 
important cause for concern. The overall mortality rate is reported to be 2.5% (Moyer and 
Balistreri, 2009), and is associated with a higher risk of overall mortality when compared to 
CF patients without liver disease (Gallagher et al., 2011). 
3. Pathophysiology of CFLD 
CFTR is expressed in the epithelial cells of the biliary tract, but not in the hepatic cells. The 
main feature of CFLD is destruction in the biliary duct. The impaired viscosity of bile, albeit 
expected, was not consistently reported in studies.  
Factors that enhance destruction of the biliary tree may lie in the epithelial toxicity of 
retained bile salt (Westaby, 2000). Other factors leading to the development of steatosis 
(fatty liver) are not related to defects in the CFTR gene and remains poorly understood. It 
has been attributed to malnutrition, essential fatty acid deficiency, carnitine or choline 
deficiency or insulin resistance (Moyer and Balistreri, 2009). Another presumed factor is the 
impairment of the architecture of the pancreas that shares a common exit with the common 
bile duct (Westaby, 2000). 
Development of CFLD, including portal biliary cirrhosis and multilobular cirrhosis, is 
attributable to the abnormal CFTR gene. This results in abnormal transport of Cl-, HCO3- 
and H20 at the apical membrane of cholangiocytes such that the regulation of fluid and 
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electrolyte content of bile is altered. As a result, bile is more viscous in CF patients than in 
non-CF individuals as with other mucous secretions.  
Bile flow is reduced and the obstruction of intrahepatic bile ducts causes damage to 
hepatocytes and cholangiocytes through periductal inflammation, bile duct proliferation 
and fibrosis in portal tracts. This also results in activation of hepatic stellate cells, production 
of collagen, and stimulation of bile duct epithelium to produce TFG- which is 
profibrinogenic (Moyer and Balistreri, 2009).  
Why some patients with early manifestations of CFLD go on to develop liver cirrhosis and 
why some do not remains unclear. Understanding these factors in longitudinal studies will 
help design strategies for management of early liver disease with the aim of halting its 
progression and obviating its complications.  
4. Genetics of CFLD 
More than 1500 CFTR gene mutations have been described (O’Sullivan and Freedman, 
2009), but there is no evidence of a phenotype relationship with specific mutations in the 
CFTR gene. In one study, (Duthie et al., 1992) they did not identify a difference in the 
frequency of Delta F 508, G551 or R553X mutations and the presence of CFLD.  
However the same group found that several human lymphocyte antigens (HLA) subtypes 
were more prevalent in patients with CFLD compared to those without (Duthie et al., 1995).  
Genetics was assumed to play a role not only in the emergence of CFLD but also in its 
prognosis. However despite several studies reviewed by Moyer and Balistreri (2009), it 
remains unclear why only a small proportion of CF patients might develop liver disease, or 
why there was such variability in severity.  
Genetic modifiers may be one way to answer this question. Modifier genes have shown to 
play a role by increasing susceptibility to the development of CFLD by up-regulating 
inflammation, fibrosis or oxidative stress. Identifying these genetic modifiers may allow 
identification of CF patients at risk of developing CFLD and thus allow early use of 
prophylactic measures (Colombo, 2007). ACE, SERPINA, CSTP1, MBL2, TGF-1 have all 
been identified as potential gene modifiers but only the SERPINA 1 Z allele has been found 
to be strongly associated with CFLD and portal hypertension (Bartlett et al., 2009). 
5. Hepatic manifestations in cystic fibrosis 
There is a broad spectrum of hepatic manifestations in cystic fibrosis as described in Table 1 
(Colombo, 2007). Of those described the most clinically relevant in CF is focal biliary 
cirrhosis which may extend into multilobular biliary cirrhosis. 
The incidence of impaired liver enzymes is high, affecting around 65% of patients with CF 
(Bhardwaj et al., 2009). Frequently these abnormalities may be transient and could relate to 
drug treatments or intercurrent infections (Moyer and Balistreri, 2009). The majority will not 
progress to clinically significant disease despite elevations of serum alanine 
aminotransferase, aspartate transferase or gamma-glutamyl transferase of up to 2.5x the 
upper limit of normal (Herrmann et al., 2010). 
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Type of lesion  Clinical manifestation Frequency (%) 
Specific alterations ascribed to the 
underlying CFTR defect  
Focal biliary cirrhosis  20–30 
 Multilobular biliary cirrhosis 10 
 Portal hypertension  2–5 
 Neonatal cholestasis  Rare 
 Sclerosing cholangitis  Rare 
 Micro-gallbladder  30 
 Cholelithiasis  15 
Lesions of iatrogenic origin  Liver steatosis  23–67 
 Drug hepatotoxicity  Undefined 
Lesions reflecting the effects of a 
disease process that occurs outside 
the liver  
Hepatic congestion  Rare 
 Common bile duct stenosis  Rare 
Table 1. Major hepatic manifestations in cystic fibrosis (adapted from Colombo, 2007) 
Steatosis is currently considered benign in cystic fibrosis with no evidence of progression to 
cirrhosis, portal hypertension or hepatic decompensation (Debray et al., 2011), while 
gallbladder abnormalities such as microgallbladder and cholelithiasis are frequently 
asymptomatic and detected on ultrasound requiring no intervention (Moyer and Balistreri, 
2009). These hepatic manifestations can however contribute to post prandial abdominal 
discomfort, abdominal pain and fatigue in CF patients. Abdominal pain and fatigue are 
highly common in CF patients occurring in 77% (Jarad, 2009) and 87% (Sarfaraz et al., 2010) 
of patients respectively in the authors’ unit. 
Development of liver cirrhosis is less common, occurring in up to 30% of patients. This 
includes focal biliary cirrhosis with around 10% of CF patients developing multilobular 
biliary cirrhosis. Fewer still progress to liver failure and portal hypertension which can be 
associated with hypersplenism and gastro-oesophageal varices (Colombo, 2007).  
Variceal bleeding in well established CFLD occurs in 30% of all cases. However it should be 
regarded as a rare complication in the adult CF population.  
This cohort with cirrhosis and established portal hypertension are also at increased risk of 
developing hypoglycemia, malnutrition, hepatic osteodystrophy and worsening pulmonary 
status through hepato-splenomegaly and ascites-induced diaphragmatic splinting and 
intrapulmonary shunting (Colombo, 2007). 
6. Investigations 
No single reliable test is available to diagnose CFLD. Diagnosis thus relies on a combination 
of clinical assessment, liver biochemistry and other investigations. Table 2 gives proposed 
diagnostic criteria which incorporate these (Debray et al., 2011). 
Hepatomegaly is often how CFLD is detected through routine examination, however, in 
isolation this is rarely associated with advanced liver disease. The slight enlargement of the 
liver size as well as the descending edge of the liver can be due to a combination of chronic 
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lung sepsis and lung hyperinflation both of which are common in patients with CF lung 
disease.  
 
Consider CFLD if at least 2 of the following are present: 
 Hepatomegaly confirmed by ultrasonography (US) 
 > 2cm below the costal margin below the midclavicular line 
 and/or splenomegaly on US 
 Abnormal liver function tests above the upper limit of normal 
 transaminases (AST and ALT) and GGT 
 on at least 3 consecutive occasions over 12 months 
 and other causes of liver disease excluded 
 US evidence of liver involvement, portal hypertension or biliary 
abnormalities 
 Positive liver histology (biopsy may be helpful where diagnostic 
uncertainty exist)  
Table 2. Diagnostic Criteria for CFLD (Debray et al., 2011) 
Each individual element of these criteria has their limitations when considered in isolation. 
Abnormal biochemistry as previously discussed can occur frequently and often transiently. 
The chronic use of prophylactic oral antibiotics such as flucloxacillin in patients with chronic 
lung infection of Staphylococcus aureus may account for this. Also, the administration of 
beta-lactam antibiotics for acute pulmonary exacerbation is known to be associated with 
transient increases in liver enzymes. There is thus a low sensitivity for raised liver enzymes 
without abnormal radiology and abnormal histology. In addition some patients with 
multilobular biliary cirrhosis may have normal liver biochemistry (Colombo, 2007). 
Ultrasonography is non-invasive and inexpensive. It can be useful in distinguishing 
between fibrosis, cirrhosis, ductal abnormalities and fatty infiltration (Colombo, 2007). The 
additional use of duplex scanning also allows detection of portal hypertension and 
portosystemic collaterals (Herrmann et al., 2010). Changes seen on US tests are more specific 
than clinical or biochemical abnormalities, with US abnormalities often preceding these 
changes. However, a normal scan does not exclude the development of future disease. The 
test is limited by both intra and interobserver variability in sonographic assessment with a 
positive predictive value of a normal US of only 33% and a sensitivity of 57% (Debray et al., 
2011).  
Williams et al (1995) devised and validated a scoring system for the severity of CFLD. The 
scoring system included the appearance of liver parenchyma, liver edge and periportal 
fibrosis. The score was found to distinguish transient liver disease from well established 
disease. The scoring system also identified sub-groups of patients who were regarded to 
have a pre-cirrhotic liver. A prospective prognostic evaluation of this scoring system has not 
yet been performed.  
Magnetic resonance imaging (MRI) is emerging as an important investigation of the 
abdomen in CF patients (Figure 1). In a case-control study, we found that the pancreas was 
absent in CF patients with and without diabetes compared to age matched non-CF patients 
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with Type I diabetes mellitus (Sequeiros et al., 2010). In another study we also reported that 
the spleen size, as measured on MRI, is reduced in patients with CF-related diabetes 
compared to those without and compared to age-matched patients with type I diabetes 
without CF (Jarad et al., 2010).  
 
 
Fig. 1. MRI scan in a 24 year old lady with CFLD demonstrating liver cirrhosis, 
splenomegaly and tortuous veins on the spleen surface. 
As for the liver, MRI scan is both a sensitive and a specific diagnostic test for CFLD. MRI can 
characterize the architecture of the liver structures (Westaby, 2000). A further delineation of 
the portal and splenic vascular bed and further enhancement of the definition of the liver 
architecture could be made through magnetic resonance cholangio-pancreatography 
(MRCP).  
MRI and MRCP are non-invasive and well tolerated procedures, but the imaging remains 
too costly for the tests to become a screening procedure or to be used for follow-up purposes 
of all CF patients.  
The presence of fibrosis on liver biopsy is both diagnostic and predictive of development of 
future portal hypertension and significant liver disease (Lewindon et al., 2011). However, 
the patchy distribution of lesions found in CFLD mean this invasive test can underestimate 
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severity which limits its use (Colombo, 2007). It is thus not a routine test in many units 
unlike in chronic liver disease that is not linked to cystic fibrosis. 
These limitations mean that CFLD often remains undetected until advanced stages 
prompting the need for other investigations. Both MRI and CT imaging can be useful in 
discriminating steatosis from fibrosis. MRCP and hepatic scintigraphy may help detect extra 
and intrahepatic biliary tree abnormalities in patients without clinically apparent disease 
and aid assessment of biliary drainage (Herrmann et al., 2010). These may play an important 
role in the future of CFLD. Other potential methods include transient elastography 
(fibroscan), which measures liver stiffness in a non invasive manner, which correlates 
closely with fibrosis and biochemical markers of fibrosis. Their value in CF remains to be 
determined (Debray et al., 2011). 
A suggested approach to investigating CFLD and its initial management is shown in Figure 2. 
Diagnosis of liver failure is similarly problematic due to the maintenance of liver function 
until the terminal phase. Clotting factors and prothrombin time should be monitored at least 
annually as this may give an indication. Liver failure should be considered if PT remains 
prolonged or if factors VII, X and II remain decreased despite vitamin K supplementation 
(Debray et al., 2011). 
7. Management of CFLD 
The mainstay of treatment for CFLD currently is optimisation of nutritional status and bile 
acid therapy - ursodeoxycholic acid (UDCA). The aim of the former is to avoid vitamin 
deficiency and malnutrition, though a proven benefit in CFLD is lacking (Herrmann et al., 
2010).  
UDCA is a bile acid that was shown to increase bile flow (Renner et al., 1980) and probably 
protects the hepatocellular structures from the harmful effects of hydrophobic bile ducts 
(Hoffman et al., 1990) by displacement of toxic hydrophobic bile acids, cytoprotection and 
stimulation of biliary bicarbonate secretion (Moyer and Balistreri, 2009).  
Ultimately, the aim of UDCA is to delay progression of disease. There is evidence of 
improved liver biochemistry (Desmond et al., 2007) shortly after introducing UDCA and 
improved histological features of liver disease afterwards (Linblad et al., 1998). However, 
evidence of improved outcomes such as reduced need for transplantations or improved 
survival is lacking (Cheng et al., 2000). UCDA is widely used as it is the only available 
therapeutic agent and is generally well tolerated with few side effects. Recommended 
dosing is 20-30 mg/kg/day. 
All patients with CFLD should receive annual liver assessment. The need for the yearly 
input of a gastroenterologist or hepatologist has been suggested (Debray et al., 2011). 
Though they may request intuitive tests and aid recognition of progression to cirrhosis, as 
well as complications such as portal hypertension, there is no evidence of superior outcome 
compared to a review by an experienced CF physician. This is important as CF patients are 
frequently seen in hospital and all receive an annual CF assessment. Adding an assessment 
by another discipline need only be introduced to a selected group of patients.  
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Fig. 2. Investigation and initial management of CFLD (adapted from Debray et al., 2011). 
Abbreviations: CF, cystic fibrosis; CFLD, cystic fibrosis liver disease; LFTs, liver function 
tests (i.e. liver enzymes including alanine transaminase, alkaline phosphatase; asparate 
transaminase and gamma glutamyl transpeptidase); MRCP, magnetic resonance 
cholangiopancreatography; MRI, magnetic resonance imaging; UCDA, ursodeoxycholic 
acid; US, ultrasound. 
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8. Management of portal hypertension 
Though clear recommendations exist for non-CF patients with cirrhosis, there is no agreed 
guidance for this very different cohort of patients. Non-selective β-blockade is 
recommended, for example, which has not been evaluated in CF where lung disease may 
mean this is contraindicated. We do however use propranolol in at least 2 patients in our 
unit without significant respiratory side effects.  
Band ligation is more effective than sclerotherapy, which can also carry a risk of bleeding 
both during and following the procedure which may result in repeated general anesthesia to 
the detriment of the patient’s lung function. There is however no long term efficacy data in 
CF patients.  
In the absence of such studies, recent guidance (Debray et al., 2011) states that all patients 
with cirrhosis and splenomegaly and/or signs of hypersplenism should receive an 
oesophagogastroduodenoscopy (OGD) every 2-3 years to screen for oesophageal varices. If 
large varices are detected these should be treated with band ligation and repeated until 
eradicated. Frequency of screening may need to be increased to annually. As with non-CF 
patients an OGD may be required more urgently in the presence of GI bleeding. 
Transjugular intrahepatic portosystemic shunt (TIPSS) procedures have been used to 
achieve portal decompression to treat recurrent bleeding both pre-transplant (Colombo, 
2007) and to allow long term survival (Herrmann et al., 2010). Surgical portal systemic 
shunting has also been used to preserve liver function, but carries this risk of acute liver 
failure and hepatic encephalopathy (Debray et al., 2011). 
Rarely extra-pulmonary bleeding can occur from tortuous splenic and gastric veins (Figure 
3). The efficacy of splenectomy and partial splenectomy remains unclear, with some studies 
suggesting this could stabilize lung function and delay progression of portal hypertension 
(Herrmann et al., 2010). Other studies exist reporting accelerated decline in lung function 
and no reduction in variceal bleeding (Debray et al., 2011) and hence it is not recommended 
currently. Thrombocytopenia and leucopenia due to hypersplenism requires no specific 
therapy. 
9. Liver transplantation 
Liver transplantation in end-stage liver disease is a viable option with encouraging results. 
There is evidence of improved lung function, nutritional status and quality of life (Columbo, 
2007). Analysis of data from the United Network for Organ Sharing (UNOS) database by 
Mendezibal et al (2011) also demonstrated a survival benefit of liver transplant in CF when 
comparing those that had received a transplant to those that were still on the waiting list. 
The difference in mortality was significant in both paediatric and adult populations. Further 
analysis from UNOS shows good survival at 1 year and 5 years post transplant of 84% and 
76% respectively (Arnon et al., 2011). This represents the largest review of outcomes 
following transplants for CFLD and supports the findings of previous smaller studies 
(Friedell et al., 2003; Melzi et al., 2006; Nash et al., 2008). However, overall survival post liver 
transplant for CFLD is less than that seen  in non-CF patients who receive liver transplants 
for other indications. The most common cause of long term mortality is progression of 
pulmonary disease (Friedell et al., 2003), though haemorrhage also represents an important 
cause of death (Arnon et al., 2011). 
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Fig. 3. CT scan in a 26 year old man with CF showing signs of liver cirrhosis, splenomegaly 
and haematoma around the spleen and within the abdominal cavity due to spontaneous 
splenic rupture. The patient died 1 week later. 
The criteria and timing for liver transplantation remain uncertain. Although the criteria 
have widened with increased experience, inclusion of patients in liver transplantation needs 
to be evaluated on a patient-by-patient assessment. This is mainly because of concomitant 
lung disease, impaired nutrition (Figure 4) and of inability of some patients to withstand the 
rigor of transplant. One school of thought is that without signs of liver decompensation, 
survival is dependent on respiratory complications (Gooding et al., 2005). However, with 
other extra-hepatic benefits, earlier transplantation may be indicated. This needs to be 
weighed up against the risks associated with liver transplantation such as graft rejection and 
drug related complications (Debray et al., 2011).  
Improved management options for the complications of portal hypertension may mean that 
transplantation ought to be considered in those with evidence of hepatocellular dysfunction 
in addition to portal hypertension, or those with rapidly deteriorating lung function. Other 
suggested indications include: the development of ascites and jaundice, intractable variceal 
bleeding, hepatopulmonary and portopulmonary syndromes, severe malnutrition 
unresponsive to intensive nutritio nal support, and deteriorating quality of life related to 
liver disease (Debray et al., 2011).  
 





Fig. 4. a) A 21 year old female CF patient with liver transplant. Please note that the patient 
needed per entero-gastric (PEG) feeding due to concomitant malnutrition and low body 
mass index. b) Liver transplant was successful with little complication despite significant 
lung disease as seen by widespread bronchiectasis on her CT scan of the chest done several 
months after transplant. 
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In some occasions when patients may need both lung and liver transplant, it would be 
indicated to undertake transplantation of both organs. With the shortage of donated organs, 
this decision needs to be taken carefully. However, survival is comparable for combined 
liver and lung transplantation where this is indicated (Arnon et al., 2011). 
10. Conclusion 
CFLD occurs relatively frequently and is the most common non-pulmonary cause of 
mortality.  
Improvements in the survival of cystic fibrosis patients mean that liver disease is likely to 
play an increasing role in long term morbidity and mortality. Current diagnosis relies on a 
combination of clinical examination and biochemistry, with old and new imaging 
techniques. UDCA is currently the only therapeutic option in CFLD, though its benefits on 
long term outcomes are not proven. Options addressing the complications of portal 
hypertension include TIPSS and OGD with variceal ligation. Orthostatic liver 
transplantation is also an option in end-stage liver disease with encouraging results. 
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1. Introduction  
Portal hypertension is the commonest cause of upper gastrointestinal bleeding in children and 
up to 30% of cases with upper gastrointestinal hemorrhage can be fatal. Extrahepatic portal 
venous obstruction (EHPVO) is the commonest cause of portal hypertension in children and 
also one of the common causes in adults in India and other tropical countries (Arora, 1998; 
Poddar, 2008; Poddar 2000). In India, EHPVO is responsible for portal hypertension in about 
one third cases of adults and more than half of the cases in children (Sarin 2002; Dilawari 
1992). EHPVO is characteristically refers to obstruction in the trunk of portal vein and it can 
extend to its branches and even splanchnic veins. Unlike cirrhosis, in EHPVO, the liver 
function is normal. The causes of portal venous obstruction and risk factors for upper 
gastrointestinal hemorrhage in children with EHPVO are not clearly understood. Most of the 
bleeds are spontaneous and some may be preceded by febrile illness, ingestion of drugs. 
Management of EHPVO involves acute management of the bleeding, secondary prophylaxis 
and shunting to reduce the portal pressure. This chapter attempts to compile the available 
evidences on EHPVO in children with special reference to experiences from India.  
2. Definitions and terminology  
EHPVO indicates portal hypertension due to blockage in the portal vein before the blood 
reaches the liver. EHPVO is a distinct disease entity of primarily vascular in nature and not 
classically associated with association of a primary liver disease. Portal vein thrombosis, a 
known complication of liver cirrhosis, other systemic diseases and malignancy, is not generally 
included in the disease entity EHPVO. Over time, EHPVO terminology has replaced the use of 
portal vein thrombosis (PVT) as it does not exclude the intrahepatic portal vein thrombosis 
and does not include formation of portal cavernoma associated with portal hypertension.  
Baveno V workshop consensus statement defined EHPVO as (De Franchis, 2010):  
 EHPVO is defined by obstruction of the extra-hepatic portal vein with or without 
involvement of the intra-hepatic portal veins and does not include isolated thrombosis 
of splenic vein or superior mesenteric vein (SMV).  
 EHPVO is characterized by features of recent thrombosis or of portal hypertension with 
portal cavernoma as a sequel of portal vein obstruction 
 Presence of cirrhosis and/or malignancy should be stated.  
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3. Epidemiology  
EHPVO is a common cause of portal hypertension in the developing countries (30-55% of all 
variceal bleeders) and is second to cirrhosis (up to 5-13%) (Arora, 1998; Valla, 2002). EHPVO 
is also the most common cause of upper gastrointestinal bleeding in children. It accounts for 
almost 70% of pediatric patients with portal hypertension (Yachha, 1996; Arora, 1998). 
Literature from different parts of India indicated that in children EHPVO is responsible for 
54% of portal hypertension (Poddar, 2008). Most (85-92%) of the upper gastrointestinal 
bleeding in Indian children was result of portal hypertension due to EHPVO (Poddar, 2008; 
Yachha, 1996). 
Investigators across India have consistently observed that EHPVO occurs commonly in 
children belonging to low and lower middle socio-economic strata attending public sector 
hospitals. Pediatric gastroenterologists practicing in private sector hospitals see such 
patients infrequently. During last 10-15 years, the number of EHPVO patients gradually 
appears to be dwindling even in public sector hospitals. Thus it appears that the disease 
may have something to do with the living condition of the families and with improving 
economic state of the families, disease may become less frequent.  
4. Etiology and pathogenesis  
4.1 Etiology 
The etiology of EHPVO in children has not been well documented. There are many etiologies 
for EHPVO namely infections, surgical procedures, vascular interventions, abdominal trauma, 
dehydration, congenital anomalies have been postulated. EHPVO is considered to be 
heterogenous with regard to etiology and pathogenesis, and vary with respect to age and 
geographical location. The causes can broadly be of five types; infection and inflammation, 
portal vein injury, developmental anomaly, prothrombotic causes and idiopathic.  
4.1.1 Infection 
Omphalitis, neonatal umbilical sepsis, intraabdominal infection, post umbilical 
catheterization have been linked to development of EHPVO in children. Although it is 
documented that portal vein thrombosis may occurs in neonates having umbilical vein 
catheterization, but most of these thrombi resolve within a short period (Larroche, 1970; 
Thompson, 1964). It is also proposed that phlebosclerosis is primary as a result of infection 
and/or and inflammation followed by thrombosis as a secondary event (Stringer, 1994). But 
evidence on this linkage is not very strong in children with EHPVO.  
4.1.2 Trauma and surgery 
Umbilical vein cannulation, abdominal surgery, and abdominal trauma in childhood could 
also lead to EHPVO (Yadav, 1993). 
4.1.3 Congenital anomaly 
Congenital defects like web, valves in the portal vein, portal vein stenosis, atresia or 
agenesis have also been reported (Odievre, 1977). There may be presence of other 
cardiovascular system congenital defects.  
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4.1.4 Prothrombotic state 
Hypercoagulable states like deficiencies of antithrombotic factors (protein-C, protein-S, anti-
thrombin III) have been reported in children with EHPVO (Bhattacharya, 2004; Pinto, 2004; 
Koshy, 1984; Dubuisson, 1997). Absence of genetic mutations in EHPVO patients and 
normal levels of antithrombotic factors in their parents suggested that the deficiency of 
antithrombotic factors may not be primarily of genetic origin, but may be secondary to the 
low hepatic blood flow due to portal vein thrombosis (low synthesis) and portosystemic 
shunt (increased clearance or consumption) (Dubuisson, 1997; Sharma, 2006). Other 
conditions like polycythemia vera, dehydration have also been proposed as the causes of 
EHPVO.  
4.1.5 Idiopathic 
Despite all efforts, the etiology of blocked portal vein remains obscure in a large proportion 
of patients. In India the majority of cases (up to 90%) are categorized as idiopathic (Poddar, 
2003). Probably this is due to want of detailed etiological work-up.  
4.2 Pathogenesis  
4.2.1 Portal vein changes 
In EHPVO, usually the entire length of the portal vein is occluded with extension into the 
splenic vein and sometimes into the superior mesenteric vein. In small proportions only the 
terminus of the portal vein at the hilum is occluded. Mostly the site of blockage is at the 
portal vein formation and in small proportions the total splenoportal axis is blocked. In a 
report by our group among Indian children with EHPVO (n=88), blockage were observed at 
portal vein formation, entire portal vein, spleninc vein and entire splenoportal axis in 39%, 
34%, 16% and 11% respectively (Arora, 2002). On gross examination, the original portal vein 
is difficult to identify as it is usually replaced by a cluster of variable-sized vessels arranged 
haphazardly within a connective tissue support, called as the portal cavernoma. In cases of 
shorter duration, cavernoma may not be there. The porto-systemic collaterals develop over 
time leading to development of verices at different places in the gastrointestinal tract, and at 
other places depending on the portal venous pressure and duration.  
In EHPVO the blockage being presinusoidal, intrahepatic venous pressure is normal and 
intrasplenic pressure is increased. The hepatic blood flow is relatively normal as the 
portoportal collateral vessels enable bypassing the blocked area. The hepatic blood flow 
may be reduced if the collaterals are not enough. EHPVO is a hyperkinetic circulatory state 
with increased cardiac output as a result of extensive porto-systemic venous collaterals.   
4.2.2 Liver changes 
Classically, in EHPVO cases liver is normal and the architectural pattern is preserved. 
Histopathology may reveal concentric condensation of reticulin fibers around portal tracts, 
sometimes extending into the parenchyma. Altered hepatic storage capacity and transport 
maximum for bromsulphalin and liodocaine (MEGX) excretion has been reported in 
EHPVO. Usually liver biopsy is not required in EHPVO cases, unless liver functions are 
deranged.  
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5. Clinical presentations  
In children, EHPVO may manifest at any age beyond the neonatal period. EHPVO can 
present in two clinical forms: recent or acute and chronic. The clinical presentation also 
differs in children and adults.  
5.1 Recent or acute EHPVO 
This can present with abdominal pain, ascites or fever. This may, however, be asymptomatic 
and go unnoticed. In recent EHPVO, there is no evidence of porto-systemic collaterals and 
portal cavernoma. The extent of obstruction in portal vein and speed of evolution of 
thrombosis predicts the clinical manifestation. If associated with infection, features of sepsis 
may be there. But many a times these may be passed as episodes of acute abdomen or 
sepsis.  
5.2 Chronic EHPVO 
Most of the EHPVO present as chronic cases with the typical presenting symptoms like 
episodes of variceal or gastrointestinal bleeding, lump in the abdomen and hypersplenism.  
EHPVO in childhood is most often chronic and presents with features of variceal bleeding 
and splenomegaly, whereas in adults it could be either acute or chronic.  
5.2.1 Variceal bleeding 
Esophageal varices are the most common site of variceal bleeding. The majority of children 
(85% to 90%) with EHPVO present with variceal bleeding (Arora, 1998; Poddar, 2008; Valla, 
2002). The usual presentation for children with EHPVO is sudden, unexpected and, often, 
massive hemetemesis. Bleeding usually occurs in first or second decade of life. Some of the 
children also present with recurrent, well-tolerated bleeds with variable degree of anemia. 
There is no significant hepatocellular failure in these patients. Although many clinicians think 
that the frequency of variceal bleeding reduces after puberty, but this has not been confirmed. 
Gastic varices are common in EHPVO. According to reports, about 70% children at 
diagnosis have gastric varices. Most of these are gastroesophageal varices while a few are 
isolated gastric varices (Sarin, 1992; Arora, 1998; Poddar, 2004). Following eradication of 
esophageal varices, gastric varices become more evident with increase in risk of bleeding 
(Poddar, 2004; Goncalves, 2000).  
Rectal varices are documented in 80-90% of adult EHPVO cases (Misra, 2005). The scanty data 
in children indicate presence of rectal varices in 36-64% (Heaton, 1993; Yachha, 1996). It also 
probably related to the severity and duration of portal hypertension or site of obstruction (at 
the junction of splenic and superior mesenteric veins leading to redistribution of portal 
pressure along the inferior mesenteric vein) (Misra, 2005; Chawla, 1991; Ganguly, 1995). 
Appearance of these varices may increase after obliteration of the esophageal varices.  
5.2.1.1 Risk factors for bleeding and rebleeding after initial sclerotherapy 
Bleeding from varices occurs usually due to erosion or rupture of variceal vessel wall. 
Bleeding due to erosion of vericeal wall is precipitated by reflux esophagitis, drug ingestion 
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(NSAIDs), and febrile illness (Yadav, 1993; Arora, 2002; Lilly, 1982). Size of varix, vessel wall 
thickness and tissue support also determine the chance of variceal bleeding. Considerable 
agreement exists regarding the relationship of variceal size to the risk of bleeding. Large 
variceal size appears to predict bleeding (Rector, 1985). Incomplete variceal obliteration has 
also been suggested as risk factor for rebleeding (Kokawa, 1993). Vessel wall thickness and 
tissue support are difficult to assess by endoscopy, but reddish-blue tense varices that are 
not obliterated on insufflations and congestive mucosa on and around the varices (cherry 
red spots) are likely to bleed (Alvarez, 1983). Evidence relating to risk of variceal 
hemorrhage secondary to raised portal pressure is inconclusive.  
Our group at AIIMS, New Delhi followed 58 children with EHPVO (age group: 5 months-
158 months) who underwent endoscopic sclerotherapy (EST) for a median period of 20.5 
months (17-31 months). About half of the patients (28 children) had one or more bleeding 
episodes (total 88 bleeding episodes) during the follow up period, out of which 21 patients 
had minor and 7 patients had major bleeding episodes. Congestive gastropathy was 
observed in all of these patients. The median time interval of occurrence of the any rebleed 
after completion of EST was 3.5 months [95% CI = 2-7]. Kaplan Meier Survival Analysis 
indicated that 50 % of patients [95% CI: 34.9 - 63.5%] had first rebleeding episode by 27 
months and most of these patients had recurrence of bleeding within 12 months. The 
relative risks of rebleeding due to risk factors were 2.37 (95% CI = 1.36 - 3.85), 8.9 (95% CI = 
2.4 - 23) and 6.1 (95% CI = 3.3 - 10.4) for fever alone, NSAID drug (Ibuprofen and 
Paracetamol) intake alone and when both fever and drug ingestion respectively. There was 
no significant difference in the nutritional status of these patients at the end of this follow up 
period (Arora, 2000).  
5.2.2 Mass abdomen 
About 10% of the children present with isolated abdominal mass due to splenomegaly 
(Arora, 1998; Mittal, 1994). EHPVO is associated with splenomagaly and size of spleen 
usually increases with age and it may even reach the right iliac fossa. Massive splenomegaly 
may result in anemia and thrombocytopenia due to hypersplenism in about 1/3rd of cases. 
In cases of acute variceal bleeding, the spleen size may reduce temporarily and reappear on 
hemodynamic stabilization. 
5.2.3 Pain abdomen 
Dull abdominal pain may be there due to the splenmegaly. Presence of continuous abdominal 
pain may indicate splenic infarction or extension of venous thrombosis (Yachha, 1996). 
5.2.4 Ascites and edema 
Ascites may develop in a proportion of children following hemorrhage or surgery, and are 
often transient. Ascites have been reported in up to one fifth of children with EHPVO 
(Webb, 1979; Rangari, 2003). Development of ascites signifies and circulatory changes. Some 
patients may also have pedal edema. Some children with EHPVO develop intractable ascites 
with no evidence of hepatic dysfunction. These patients are likely to benefit from large 
peritoneal drainage or may require shunt surgery. In all cases of ascites, hepatic dysfunction 
must be carefully looked for.  
 
Portal Hypertension – Causes and Complications 
 
44
5. Clinical presentations  
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diagnosis have gastric varices. Most of these are gastroesophageal varices while a few are 
isolated gastric varices (Sarin, 1992; Arora, 1998; Poddar, 2004). Following eradication of 
esophageal varices, gastric varices become more evident with increase in risk of bleeding 
(Poddar, 2004; Goncalves, 2000).  
Rectal varices are documented in 80-90% of adult EHPVO cases (Misra, 2005). The scanty data 
in children indicate presence of rectal varices in 36-64% (Heaton, 1993; Yachha, 1996). It also 
probably related to the severity and duration of portal hypertension or site of obstruction (at 
the junction of splenic and superior mesenteric veins leading to redistribution of portal 
pressure along the inferior mesenteric vein) (Misra, 2005; Chawla, 1991; Ganguly, 1995). 
Appearance of these varices may increase after obliteration of the esophageal varices.  
5.2.1.1 Risk factors for bleeding and rebleeding after initial sclerotherapy 
Bleeding from varices occurs usually due to erosion or rupture of variceal vessel wall. 
Bleeding due to erosion of vericeal wall is precipitated by reflux esophagitis, drug ingestion 
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(NSAIDs), and febrile illness (Yadav, 1993; Arora, 2002; Lilly, 1982). Size of varix, vessel wall 
thickness and tissue support also determine the chance of variceal bleeding. Considerable 
agreement exists regarding the relationship of variceal size to the risk of bleeding. Large 
variceal size appears to predict bleeding (Rector, 1985). Incomplete variceal obliteration has 
also been suggested as risk factor for rebleeding (Kokawa, 1993). Vessel wall thickness and 
tissue support are difficult to assess by endoscopy, but reddish-blue tense varices that are 
not obliterated on insufflations and congestive mucosa on and around the varices (cherry 
red spots) are likely to bleed (Alvarez, 1983). Evidence relating to risk of variceal 
hemorrhage secondary to raised portal pressure is inconclusive.  
Our group at AIIMS, New Delhi followed 58 children with EHPVO (age group: 5 months-
158 months) who underwent endoscopic sclerotherapy (EST) for a median period of 20.5 
months (17-31 months). About half of the patients (28 children) had one or more bleeding 
episodes (total 88 bleeding episodes) during the follow up period, out of which 21 patients 
had minor and 7 patients had major bleeding episodes. Congestive gastropathy was 
observed in all of these patients. The median time interval of occurrence of the any rebleed 
after completion of EST was 3.5 months [95% CI = 2-7]. Kaplan Meier Survival Analysis 
indicated that 50 % of patients [95% CI: 34.9 - 63.5%] had first rebleeding episode by 27 
months and most of these patients had recurrence of bleeding within 12 months. The 
relative risks of rebleeding due to risk factors were 2.37 (95% CI = 1.36 - 3.85), 8.9 (95% CI = 
2.4 - 23) and 6.1 (95% CI = 3.3 - 10.4) for fever alone, NSAID drug (Ibuprofen and 
Paracetamol) intake alone and when both fever and drug ingestion respectively. There was 
no significant difference in the nutritional status of these patients at the end of this follow up 
period (Arora, 2000).  
5.2.2 Mass abdomen 
About 10% of the children present with isolated abdominal mass due to splenomegaly 
(Arora, 1998; Mittal, 1994). EHPVO is associated with splenomagaly and size of spleen 
usually increases with age and it may even reach the right iliac fossa. Massive splenomegaly 
may result in anemia and thrombocytopenia due to hypersplenism in about 1/3rd of cases. 
In cases of acute variceal bleeding, the spleen size may reduce temporarily and reappear on 
hemodynamic stabilization. 
5.2.3 Pain abdomen 
Dull abdominal pain may be there due to the splenmegaly. Presence of continuous abdominal 
pain may indicate splenic infarction or extension of venous thrombosis (Yachha, 1996). 
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Ascites may develop in a proportion of children following hemorrhage or surgery, and are 
often transient. Ascites have been reported in up to one fifth of children with EHPVO 
(Webb, 1979; Rangari, 2003). Development of ascites signifies and circulatory changes. Some 
patients may also have pedal edema. Some children with EHPVO develop intractable ascites 
with no evidence of hepatic dysfunction. These patients are likely to benefit from large 
peritoneal drainage or may require shunt surgery. In all cases of ascites, hepatic dysfunction 
must be carefully looked for.  
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5.2.5 Ectopic varices 
These have been reported in 27-40% of patients with EHPVO, and are commonly seen in the 
duodenum, anorectal region and gallbladder bed (Sarin, 2006). Bleeding from the varices in 
duodenum and anorectal regions are not uncommon.  
5.2.6 Jaundice 
Jaundice is rarely a presenting feature of EHPVO and is generally due to portal biliopathy or 
stricture of bile duct in longstanding cases.  
5.3 Complications and sequelae of EHPVO 
EHPVO is associated with several complications and sequalae those need mention from the 
clinical manifestation and management point of views. The documented sequelae observed 
in long course of EHPVO are as follows.  
5.3.1 Portal biliopathy 
Portal biliopathy refers to abnormalities of the extrahepatic and intrahepatic bile ducts in 
patients with portal hypertension. These include compression by paracholedochal collaterals 
on bile ducts resulting in displacement, narrowing, strictures, angulation, dilatations and 
irregularity of bile ducts. Extrinsic compression, ischemia, and a combination of both have 
been proposed as the possible mechanisms for this. Although portal biliopathy features have 
been reported in 80-100% of adult patients with EHPVO on endoscopic retrograde cholangio-
pancreatography (ERCP), up to one fifth are symptomatic (Dilawari, 1992; Khuroo, 1993; 
Malkan, 1999; Nagi, 2000; Poddar, 2001). These changes may become severe enough to cause 
obstructive jaundice and choledocholithiasis and cholelithiasis due to bile stasis. 
Cholangiographic changes are also evident in children with EHPVO, but mostly symptomatic 
in adulthood (Poddar, 2011). Although, biliary abnormalities are common in portal 
hypertension, only a few patients present with jaundice, pain and cholangitis. 
Choleodocholithiasis has been reported to occur in 17% of patients with portal biliopathy 
(Bhatia, 1995). ERCP is the definitive method for diagnosis of biliopathy. MRCP is a good non-
invasive alternative to ERCP. However, as the majority of patients with biliopathy are 
asymptomatic, ERCP is recommended only if a therapeutic intervention is contemplated. 
5.3.2 Ectopic varices 
Gall bladder varices are observed in 34% of adult patients with EHPVO (Chawla, 1995). 
Reports in children with EHPVO are scanty. Presence of portal vein thrombosis is an 
important determinant for the development of gall bladder varices. Rectal varices may be 
seen in up to 80% of patients with EHPVO and the development is related to the duration. 
These varices may also bleed profusely (Sarin, 1992). Gall bladder varices are reported in 12-
30% of adults with EHPVO (Chawla, 1995; West, 1991). 
5.3.3 Gastropathy and colopathy 
Gastropathy and colopathy represent congested mucosa at different parts of gastrointestinal 
tract which may present as occult gastrointestinal bleeding, but sometimes also as overt 
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bleeding. About one fourth of the EHPVO children have gastropathy at presentation, but 
the prevalence increases significantly (2 times or more) after variceal eradication (Hyams, 
1993; Poddar, 2004). Portal colopathy may be seen in up to half of the patients with EHPVO 
(Sarin, 1992; Arora, 1999).  
5.3.4 Hyersplenism 
Massive splenomegaly may cause pooling and excessive destruction of the pooled blood cell 
components leading to thrombocytopenia, leucopenia and anemia. It can also predispose to 
infection and or bleeding. The hypersplenism does not correlate with splenic size. Splenic 
sequestration crisis may occur leading to hypovolemic shock and death. 
6. Specific issues in children  
6.1 Growth retardation 
EHPVO in children often reported to be associated with growth retardation.  
Reports from India indicated that the majority of the Indian children with EHPVO were 
stunted compared to the national control or to the National Center for Health Statistics 
(USA) reference (Mehrotra, 1997; Sarin, 2002; Arora, 2000). It also appears that the lean mass 
building is more likely to be affected than the fat storage (Mehrotra, 1997). Although the 
growth velocity have not been documented in any of these studies but the Z scores for 
height and weight at diagnosis and during follow-up after sclerotherapy were not 
statistically different. One study from India reported lower growth velocity in majority of 
children with EHPVO compared to the controls despite adequate nutrition (Sarin, 1992). A 
report from Brazil (n= 24; median age 5.9 years) reported that children with EHPVO had 
adequate growth for the age at diagnosis and over follow up period of 3.8±2.5 years 
compared to the NCHS reference (Bellomo-Brandao, 2003). Although the exact mechanism 
of the growth failure is not known, the following possible mechanisms have been proposed.  
- Poor substrate utilization or/and malabsorption due to portal hypertensive enteropathy 
is the proposed mechanism. This is supported by improved growth in many children 
with EHPVO after shunt surgery (Menon, 2005).  
- Impaired synthesis of growth factors due to shunting of blood away from the liver is 
another hypothesis . Significantly increased levels of growth hormone and decreased 
levels of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding 
protein-3 (IGFBP-3) have been noted in EHPVO patients, suggesting growth hormone 
resistance (Mehrotra, 1997; Nihal, 2009). It is proposed that reduced portal blood flow 
results in decreased insulin reaching the liver and thereby decreased production of IGF-
I and IGFBP-3. Shunt surgery, mesenterico-left portal vein bypass (MLPVB) with 
improvement in growth parameters in children with EHPVO supports this hypothesis 
(Lautz, 2009; Stringer, 2007).  
- Frequency of bleeding has been linked to the growth in these children. It is observed 
that children with frequent bleeding have severe growth retardation while children 
with asymptomatic course are normal or near normal (Mowat, 1987). 
While growth parameters in children with EHPVO have shown improvement after shunt 
surgery, no change in growth trend were documented in children after sclerotherapy 
(Arora, 2000; Sarin, 2002), even with adequate caloric intake (Sarin, 1992). This also support 
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5.2.5 Ectopic varices 
These have been reported in 27-40% of patients with EHPVO, and are commonly seen in the 
duodenum, anorectal region and gallbladder bed (Sarin, 2006). Bleeding from the varices in 
duodenum and anorectal regions are not uncommon.  
5.2.6 Jaundice 
Jaundice is rarely a presenting feature of EHPVO and is generally due to portal biliopathy or 
stricture of bile duct in longstanding cases.  
5.3 Complications and sequelae of EHPVO 
EHPVO is associated with several complications and sequalae those need mention from the 
clinical manifestation and management point of views. The documented sequelae observed 
in long course of EHPVO are as follows.  
5.3.1 Portal biliopathy 
Portal biliopathy refers to abnormalities of the extrahepatic and intrahepatic bile ducts in 
patients with portal hypertension. These include compression by paracholedochal collaterals 
on bile ducts resulting in displacement, narrowing, strictures, angulation, dilatations and 
irregularity of bile ducts. Extrinsic compression, ischemia, and a combination of both have 
been proposed as the possible mechanisms for this. Although portal biliopathy features have 
been reported in 80-100% of adult patients with EHPVO on endoscopic retrograde cholangio-
pancreatography (ERCP), up to one fifth are symptomatic (Dilawari, 1992; Khuroo, 1993; 
Malkan, 1999; Nagi, 2000; Poddar, 2001). These changes may become severe enough to cause 
obstructive jaundice and choledocholithiasis and cholelithiasis due to bile stasis. 
Cholangiographic changes are also evident in children with EHPVO, but mostly symptomatic 
in adulthood (Poddar, 2011). Although, biliary abnormalities are common in portal 
hypertension, only a few patients present with jaundice, pain and cholangitis. 
Choleodocholithiasis has been reported to occur in 17% of patients with portal biliopathy 
(Bhatia, 1995). ERCP is the definitive method for diagnosis of biliopathy. MRCP is a good non-
invasive alternative to ERCP. However, as the majority of patients with biliopathy are 
asymptomatic, ERCP is recommended only if a therapeutic intervention is contemplated. 
5.3.2 Ectopic varices 
Gall bladder varices are observed in 34% of adult patients with EHPVO (Chawla, 1995). 
Reports in children with EHPVO are scanty. Presence of portal vein thrombosis is an 
important determinant for the development of gall bladder varices. Rectal varices may be 
seen in up to 80% of patients with EHPVO and the development is related to the duration. 
These varices may also bleed profusely (Sarin, 1992). Gall bladder varices are reported in 12-
30% of adults with EHPVO (Chawla, 1995; West, 1991). 
5.3.3 Gastropathy and colopathy 
Gastropathy and colopathy represent congested mucosa at different parts of gastrointestinal 
tract which may present as occult gastrointestinal bleeding, but sometimes also as overt 
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bleeding. About one fourth of the EHPVO children have gastropathy at presentation, but 
the prevalence increases significantly (2 times or more) after variceal eradication (Hyams, 
1993; Poddar, 2004). Portal colopathy may be seen in up to half of the patients with EHPVO 
(Sarin, 1992; Arora, 1999).  
5.3.4 Hyersplenism 
Massive splenomegaly may cause pooling and excessive destruction of the pooled blood cell 
components leading to thrombocytopenia, leucopenia and anemia. It can also predispose to 
infection and or bleeding. The hypersplenism does not correlate with splenic size. Splenic 
sequestration crisis may occur leading to hypovolemic shock and death. 
6. Specific issues in children  
6.1 Growth retardation 
EHPVO in children often reported to be associated with growth retardation.  
Reports from India indicated that the majority of the Indian children with EHPVO were 
stunted compared to the national control or to the National Center for Health Statistics 
(USA) reference (Mehrotra, 1997; Sarin, 2002; Arora, 2000). It also appears that the lean mass 
building is more likely to be affected than the fat storage (Mehrotra, 1997). Although the 
growth velocity have not been documented in any of these studies but the Z scores for 
height and weight at diagnosis and during follow-up after sclerotherapy were not 
statistically different. One study from India reported lower growth velocity in majority of 
children with EHPVO compared to the controls despite adequate nutrition (Sarin, 1992). A 
report from Brazil (n= 24; median age 5.9 years) reported that children with EHPVO had 
adequate growth for the age at diagnosis and over follow up period of 3.8±2.5 years 
compared to the NCHS reference (Bellomo-Brandao, 2003). Although the exact mechanism 
of the growth failure is not known, the following possible mechanisms have been proposed.  
- Poor substrate utilization or/and malabsorption due to portal hypertensive enteropathy 
is the proposed mechanism. This is supported by improved growth in many children 
with EHPVO after shunt surgery (Menon, 2005).  
- Impaired synthesis of growth factors due to shunting of blood away from the liver is 
another hypothesis . Significantly increased levels of growth hormone and decreased 
levels of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding 
protein-3 (IGFBP-3) have been noted in EHPVO patients, suggesting growth hormone 
resistance (Mehrotra, 1997; Nihal, 2009). It is proposed that reduced portal blood flow 
results in decreased insulin reaching the liver and thereby decreased production of IGF-
I and IGFBP-3. Shunt surgery, mesenterico-left portal vein bypass (MLPVB) with 
improvement in growth parameters in children with EHPVO supports this hypothesis 
(Lautz, 2009; Stringer, 2007).  
- Frequency of bleeding has been linked to the growth in these children. It is observed 
that children with frequent bleeding have severe growth retardation while children 
with asymptomatic course are normal or near normal (Mowat, 1987). 
While growth parameters in children with EHPVO have shown improvement after shunt 
surgery, no change in growth trend were documented in children after sclerotherapy 
(Arora, 2000; Sarin, 2002), even with adequate caloric intake (Sarin, 1992). This also support 
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the proposed substrate metabolism, insulin and growth factor mediated mechanisms as the 
cause of growth failure. The overall nutritional status and underlying etiology and the 
associated complications of recurrent bleeds may influence the growth in children with 
EHPVO.  
6.2 Mental function and encephalopathy 
Mild cognitive and psychomotor deficit has been reported in patients with EHPVO in 
absence of liver disease (Sarin, 2006). Hyperammonia as a result of porto-systemic shunting 
in EHPVO may lead to generalized low grade cerebral edema. Abnormal cognitive 
functions may be evident on neuropsychological tests in some of these patients with 
apparently normal neurological status, which is described as having minimal hepatic 
encephalopathy. Normal liver functions probably reduce the severity of hepatic 
encephalopathy. A term type B hepatic encephalopathy has been proposed for this 
condition (Ferenci, 1998). In a recent Indian series of children, about one-third of children 
with EHPVO had abnormal neuropsychological test findings (visual-motor coordination 
and spatial orientation), raised blood ammonia, abnormal MRI signal, and abnormal brain 
metabolites on MR spectroscopy compared to the normal children (Yadav, 2010).  
7. Diagnosis and investigation findings  
A child with upper gastrointestinal bleeding (manifesting as either hematemesis and/or 
malena) and splenomegaly but no features of chronic liver disease is likely to be suffering 
from EHPVO. Normal liver function test and absence of virologic markers in a child with 
portal hypertension further suggest towards EHPVO. But the other causes of non-cirrhotic 
portal hypertension and compensated childhood cirrhosis are to be excluded. Imaging of 
spleno-portal axis is the mainstay for the diagnosis of EHPVO. According to Baveno V 
consensus statement, EHPVO is diagnosed by Doppler US, CT, or MRI, which demonstrate 
portal vein obstruction, presence of intraluminal material or portal vein cavernoma. Recent 
EHPVO is characterized by demonstrated portal venous obstruction without cavernoma (De 
Franchis, 2010).  
7.1 Ultrasonography 
Ultrasound (US) is a reliable non-invasive diagnostic tool with a high degree of accuracy for 
the detection of blockage in splenoportal axis and portal portal cavernoma, and is the 
investigation of choice (Sharma, 1997). Usually the normal portal vein and branches are 
invisible and are replaced by multiple tortuous collateral veins with hepatopetal flow, the 
cavernomatous transformation of the portal vein. Large collateral vein may simulate to be 
portal vein but tortuosity and presence of surrounding small channels help in 
differentiation. Portal vein thrombus may be observed as an echogenic lesion within the 
vessel, although a recently formed thrombus may be anechoic. Colour Doppler imaging is 
very helpful in detecting portal vein flow and diagnosing portal vein obstruction, spleno-
portal collaterals and shunts with sensitivity of 70 - 90% and specificity of 99% (Nyandak, 
2011). Ultrasound may also indicate about the liver pathology (size and echogenicity) and 
portal biliopathy which may have intrahepatic bile duct dilatation due to compression of the 
 
Extra Hepatic Portal Venous Obstruction in Children 
 
49 
common bile duct by the cavernoma. Endoscopic ultrasound (EUS) may further advance the 
diagnostic accuracy in patients with portal vein thrombosis.  
7.2 CECT 
In contrast-enhanced CT scan, thrombus may be seen as a nonenhanced intraluminal-filling 
defect. CECT has the advantage of displaying varices and parenchymal hepatic 
abnormalities also. The combination of CT scan and Doppler ultrasound is common in the 
evaluation of portal vein obstruction.  
7.3 MRI 
MRI and magnetic resonance angiography (MRA) are helpful for evaluating hepatic 
parenchymal details, to quantitate portal and hepatic vessel flow for planning of 
interventions, such as shunt surgery. MRI can help detecting and differentiating acute and 
old clots and blockage due to tumor thrombi. MRI and MRA are highly sensitive and 
specific for detecting both the thrombi and submucosal, serosal, paraoesophageal collaterals. 
CT and MRA may be more useful for detecting the recent EHPVO.  
7.4 Endoscopy 
Upper gastrointestinal endoscopy is must for all EHPVO patients to detect the status of 
varices, any site of bleeding and associated congestive gastropathy. For detecting the lower 
gastrointestinal bleeding due to rectal or colonic varices, lower gastrointestinal endoscopy 
may be needed.  
7.5 Biochemical tests 
Biochemical liver function test parameters are usually within normal range, unless 
associated with underlying liver disease. But with longstanding disease liver function may 
deteriorate. Viral markers for hepatotropic viruses are to be screened as these children are at 
high risk for blood borne transmission due to repeated blood transfusions. Liver biopsy is 
not indicated in EHPVO unless underlying liver pathology is suspected. Screening for 
prothrombotic disorders may help in identifying underlying coagulopathy.  
7.6 Radionuclide scan 
In cases of gastrointestinal bleeding not visualized by endoscopy may need radionuclide 
scanning (99m Technetium sulfur colloid and 99m technetium pertechnate labeled RBCs) to 
detect the site of bleeding if not evident on endoscopy. 99m Tc scan can even detect bleeding 
rate of 0.1–0.5 mL/min. Radionuclide scan is only rarely required.  
7.7 Additional tests 
Additional tests like ERCP and MRCP may be indicated to detect the presence of portal 
biliopathy, if suspected. Endoscopic retrograde cholangiopancreatography (ERCP) is 
indicated for confirming portal biliopathy, particularly if there are features of cholangitis or 
obstructive jaundice.  
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the proposed substrate metabolism, insulin and growth factor mediated mechanisms as the 
cause of growth failure. The overall nutritional status and underlying etiology and the 
associated complications of recurrent bleeds may influence the growth in children with 
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in EHPVO may lead to generalized low grade cerebral edema. Abnormal cognitive 
functions may be evident on neuropsychological tests in some of these patients with 
apparently normal neurological status, which is described as having minimal hepatic 
encephalopathy. Normal liver functions probably reduce the severity of hepatic 
encephalopathy. A term type B hepatic encephalopathy has been proposed for this 
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spleno-portal axis is the mainstay for the diagnosis of EHPVO. According to Baveno V 
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portal vein but tortuosity and presence of surrounding small channels help in 
differentiation. Portal vein thrombus may be observed as an echogenic lesion within the 
vessel, although a recently formed thrombus may be anechoic. Colour Doppler imaging is 
very helpful in detecting portal vein flow and diagnosing portal vein obstruction, spleno-
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common bile duct by the cavernoma. Endoscopic ultrasound (EUS) may further advance the 
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8. Management  
8.1 Concepts and principles of management 
Management of EHPVO depends on the age of the patient, the site of obstruction and the 
clinical presentation. Liver involvement necessitates modification in approach to 
management. Management in children also needs to address the nutrition to ensure optimal 
growth.  
8.2 Prophylaxis 
Prophylaxis is very important in cases with portal hypertension to reduce the risk of initial 
bleeding (primary prophylaxis) or rebleeding (secondary prophylaxis) through reducing the 
vascular pressure in splenoportal axis.  
8.2.1 Primary prophylaxis 
Evidence on the role of primary prophylaxis in the management of portal hypertension and 
portal hypertension has not been adequately studied in children. Use of Propranolol (1-
2mg/kg body weight/day) as primary prophylaxis has been shown to be effective in 
reducing bleeding compared to secondary prophylaxis (15.6% vs 53.3% respectively) 
(Ozsoylu, 2000). So, children with varices on endoscopy are to be initiated on beta blocker, 
but follow up endoscopy is to be done to check the status every 6-12 monthly interval. 
Prophylactic endoscopic sclerotherapy and variceal obliteration is also in practice. Use of 
prophylactic EST children with portal hypertension had lower bleeding episodes (24%) 
compared to controls (42%) over a median follow-up of 4.5 years (Goncalves, 2000). But the 
evidence and experience in children is limited to support recommendation of prophylactic 
EST or EVL.  
8.2.2 Secondary prophylaxis 
Evidences on secondary prophylaxis are better than that of primary prophylaxis. Beta 
blockers are in use for reducing portal pressure and thereby reducing risk or variceal 
bleeding. Propranolol is commonly used at dosage 2mg/kg body weight/day in 2 divided 
doses. Heart rate is monitored and dosage is adjusted to prevent fall of heart rate more than 
20% of baseline or absolute heart rate below 60/minute. Metaanalysis indicated the benefit 
of beta blocker in reducing variceal bleeding (Sarin, 1996). About 20% of the patients do not 
respond to the beta blockers and some cannot be given due to contraindications like 
congestive heart failures, peripheral vascular diseases, chronic obstructive pulmonary 
diseases, asthma, and insulin dependent diabetes mellitus.  
8.2.3 Management of gastrointestinal bleeding 
Gastrointestinal bleeding related to portal hypertension and EHPVO may be of variceal or 
mucosal in nature. Variceal bleeding may be of acute nature presenting as life threatening 
episode or of chronic with recurrent episodes or malena with or without anemia. Usually 
acute variceal bleedings are life threatening with sudden onset and may be associated with 
loss of large volumes of blood. It can be fatal in 30-40% of cases.  
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Quick history and clinical examination is to be done to rule out non-GI bleeding, assess the 
severity of bleeding and hemodynamic status. There is no controversy about the 
management of acute variceal bleeding and involves the following five steps. 
i. Emergency resuscitation and hemodynamic stabilisation    
ii. Identification of source and site of bleeding  
iii. Stopping bleeding source   
iv. Monitoring  
v. Variceal obliteration  
While planning the management of acute bleeding, along with hemodynamic status, liver 
function status is also to be assessed as soon as possible to plan the management strategy. 
Urgent upper gastrointestinal endoscopy should be undertaken at the earliest after full 
resuscitation, to identify source and to intervene to stop bleeding.  
8.3 Endoscopic management of variceal bleeding  
8.3.1 Management of esophageal variceal bleeding 
Endoscopic variceal sclerotherapy (EST) and endoscopic variceal ligation (EVL) are two 
effective methods of controlling acute bleeding from esophageal varices. EST involved 
injection of sclerosant (sclerotherapy) into the varix and/or surrounding submucosa. 
Commonly used sclerosants ate sodium morruhate (1.5%), tetradecyl sulfate (0.5-1%), 
phenol (3%) and polidocanol (1%). EST is effective in eradicating esophageal varices in 88-
100% cases. However, complications like retrosternal pain (30-60%), fever (39%), ulcer (8% 
to 30%) and stricture (6% to 20%) are often encountered with EST (Poddar, 2011; Arora, 
2002). Meta-analysis of sclerotherapy in adults has demonstrated its advantage over 
vasopressin; and comparable efficacy with somatostatin or octreotide in controlling acute 
variceal bleeding (De Franchis, 1999). On the other hand endoscopic variceal ligation (EVL) 
involves ligation of the varix using bands. Although, EVL has the advantages of rapid 
eradication of varices requiring fewer sessions and portending fewer complications, use in 
younger children (< 2 years) may be an issue. Over the years, EVL has become the preferred 
mode of treatment of variceal bleeding in adults. However, the additional cost of banding is 
a constraint, especially in developing countries. The limited experience of EVL in children 
suggests its superiority over EST (Zargar, 2002).  
Newer endoscopic treatment modalities like thermal coagulation, electrocoagulation and 
laser photocoagulation are also being tried in adults. But the experience in children is not 
available.  
After initial control of bleeding, eradication of varices is necessary to prevent subsequent 
bleeding. Either EST or EVL in isolation or EST followed by EVL can be adopted for this. 
EVL alone although appears to be simpler and effective for initial eradication of varices, 
recurrence of varices is high, as obliteration of smaller varices and perforators is difficult. 
EST/EVL sessions are repeated at 1-2 weekly interval and usually 6-10 sessions are required 
to completely obliterate the esophageal varices. Variceal recurrence has been documented in 
40% of children after 2 years of EVL (McKiernan, 2002). So a combination of EVL and EST, 
initial EVL followed by low-dose EST appears to be more effective in children. It reduces the 
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sessions required, complications associated with large-dose EST for initial variceal 
eradication and the risk of variceal recurrence. Two studies from India supported this 
combination intervention (Poddar, 2005; Poddar, 2011).  
8.3.2 Management of gastric varices 
The experience in children is limited. Gastric varices bleed less frequently but when they do, 
they bleed profusely. Endoscopic injection of tissue adhesive agent (n-butyl 2 cyanoacrylate) 
has been effective in controlling such bleeding, as EST or EVL may not be suitable. Large 
gastric varices with or without bleeding are considered as an indication for shunt surgery.  
8.3.3 Management of colorectal varices 
Management of bleeding rectal varices include sclerotherapy or band ligation. For presence 
of larger rectal varices and colopathy with or without bleeding, shunt surgery may be 
considered.  
8.4 Medical management of variceal bleeding 
Several drugs are also used to reduce the portal venous pressure and thereby variceal 
bleeding before undertaking endoscopic therapy. These agents enable stabilization of the 
patient till the definite interventions are done or if not possible.  
8.4.1 Vasopressin 
Vasopressin is the most potent splanchnic vasoconstrictor. It reduces blood flow to all 
splanchnic organs, decreasing portal venous inflow and thereby decreasing portal pressure. 
Vasopressin is administered as continuous infusion and increased till maximum dosage is 
reached in titration with the bleeding. The infusion is to be continued for at least 24-48 hours 
after stoppage of bleeding. In about 60% of the patients bleeding is controlled using this 
agent (Tuggle, 1988). Although this drug in adults has been shown to control bleeding yet 
the mortality does not decrease and dose at highest level may be associated with 
complications. The usage is limited by adverse effects related to vasoconstriction in 
splanchnic bed leading to bowel ischemia and systemic circulation resulting in hypertension 
and myocardial ischemia. To minimize the systemic adverse effects, vasopressin should 
always be accompanied by intravenous nitroglycerin.  
8.4.2 Terlipressin 
Terlipressin is a synthetic analogue of vasopressin with longer biological activity and 
significantly fewer adverse effects. Terlipressin may have more sustained hemodynamic 
effects in patients with bleeding varices.  
8.4.3 Somatostatin 
Natural hormone somatostatin decreases portal pressure by causing splanchnic 
vasoconstriction. It is associated with lesser side effects compared to vasopressin. There is 
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limited experience in children. In adult patients somatostatin is effective in 64-92% cases 
(Burroughs, 1990). Blood sugar is to be monitored every 6 hourly to detect hypoglycemia.  
8.4.4 Octreotide 
It is a synthetic analogue of somatostatin and effective in controlling acute variceal bleeding 
in most (84-95%) of adult patients. It can be given as infusion or intermittent subcutaneous 
injections. Monitoring is similar to Somatostatin.  
There are limited data on the use of pharmacological agents for the control of acute bleeding 
in children with EHPVO. However, if EHPVO is due to acute thrombophilia, there is a 
theoretical risk of a decrease in splanchnic blood flow induced by bleeding and by 
therapeutic vasconstrictive agents that may cause extension of thrombus in the portal 
venous system resulting in intestinal ischemia.  
8.5 Other interventions to manage acute variceal bleeding  
8.5.1 Balloon tamponade 
Direct compression of varices with balloon (Sengstaken-Blackemore tube) has been used to 
stop bleeding. The smaller tube is also available for pediatric use. It has two balloons, one 
each for esophageal and gastric compression and one lumen for aspiration of gastric 
contents. The balloons are inflated using air or saline to compresses the varices at 
gastroesophageal junction and in esophagus. Intermittent deflation of the balloon is 
important to prevent mucosal ischemia. Aspiration is another complication that can 
potentially be fatal. This balloon device can control acute variceal bleeding up to 80% of 
cases (Pitcher, 1971; Brodoff, 1980). Positioning of the tube and is to be confirmed with plain 
X-ray abdomen. Selection of appropriate tube size, experience and following simple 
precautions are necessary to prevent tissue necrosis and aspiration.  
8.5.2 Transjugular Intrahepatic Portosystemic Shunt (TIPS) 
This procedure involves creation of an artificial shunt between hepatic vein and portal vein 
within liver via a catheter passed through internal jugular vein. The tract maintained by a 
self expandable metal stent enables decompression of the portal system. Mostly it has been 
used in patients of cirrhosis awaiting liver transplantation. This is a technically difficult 
procedure, costly and needs expertise. The experience in children is small and success rates 
variable between 75-90% (Heyman, 1999).  
8.5.3 Management of mucosal bleeding 
Bleeding or oozing may occur from mucosal lesions associated with congestive gastropathy 
or colopathy due to portal hypertension. Management of gastropathy involves 
neutralization of the gastric acid and stoppage of bleeding from the sites/ lesions. The 
medications used are:  
- Antacids for neutralizing the gastric acid.  
- H2 receptor blockers or proton pump blockers to reduce the gastric acid secretion. 
Duration of use is to be decided based on the nature of mucosal lesion.  
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- Sucralfate forms a protective barrier on the mucosal lesions and prevent contact of 
gastric acid.  
Management of colopathy is difficult and the endoscopic photocoagulation or laser 
coagulation like measures may be helpful. Additionally the beta-blockers are recommended 
for these patients. Recurrent bleeding from portal hypertensive gastropathy and/or 
colopathy usually indicates shunt surgery.  
The flow chart of managing a child with variceal and/or mucosal bleeding is given below.  
 
 




Flow chart: Evaluation and management of upper gastrointestinal bleeding  
8.5.4 Management of acute portal thrombosis 
Spontaneous resolution of recent portal thrombus is rare. Management includes 
conservative medical and surgical interventions. The symptomatic patients with recent 
EHPVO should be started on low molecular weight heparin immediately after detection 
followed by oral anticoagulant therapy. In asymptomatic patients, if detected early, 
anticoagulation should be considered. Dosage of anticoagulation therapy is to be titrated 
with target to maintain international normalized ration (INR) around 2-3. Baveno V 
consensus statement recommends anticoagulation for at least three months, unless long 
term/lifelong therapy is indicated for underlying persistent prothrombotic state (De 
Franchis, 2010). Repeat Doppler is to be done after 3-6 months to check for recanalisation of 
portal vein. In acute thrombosis cases, evidence of infection must be ruled out. If any 
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evidence of infection is there, antibiotic therapy should be given. Advanced minimally 
invasive intervention techniques like direct thrombolysis of portal vein, thrombolysis 
through TIPS are being used. But experience in children is limited.  
8.5.5 Surgical management of EHPVO 
Surgical management of EHPVO includes shunt and non-shunt procedures. The shunt 
procedures aim at reducing portal pressure by diverting the blood from the high-pressure 
portal venous system to the systemic circuit. Shunt surgeries are recommended for EHPVO 
cases not responding to medical and endoscopic management and if associated with 
complications. The indications for shunt surgery include failure of endotherapy to control 
bleeding, presence of gastric or ectopic varices (not amenable to endoscopic management), 
and associated complications like portal biliopathy and large rectal varices. Emergency 
shunt surgery is undertaken now only rarely due to wide availability of endoscopic 
management. The additional indications for shunt surgery include portal biliopathy, severe 
growth failure, massive splenomegaly, hypersplenism, rare blood group, isolated splenic 
vein thrombosis, non- compliance of elective EST/EVL and poor chance of follow up (living 
in remote area). Individualization of each child with EHPVO for shunt surgery is to be done 
considering all the aspects and in consultation with the surgical team.  
Shunts may be non-selective shunts or selective shunts, partial shunts and the more recently 
introduced "Rex shunt"(mesenterico-left portal bypass). 
The non-selective shunts enable complete decompression of the entire portal venous system by 
diverting total portal blood flow away from the liver. These shunts are end to side and side-to-
side portacaval shunts, central lienorenal shunt, end to side mesocaval shunt and large 
diameter interposition portacaval or mesocaval shunts. Although these shunts are effective in 
controlling variceal bleeding, encephalopathy is a concern in patients with poor liver 
functions. Follow up studies have shown shunt patency in 85-98% of children with long term 
survival in >95% cases (Lautz, 2009; Bismuth, 1980; Alvarez, 1983; Gauthier, 1989; Mitra, 1993; 
Prasad, 1994; Orloff, 1994; Superina, 2006; Shariff, 2010). Risk of variceal recurrence and re-
bleed is there in case of shunt blockage. But there is no report of post shunt encephalopathy in 
EHPVO cases. Splenectomy usually done with central lienorenal shunt has not been found to 
be associated with an increased risk of post-splenectomy sepsis (Arora, 2002). 
The selective shunts divert the blood of gastroesophageal-splenic segment and maintain the 
blood flow in mesenteric segment based on the functional classification of portal venous 
system into the splenogastric and mesenteric segments. This enables portal decompression 
with maintenance of hepatopetal portal perfusion, mesenteric venuos pressure and 
hepatotrophic factors. Distal splenorenal shunt, a selective shunt has technical advantage of 
lower chance of post-shunt encephalopathy. The mesoportal bypass (MPB) is a recent 
advancement in shunt restoring mesenteric blood flow to the liver through the Rex venous 
recessus (interposition of a jugular venous allograft between the superior mesenteric vein 
and the intrahepatic left portal vein). This "Rex shunt" restores the physiological hepatopetal 
flow and thereby corrects the liver dysfunction, coagulation parameters and also improves 
the growth potential (Superina, 2006; Mack, 2003; Lautz, 2009). It appears that doing the Rex 
shunt early after diagnosis rather than waiting till complications will be beneficial. But in 
want of clear evidence and experience, there is no consensus on this issue.   
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A subgroup of EHPVO patients may not be suitable for shunt surgery in view of 
complicated vascular anatomy due to extensive thrombosis of the splenoportal axis, prior 
splenectomy or a previously performed but failed shunt procedure. These cases merit non-
surgical management and non-shunt surgical procedures, if required. 
8.5.6 Portosystemic shunt vs endoscopic sclerotherapy 
In a randomized clinical trial by our group in India, we assessed the complications, technical 
problems and rebleeding rates after EST and shunt surgery. Out of the 297 children with 
EHPVO screened, 156 children were randomized into surgical and EST groups (78 children 
in each group). Out of the 78 children randomized into in surgical group, 8 opted out before 
intervention and 28 could not undergo surgery due to technical reason (blockage of splenic 
vein) and hence received EST. Out of the 78 children in EST group, 75 children undergone 
EST (2 opted out before intervention and 1 died). The children were followed up (median 
follow up period 24 months; range: 21-29 months). The pooled incidence of bleeds decreased 
from 0.11/month in pre-intervention period to 0.014/month in post-intervention phase, 
when both the interventions were considered together. The fall in the incidence rate for 
major bleeds was higher (0.05 to 0.002) than that for minor bleeds (0.06 to 0.013). Survival 
analysis showed that among the children who underwent EST, 25% had rebleeding by 16.9 
months after intervention while 50% had rebleeding by 38.4 months. Children who 
underwent surgery had rebleeding by 18.3 months in 25% subjects and less than half of 
these subjects ever rebled. Survivor function at various 6 monthly time intervals during 
follow up was similar between EST and surgery groups. This was true for any kind of re-
bleed; major bleeds and minor bleeds. Relative risk of rebleeding after controlling for period 
of follow up was similar for all types of bleeds. Recurrence of esophageal varices was higher 
in surgery group  compared to the EST group. By 6 months, half of the patients who 
underwent surgical intervention, had recurrence of varices, while the same was observed 
after 24 months in patients who underwent EST. But the risk of rebleeding was not 
influenced by recurrence of varices. Risk of re-bleeding was associated with the age of 
intervention, lesser rebleeding was noticed among children aged >10 years. Hypersplenism 
was observed in 17 children in the EST group compared to 3 children in the surgery group. 
Eight patients in the EST group died compared to 6 patients in the surgery group. It 
appeared from this data that both EST and surgery appear to perform equally well to 
control rebleeding in EHPVO patients. (Arora, 2004).  
8.6 Management of special situations related to EHPVO   
8.6.1 Portal biliopathy 
Symptomatic portal biliopathy is a definite indication for intervention. Primary biliary tract 
surgery is associated with significant morbidity and mortality due to presence of extensive 
collaterals around the bile ducts. Some experts suggest shunt surgery first and if it fails to 
resolve biliary obstruction, then to undertake staged biliary surgery (Chaudhary 1998). 
While others recommend endoscopic management of biliary obstruction first and if 
obstruction persists, then to do the shunt surgery (Khare, 2005). Presence of 
choledocholithiasis without biliary stricture can be managed by endoscopic sphincterotomy 
and stone removal. Presence of stricture may need balloon dilatation and stent placement. In 
cases of endoscopic failure, portosystemic shunt followed by biliary surgery should be 
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evidence of infection is there, antibiotic therapy should be given. Advanced minimally 
invasive intervention techniques like direct thrombolysis of portal vein, thrombolysis 
through TIPS are being used. But experience in children is limited.  
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cases not responding to medical and endoscopic management and if associated with 
complications. The indications for shunt surgery include failure of endotherapy to control 
bleeding, presence of gastric or ectopic varices (not amenable to endoscopic management), 
and associated complications like portal biliopathy and large rectal varices. Emergency 
shunt surgery is undertaken now only rarely due to wide availability of endoscopic 
management. The additional indications for shunt surgery include portal biliopathy, severe 
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Shunts may be non-selective shunts or selective shunts, partial shunts and the more recently 
introduced "Rex shunt"(mesenterico-left portal bypass). 
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side portacaval shunts, central lienorenal shunt, end to side mesocaval shunt and large 
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EHPVO cases. Splenectomy usually done with central lienorenal shunt has not been found to 
be associated with an increased risk of post-splenectomy sepsis (Arora, 2002). 
The selective shunts divert the blood of gastroesophageal-splenic segment and maintain the 
blood flow in mesenteric segment based on the functional classification of portal venous 
system into the splenogastric and mesenteric segments. This enables portal decompression 
with maintenance of hepatopetal portal perfusion, mesenteric venuos pressure and 
hepatotrophic factors. Distal splenorenal shunt, a selective shunt has technical advantage of 
lower chance of post-shunt encephalopathy. The mesoportal bypass (MPB) is a recent 
advancement in shunt restoring mesenteric blood flow to the liver through the Rex venous 
recessus (interposition of a jugular venous allograft between the superior mesenteric vein 
and the intrahepatic left portal vein). This "Rex shunt" restores the physiological hepatopetal 
flow and thereby corrects the liver dysfunction, coagulation parameters and also improves 
the growth potential (Superina, 2006; Mack, 2003; Lautz, 2009). It appears that doing the Rex 
shunt early after diagnosis rather than waiting till complications will be beneficial. But in 
want of clear evidence and experience, there is no consensus on this issue.   
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undertaken (Khare 2005). There is no clear consensus regarding timing of biliary surgery 
after shunt surgery. The experience in children in this context is limited. Children with 
portal biliopathy undergoing shunt surgery may have normalization of serum 
aminotransferases and gamma glutamyl transpeptidase (GGT) levels within 1 to 6 weeks 
after surgery (Gauthier, 2005). Shunt surgery is indicated in children with symptomatic 
portal biliopathy or even asymptomatic portal biliopathy in presence of growth failure, 
symptomatic hypersplenism or ectopic varices. 
8.6.2 Hypersplenism 
Traditionally, hypersplenism has been treated by splenectomy, open or laparoscopic. In 
view of the risk of overwhelming sepsis in children who are asplenic, the risks and benefits 
must be carefully weighed when splenectomy is being considered. Age of removal of spleen 
is an important consideration; risk of overwhelming sepsis may increase if child is less than 
5 years. Vaccines against pneumococcus, Haemophilus influenza and meningococcus should 
be administered to all children particularly these below 5 years, who are about to undergo 
splenectomy, at least 10 days before splenectomy. Additionally, antibiotic prophylaxis 
(penicillin) is recommended to asplenic children who have not received vaccines. In recent 
times, alternative technique of partial splenic embolisation (PSE) is in use (Dwivedi, 2002). It 
causes ischemic necrosis of a part of spleen and thereby decreases in splenic size and 
hypersplenism. It allows the preservation of adequate splenic tissue and thereby prevents 
the immunological function and protection against overwhelming infection.  
8.6.3 Coagulopathy 
The management of coagulopathy depends on the cause. There is no consensus or clear 
guideline about anticoagulant therapy for prothrombotic conditions in chronic EHPVO. In a 
patient with established chronic EHPVO, anticoagulants are recommended only if there is a 
history of recurrent thrombotic episodes and after shunt surgery (Valla, 2002). 
Anticoagulation therapy is contraindicated in cases with active variceal bleeding and can be 
initiated after variceal obliteration and patient is on beta blocker drug.  
9. Natural history  
The natural course of EHPVO is mainly determined by the age at presentation, presence or 
absence of underlying liver disease, associated systemic diseases. Most patients with 
EHPVO in the absence of liver disease and systemic disease have a relatively benign course. 
Morbidity is mainly related to variceal bleeding, recurrent thrombosis (if associated with 
prothrombotic disorder), symptomatic portal biliopathy, and hypersplenism. In case of 
children with EHPVO, especially in developing countries, nutritional status and growth 
retardation also influence the outcome.  
9.1 Quality of life with EHPVO 
Children with EHPVO suffering in view of repeated episodes of bleeding, undergoing 
diagnostic and therapeutic procedures, associated complications and morbidities, delayed 
growth, may have psychological issues that may impeded their ability and potential in 
physical, emotional, social, academic and other extracurricular segments. A study among 
 
Extra Hepatic Portal Venous Obstruction in Children 
 
59 
Indian children with EHPVO compared the quality of life (QOL) scores in children before 
variceal eradication, after variceal eradication and after surgery with controls. Overall 
children with EHPVO had lower median QOL scores in physical, emotional, social, and 
school functioning health domains compared to controls. Esophageal variceal eradication 
had no significant effect on QOL, but QOL improved after surgery. Most likely surgery 
provided a feeling of cure and reduced further risk and morbidity for both patient and the 
parents and thus resulted improvement in psychological status. Spleen size significantly 
influenced quality of life (QOL) scores and children with massive splenomegaly had poor 
QOL scores as compared with patients with mild and moderate splenomegaly. Total, 
physical, and psychosocial QOL scores were significantly lower in children with growth 
retardation. Both spleen size and growth retardation were independent predictors that affect 
the QOL (Radha Krishna, 2010).  
10. Prognosis 
Unlike patients with chronic liver disease, patients with EHPVO have a good prognosis as 
their liver functions are preserved. Mortality is mainly due to variceal bleeding and it is to 
the tune of 5% (Mowat, 1986). Long term studies after endotherapy have shown almost no 
mortality. Many of these bleeding episodes occurred within the first 4-10 years of variceal 
eradication (Zargar, 2004; Thomas, 2009; Stringer, 1994). The risk of rebleeding reduces with 
increasing age, especially after 10 years of age. With increasing age of survival, children 
with EHPVO are likely to face the longer term consequences in nutrition, mental function 
and portal biliopathy. Long term follow up studies shall be able to answer some of the 
unanswered issues in EHPVO.  
11. Conclusion  
Extrahepatic portal venous obstruction is the commonest cause of portal hypertension and 
variceal bleeding in children. With the availability of diagnostic facilities and effective 
endotherapy, the mortality due to EHPVO related emergencies has become rare. But with 
increasing survival, the sequelae and related morbidities are rising. The evolving surgical 
interventions have raised the hope of averting the long term complications of EHPVO. 
Further generation of evidence on etiology and course of disease including the effect of 
management in children with EHPVO is required, especially in developing countries. At the 
same time availability of trained manpower and facilities for management of acute 
emergencies and advanced surgical interventions will further improve the outcome.  
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Portal Vein Thrombosis with Cavernous 
Transformation in Myeloproliferative 
 Disorders: Review Update 
Anca Rosu, Cristian Searpe and Mihai Popescu 
University of Medicine and Pharmacy Craiova,  
Romania 
1. Introduction 
Portal vein thrombosis (PVT) refers to the complete or partial obstruction of blood flow in 
the portal vein, due to the presence of a thrombus into the vessel lumen  (Bayraktar & 
Harmanci, 2006) 
Cavernous transformation of portal vein consists in the development of a network of 
tortuous collateral vessels bypassing the obstructive area due to chronic PVT. First described 
in 1869 by Balfour and Stewart, it was Köbrich in 1928 that used for the first time the term of 
“cavernoma” to define the newly developed network of small vessels as a result of 
recanalization of the thrombotic portal vein. Once the liver blood supply decreases 
significantly, the compensatory mechanism is activated and collaterals begin to form within 
a few days after the obstruction and organize into a cavernous transformation in 3-5 weeks. 
(Cai, 2009)  
Based on a case previously communicated by us - (A case of portal cavernoma – associated 
thrombocythemia - A. Rosu, C. Searpe, V. Sbarcea, Z. Stoica, M. Popescu. J Gastrointestin 
Liver Dis 2007 16(1): 97-100), a review of the published English literature was performed 
using PubMed® (http://www.ncbi.nlm.nih.gov/PubMed) and Medline database. The 
search of screened articles was made for the keywords “portal vein thrombosis”, “portal 
cavernoma” and "myeloproliferative disorders" (MPD). Articles were selected if a review of 
the title and/or abstract suggested the association of portal vein thrombosis with cavernous 
transformation in patients with myeloproliferative diseases.  
2. Epidemiology 
2.1 Epidemiology of PVT 
In the era of continuous and impressive development of the imagistic techniques  (contrast-
enhanced ultrasound, spiral CT-scan, high definition MRI etc) the diagnosis of portal vein 
thrombosis (PVT) is no longer a rare condition since recent studies estimates it’s incidence at 
1,1% in the general population (Ogren et al., 2006). Also PVT is considered to account for 5 
to 10% of patients with portal hypertension (Wang et al., 2005). 
 
Portal Hypertension – Causes and Complications 
 
64
[76] Stringer MD, Howard ER. Long term outcome after injection sclerotherapy for 
esophageal varices in children with extra hepatic portal hypertension. Gut. 
1994;35;257–9. 
[77] Stringer MD. Improved body mass index after mesenterico-portal bypass. Pediatr Surg 
Int. 2007;23:539–43. 
[78] Superina R, Bambini DA, Lokar J, Rigsby C, Whittington PF. Correction of extrahepatic 
portal vein thrombosis by the meserteric to left portal vein bypass. Ann Surg. 
2006;243:515–21.  
[79] Thomas V, Jose T, Kumar S. Natural history of bleeding after esophageal variceal 
eradication in patients with extrahepatic portal venous obstruction; a 20-year 
follow-up. Indian J Gastroenterol.2009;28:206–11. 
[80] Thompson EN, Sherlock S.The etiology of portal vein thrombosis with particular 
reference to the role of infection and exchange transfusion. Q J Med 1964;33:465-480. 
[81] Tuggle DW, Bennett KG, Scott J, Tunell WP. Intravenous vasopressin and gastrointestinal 
hemorrhage in children. J Pediatr Surg 1988; 23 : 627-629. Bottom of Form 
[82] Valla D C, Condat B, Lebrec D. Spectrum of portal vein thrombosis in the West. J 
Gastroenterol Hepatol 2002; 17 (Suppl. 3): S224-7. 
[83] Webb L J, Sherlock S. The etiology, presentation and natural history of extra-hepatic 
portal venous obstruction. Q J Med 1979; 192: 627-39. 
[84] West MS, Garra BS, Horti SC, et al. Gallbladder varices: Imaging findings in patients 
with portal hypertension. Radiology 1991;179:179-82 
[85] Yachha S K, Khandur A, Sharma B C, Kumar M. Gastrointestinal bleeding in children. J 
Gastroenterol Hepatol 1996; 11: 903-7. 
[86] Yachha SK, Dhiman RK, Gupta R, Ghoshal UC. Endosonographic evaluation of the 
rectum in children with extrahepatic portal venous obstruction. J Pediatr 
Gastroenterol Nutr. 1996; 23:438–41.  
[87] Yadav S, Dutta A K, Sarin S K. Do umbilical vein catheterization and sepsis lead to 
portal vein thrombosis? A prospective, clinical and sonographic evaluation. J 
Pediatr Gastroenterol Nutr 1993; 17: 392-6. 
[88] Yadav S, Srivastava A, Srivastava A, et al. Encephalopathy assessment in children with 
extra-hepatic portal vein obstruction with MR, psychometry and critical flicker 
frequency. J Hepatology. 2010; 52 (3): 348-354.) 
[89] Zargar SA, Javid G, Khan BA, Yattoo GN, Shah AH, Gulzar GM, et al. Endoscopic 
ligation compared with sclerotherapy for bleeding esophageal varices in children 
with extrahepatic portal venous obstruction. Hepatology. 2002; 36:666–72. 
[90] Zargar SA, Yattoo GN, Javid G, Khan BA, Shah AH, Shah NA, et al. Fifteen-year follow 
up of endoscopic injection sclerotherapy in children with extrahepatic portal 
venous obstruction. J Gastroenterol Hepatol. 2004; 19:139–45. 
4 
Portal Vein Thrombosis with Cavernous 
Transformation in Myeloproliferative 
 Disorders: Review Update 
Anca Rosu, Cristian Searpe and Mihai Popescu 
University of Medicine and Pharmacy Craiova,  
Romania 
1. Introduction 
Portal vein thrombosis (PVT) refers to the complete or partial obstruction of blood flow in 
the portal vein, due to the presence of a thrombus into the vessel lumen  (Bayraktar & 
Harmanci, 2006) 
Cavernous transformation of portal vein consists in the development of a network of 
tortuous collateral vessels bypassing the obstructive area due to chronic PVT. First described 
in 1869 by Balfour and Stewart, it was Köbrich in 1928 that used for the first time the term of 
“cavernoma” to define the newly developed network of small vessels as a result of 
recanalization of the thrombotic portal vein. Once the liver blood supply decreases 
significantly, the compensatory mechanism is activated and collaterals begin to form within 
a few days after the obstruction and organize into a cavernous transformation in 3-5 weeks. 
(Cai, 2009)  
Based on a case previously communicated by us - (A case of portal cavernoma – associated 
thrombocythemia - A. Rosu, C. Searpe, V. Sbarcea, Z. Stoica, M. Popescu. J Gastrointestin 
Liver Dis 2007 16(1): 97-100), a review of the published English literature was performed 
using PubMed® (http://www.ncbi.nlm.nih.gov/PubMed) and Medline database. The 
search of screened articles was made for the keywords “portal vein thrombosis”, “portal 
cavernoma” and "myeloproliferative disorders" (MPD). Articles were selected if a review of 
the title and/or abstract suggested the association of portal vein thrombosis with cavernous 
transformation in patients with myeloproliferative diseases.  
2. Epidemiology 
2.1 Epidemiology of PVT 
In the era of continuous and impressive development of the imagistic techniques  (contrast-
enhanced ultrasound, spiral CT-scan, high definition MRI etc) the diagnosis of portal vein 
thrombosis (PVT) is no longer a rare condition since recent studies estimates it’s incidence at 
1,1% in the general population (Ogren et al., 2006). Also PVT is considered to account for 5 
to 10% of patients with portal hypertension (Wang et al., 2005). 
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The concept of PVT as a rare disease is mainly based on clinical series and case reports 
(Amitrano, 2004), therefore accurate epidemiological data about PVT are difficult to obtain. 
An epidemiological study performed and conducted in southern Sweden (Ogren et al., 2006) 
based on the study of 23 796 autopsies, reported the incidental finding of a PVT in about 1% 
of the general population. Authors reported that 28% of PVT patients had cirrhosis, 23% 
primary and 44% secondary hepatobiliary malignancy, 10% major abdominal infectious or 
inflammatory disease and 3% had a myeloproliferative disorder. Other studies reveal that 
prevalence of PVT in autopsy studies in USA and Japan ranges from 0.05% to 0.5% (Wang et 
al., 2005).  
Actually, thanks to the availability of more sensitive and less invasive imaging, together 
with the existence of curative or palliative procedures, PVT is routinely investigated and 
defined without any difficulty. Thus, PVT seems more frequent than expected: it is 
estimated to be responsible for 5%-10% of the overall cases of portal hypertension, which 
can be 40% in western countries (Wang et al., 2005). 
2.2 Epidemiology of MPD with PVT  
The annual incidence of myeloproliferative syndrome is 2,1-3,5 per 100000 peoples (Kutti & 
Ridell, 2001). From the four entities comprising the myeloproliferative syndrome according 
to the FAB classification (essential thrombocythemia, polycythaemia vera, chronic 
myelogenous leukemia and idiopathic myelofibrosis), essential thrombocythemia is 
considered the most frequent disease with an annual incidence of 0,7-2,5 per 100000 peoples 
(Cai et al., 2009; Girodon et al., 2009; Rollison et al., 2008). The transformation to acute 
myelogenous leukemia is recorded in 0,6-5% of patients and the overall 10-year survival rate 
is 64-80% (Fenaux et al., 1990). 
In many patients with non-cirrhotic non-malignant PVT, a systemic, thrombophilic risk 
factor is often present. Over the last two decades, some of, either inherited or acquired, 
systemic conditions that result in a thrombogenic phenotype have been identified as risk 
factors for the development of PVT. 
MPD remains the major latent or patent cause of extrahepatic PVT (Diaz et al., 2001 ; Valla et 
al., 1988; Valla & Condat, 2000). In non-cirrhotic and non-tumoral PVT cases in the West, 
MPD (i.e. polycythaemia vera, essential thrombocythaemia and myelofibrosis) with a 
combination of several prothrombotic factors constitute the most common identifiable cause 
with an estimated prevalence of 30%-60% (Cai et al., 2009; Kiladjian et al., 2006; Kutti & 
Ridell, 2001). In another study, a myeloproliferative disorder (MPD) was found in 37% of 
patients with non-cirrhotic non-malignant PVT (Kiladjian et al., 2006). 
Essential thrombocytaemia (ET) is frequently associated with thrombotic complications in the 
large abdominal vessels. It was reported a prevalence of 4% for abdominal vein thrombosis in 
460 consecutive patients with ET (Gangat et al., 2006), but did not provide detailed information 
on portal vein thrombosis. The risk factors for thrombosis in ET patients include age, 
thrombotic history, cardiovascular risk factors and genetic or acquired thrombophilia 
(Landolfi et al., 2008). It seems likely that elevated platelet count is involved in thrombotic 
events in ET. However, the degree of elevation does not appear to be important, relatively low 
platelet counts often being associated with thrombosis (Harrison, 2005). 
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3. Etiology and pathogenesis 
Portal vein thrombosis is the result of a complex mechanism involving multiple local and 
systemic risk factors with effect on coagulability, blood flow and endothelium integrity. 
Blood flow obstruction in the portal vein is the result of invasion, thrombosis, constriction 
and frequently, a combination of the above-mentioned mechanisms. A list of most common 
conditions associated with portal vein thrombosis is presented in table 1 and 2 (Chawla et 
al., 2009; Gurakan et al., 2004; Hoekstra & Janssen, 2009; Janssen, 2001; Rosendaal, 1999; 
Valla & Condat, 2000; Valla et al., 2002). 
 
Inherited 
Anticoagulant deficiency syndroms (antithrombin-III, protein-C, 
protein-S) 
Mutation involving coagulating factor II (G20210A) or V (G1691) 
Plasminogen deficiency 
MTHFR homozygote mutation TT677 
TAFI (thrombin activatable fibrinolysis inhibitor) gene mutation 
Sickle cell disease 
Acquired 
Myeloproliferative disorders (polycythemia vera, essential 
thrombocythemia) 








Primary biliary cirrhosis 
Systemic lupus erythematosus 
Rheumatoid arthritis 
Wegener disease 




Table 1. Systemic hypercoagulability conditions associated with portal vein thrombosis 
Noteworthy are the local factors predisposing to portal location instead of peripheral 
venous thrombosis in patients with hypercoagulability associated diseases. These factors 
are: local inflammatory diseases, injury of the portal venous tract, liver cirrhosis and 
abdominal cancer (table 2). 
Although in most cases thrombosis of the portal vein has an identifiable cause, less than 20% 
are considered to be idiopathic. In children, umbilical vein sepsis and neonatal umbilical 
vein catheterization are the main causes of portal vein thrombosis. In adults, liver cirrhosis, 
abdominal malignant tumors and association of different hypercoagulability states explains 
the vast majority of portal vein thrombosis.  
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Liver cirrhosis  
Nodular regenerative hyperplasia  






Iatrogenic injury of the portal 
venous tract 
Endoscopic sclerotherapy of esophageal varices 
Alcoolisation/chemoembolisation/radiofrequency 
ablation of hepatic tumors 
TIPS / surgical porto-systemic shunt 
Hepatectomy or liver transplantation 
Splenectomy 









Surgery of the portal tract 
Endothelial injury due to cytostatics (cisplatin, 
cyclophosphamide, methotrexate, 5-fluorouracil) or 
radiation therapy 





Acute or chronic pancreatitis 
Tuberculous lymphadenitis 
Inflammatory bowel diseases (Crohn’s disease, 
ulcerative colitis) 
Hepatic hydatid cyst 






Choledochal cyst  
Retroperitoneal fibrosis  
Abdominal trauma  
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Portal vein malformations  
 
in children with polimalformation 
Cardiovascular diseases Budd-Chiari syndrome 
Sinusoidal obstruction syndrome 
Constrictive pericarditis 
Tricuspid insufficiency 
Tumour of the right atrium 
Table 2. Local conditions associated with high risk of PVT 
In patients with liver cirrhosis the incidence of PVT is reported to be between 6 and 17%, 
with a higher incidence in more advanced stages of the liver disease. The association 
between liver cirrhosis and hepatocellular carcinoma increases the incidence of PVT over 
44%. Additional attention should be paid in cirrhotic patients with underlying 
prothrombotic condition due to the non-specific decrease in the plasmatic level of 
coagulation inhibitors even in well-compensated liver cirrhosis. In a recent study it was 
showed that patients with chronic liver diseases, especially liver cirrhosis, have an increased 
relative risk of venous thromboembolism, contradicting the classical hypothesis of 
autoanticoagulation in cirrhotic patients (Søgaard et al., 2009). This procoagulant status was 
scientifically related to prohemostatic changes of the coagulation factors recorded in chronic 
liver diseases: elevated levels of factor VIII and von Willebrand factor concomitant with low 
levels of protein C, protein S, antithrombin-III, plasminogen and ADAMTS-13 (a naturally 
occurring plasma metalloprotease that limits in vivo functions of von Willebrand factor on 
platelets). 
Hepatocellular carcionoma and pancreatic cancer are the most frequent abdominal 
malignancies associated with PVT through a compression/invasion/hypercoagulability 
mechanisms. Hormonal factors might also play a role in this process, especially in men 
(Bick, 1992). 
Primary myeloproliferative diseases (especially polycytemia vera and essential 
thrombocythemia) are the most often cause of PVT when cirrhosis or cancer is excluded. In a 
recent study the incidence of myeloproliferative disorders are estimated to be found in 37% 
of patients with non-cirrhotic/non-malignant PVT (Kiladjian et al., 2006). These diseases are 
often asymptomatic at the moment of PVT diagnose and therefore a bone marrow biopsy is 
required. Recently the discovery of the V617F mutation of the Janus kinase 2 (JAK2) in 
patients with myeloproliferative disorders has been facilitating the diagnosis. JAK2 
mutation it has been identified in 95% of patients with polycythemia vera and in 50 to 60% 
of patients with essential thrombocythemia. Thus, JAK2 mutation it is now recommended 
by WHO as a major diagnostic criterion for myeloproliferative disorders (Tefferi et al., 2007). 
In a study on 74 women with essential thrombocythemia the incidence of thrombosis was 
18%, of which major thrombotic episodes were found in 7% (Tefferi et al., 2000). In another 
retrospective study of 102 patients with myeloproliferative disorders, the rate of 
thromboembolic complications in patients with polycythemia vera was 16.7%, 13.8% in 
patients with myelofibrosis and 7.5% in patients with essential thrombocythemia 
(Brodmann et al., 2000). The cytoreductive therapy with hydroxyurea and supplemental 
phlebotomy when necessary significantly reduced the risk of thrombosis when compared to 
control group treated with phlebotomy alone. 
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The algorithm proposed by AASLD in 2009 for the identification of the PVT etiology is 
presented in the next table. 
 
1. Check first for cirrhosis, cancer of the abdominal organs and an inflammatory focus 
in the abdomen based on initial CT scan and sonography followed by additional 
procedures, as appropriate 
2. Check for multiple, concurrent risk factors for thrombosis, in all patients without 
advanced cirrhosis or cancer 
3. Do not rule out a diagnosis of myeloproliferative disease solely on the basis of 
normal or low peripheral blood cell counts 
4. When coagulation factor levels are decreased, consider low levels of protein C, 
protein S or antithrombin as a possible consequence of liver dysfunction; consider 
inherited deficiency when screening of a first-degree relative is positive 
Table 3. Algorithm for investigating the cause of PVT (DeLeve et al., 2009) 
4. Pathophisiology 
Portal vein thrombosis is the main cause of presinusoidal portal hypertension. Frequently 
the initial placement of the thrombus is in the portal vein trunk but sometimes it is the result 
of the extension of a thrombus located on the intrahepatic branches of the portal vein or 
from the splenic vein. According to the location and extension of the thrombus, a grading 
system was proposed for a better evaluation of the disease prognosis (Naonami et al., 1992).  
 
Grade of PVT Thrombus description 
1 Occlusion of intrahepatic portal vein branches 
2 Occlusion of right or left portal vein main branches 
3 Partial occlusion of the portal vein trunk 
4 Complete occlusion of the portal vein trunk 
Table 4. PVT grading system 
As a limited form of PVT, the term of “obliterative portal venopathy” was proposed in order 
to describe the thrombosis of intrahepatic portal vein branches in the absence of liver 
cirrhosis, inflammation or hepatic neoplasia (Cazals-Hatem et al., 2011). 
Within days after the acute thrombosis of the portal vein, a cavernous transformation is 
taking place as a result of small varices proliferation around the former portal vein 
concomitant with a recanalisation of the thrombus through a neoangiogenesis process. The 
result is a spongy, tendril-like convolution of small vessels developed in the area of porta 
hepatis in order to compensate and by-pass the obstruction of the blood flow. Additionally, 
the reduced venous blood supply may be compensated by increasing arterial perfusion, 
which is documented by Doppler ultrasonography. 
Chronic portal hypertension and fibroblasts activation inside the cloth leads to the 
development of a network of tortuous small vessels inside and around the former portal 
vein acting like a by-pass for the stenotic segment of the portal vein – the so-called portal 
cavernoma. This process starts from the moment of the acute thrombosis and evolves over 
the next weeks and months together with the development of porto-portal and porto-
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systemic collaterals until equilibrium is established between prestenotic and poststenotic 
segment of the portal vein. Moreover, the development of porto-systemic collaterals may 
lead to a deterioration of the portal encephalopathy. 
The natural history of PVT is still unclear, but two possible mechanisms can be involve in 
the asymptomatic status of the patients: one of them might be the flux augmentation in the 
hepatic artery as a compensation of the decreased flow in the portal vein; the second one 
involves the cavernous transformation with fast development of a tortuous network of 
collateral veins with periportal distribution around biliary ducts, gallbladder, gastric 
antrum, duodenu and pancreas (Henderson et al., 1992).  
PVT and development of a portal cavernoma determines a prehepatic portal hypertension 
with an elevated blood pressure in the obstructed splanhnic territory with hepatopetal 
collateral network, condition known as cavernoma (Ohnishi et al., 1984). As a consequence 
of PVT with cavernous transformation the portal biliopathy can develop (Perlemuter et al., 
1996). Another consequence might be a hyperkinetic status with higher cardiac output and 
lower vascular resistance due to portal obstruction and to portal-systemic collateral 
circulation (Ohnishi et al., 1984).  
5. Clinical features 
Clinical presentation always depends on the onset and the extent of the portal thrombosis as 
well as of the development of collateral circulation. 
5.1 Acute PVT 
In acute PVT patients can complain of abdominal pain, nausea, vomiting, fever, diarrhoea 
and haematochezia – symptoms due to intestinal congestion and ischemia. If venous 
obstruction is not quickly controlled, some severe complications might occur: enteral 
perforation, septic shock, peritonitis and exitus due to multiorgan failure. The physical 
examination reveals splenomegaly in almost all cases, whereas ascites is present before the 
onset of collateral circulation, caused by intestinal venous stasis (Kocher & Himmelmann, 
2005; Ponziani et al., 2010). 
5.2 Chronic PVT 
Usually asymptomatic, the clinical presentation for PVT is almost always 
hematemesis/melaena due to variceal bleeding. Abdominal pain is not present commonly 
unless the extension of the PVT into the mesenteric branches causes mesenteric ischemia. An 
episode of gastrointestinal bleeding is often reported as the first presenting symptom in 
about 20%-40% of cases (Hoekstra & Janssen 2009), taking into account that in patients with 
cirrhosis and PVT the risk for variceal bleeding is estimated to be more than 80-120 times 
higher than in cases without cirrohsis (Condat et al, 2001). Ascites and encephalopathy are 
rare events and only transient. They are more frequent after an episode of gastrointestinal 
bleeding or might be associated with renal failure or sepsis especially in older patients 
(Sobhonslidsuk & Reddy, 2002).  
In pylephlebitis patients usually features high fever and chills associated with painful liver 
at clinical examination.  
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systemic collaterals until equilibrium is established between prestenotic and poststenotic 
segment of the portal vein. Moreover, the development of porto-systemic collaterals may 
lead to a deterioration of the portal encephalopathy. 
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the asymptomatic status of the patients: one of them might be the flux augmentation in the 
hepatic artery as a compensation of the decreased flow in the portal vein; the second one 
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collateral veins with periportal distribution around biliary ducts, gallbladder, gastric 
antrum, duodenu and pancreas (Henderson et al., 1992).  
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lower vascular resistance due to portal obstruction and to portal-systemic collateral 
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and haematochezia – symptoms due to intestinal congestion and ischemia. If venous 
obstruction is not quickly controlled, some severe complications might occur: enteral 
perforation, septic shock, peritonitis and exitus due to multiorgan failure. The physical 
examination reveals splenomegaly in almost all cases, whereas ascites is present before the 
onset of collateral circulation, caused by intestinal venous stasis (Kocher & Himmelmann, 
2005; Ponziani et al., 2010). 
5.2 Chronic PVT 
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hematemesis/melaena due to variceal bleeding. Abdominal pain is not present commonly 
unless the extension of the PVT into the mesenteric branches causes mesenteric ischemia. An 
episode of gastrointestinal bleeding is often reported as the first presenting symptom in 
about 20%-40% of cases (Hoekstra & Janssen 2009), taking into account that in patients with 
cirrhosis and PVT the risk for variceal bleeding is estimated to be more than 80-120 times 
higher than in cases without cirrohsis (Condat et al, 2001). Ascites and encephalopathy are 
rare events and only transient. They are more frequent after an episode of gastrointestinal 
bleeding or might be associated with renal failure or sepsis especially in older patients 
(Sobhonslidsuk & Reddy, 2002).  
In pylephlebitis patients usually features high fever and chills associated with painful liver 
at clinical examination.  
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Physical examination might be completely normal but, sometimes, cholestasis, cholangitis, 
choledocholithiasis, cholecystitis might occur, configuring the so-called “portal biliopathy”. 
6. Biologic and imaging studies 
Liver laboratory test are usually normal or characteristic for the underlying liver disease. A 
cholestatic syndrome can develop in PVT associated with portal biliopathy and the 
ERCP/MRCP frequently reveals a false image of cholangiocarcinoma due to the external 
compression of the common bile duct by the tortuous vessels of the cavernoma. In case of 
pylephlebitis blood culture usually reveals Bacteroides species and special attention should be 
paid for the identification of the abdominal origin of the infection. 
Beside the eso-gastric varices revealed by the upped digestive endoscopy, other collateral 
venous circulation can develop in the gallbladder, duodenal, jejunal or rectal walls.  
The abdominal ultrasound with Doppler/power-Doppler examination is the investigation 
of choice in PVT diagnose (sensitivity over 90%). It reveals the presence of the hypo- or 
hyperechoic material (depending on the age of the thrombus) inside the portal lumen. The 
examiner must bear in mind that frequently a difficult-to-identify portal vein suggests an 
old PVT. Additionally, a study from 2009 revealed that portal flow velocity below 15cm/s is 
an important predictive factor for PVT development (Søgaard et al., 2009). 
 
Fig. 1. Patient M.I. 47 years old diagnosed with ET – Doppler ultrasound revealing multiple 
small venous vessels replacing the former portal vein. 
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Fig. 2. Patient M.I. – Doppler ultrasound showing an old (hyperechoic) thrombus occluding 
the portal vein. 
The next step in the PVT diagnose algorithm is the magnetic resonance angiography with 
better results than the CT-scan in identifying the characteristic changes involving the portal 
trunk. 
 
Fig. 3. Patient M.I. - CT scan with i.v. contrast revealing hypodense thrombus and portal 
cavernoma: heterogonous mass at the level of the portal vein due to cavernouse 
transformation; homogeneous splenomegaly. 
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Contrast enhanced ultrasonography is indicated for a better visualization of the thrombus, 
in differentiating between benign and malignant thrombosis or for the disclosure of 
cavernous transformation of the portal vein. When differentiating between benign and 
malignant thrombosis the absence of contrast inside the thrombus is suggestive for benign 
cloth while contrast enhancement of the thrombus is highly suggestive for neoplastic 
invasion of the portal vein. 
Endoscopic ultrasound was recently added to the imaging armamentory showing a higher 
sensitivity and specificity than conventional ultrasound and CT/MR-scan in detecting 
small, non-occlusive thrombi and incipient malignant invasion of the portal and splenic 
veins.  
The portal venography can be useful before surgical treatment is intended. 99mTc-DTPA 
(diethylenetriamine pentaacetic acid) scintigraphy reveals only the arterial peak with the 
absence of the portal peak on the time-activity curve. 
 
Fig. 4. Patient M.I. - Coronal MRI T2 weighted FRFSE fat-sat depicting portal cavernoma: 
dilated portal vein with heterogeneous signal due to the cavernous transformation. 
Associated homogeneous splenomegaly 14 cm diameter. 
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Fig. 5. Coronal MRI T2 weighted fat-sat of the same patient. The permeable lumen having a 
thread-like hypersignal on T2 weighted image, in the center of the portal vein along with 
dilated, partially thrombotic, portal vein. 
 
Fig. 6. The same case – axial T2 weighted fat-sat. In addition to the changes of the portal vein 
the image reveals homogeneous splenomegaly; dilated, partially dilated splenic vein; portal 
type collateral venous flow. 
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Fig. 7. The same case – axial T1 weighted fat-sat with i.v. contrast. Cavernous transformation 
of the portal vein with contrast enhancement of the fibrotic thrombi. The central thread-like 
permeable lumen shows a reduced flow signal. 
 
Fig. 8. The same case – coronal T1 weighted fat-sat with contrast. Same changes as in figure 7. 
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Fig. 9 and 10. The same case – angio-MRI sequence. Inhomogeneous signal of the portal vein 
with chronic thrombosis. 
 




Fig. 7. The same case – axial T1 weighted fat-sat with i.v. contrast. Cavernous transformation 
of the portal vein with contrast enhancement of the fibrotic thrombi. The central thread-like 
permeable lumen shows a reduced flow signal. 
 
Fig. 8. The same case – coronal T1 weighted fat-sat with contrast. Same changes as in figure 7. 
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Fig. 9 and 10. The same case – angio-MRI sequence. Inhomogeneous signal of the portal vein 
with chronic thrombosis. 
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7. Diagnosis algorithm 
The algorithm for PVT diagnose proposed by AASLD in 2009 is presented in the next table. 
 
Acute thrombosis Chronic thrombosis 
1. Consider a diagnosis of acute PVT 
in any patient with abdominal pain 
of more than 24 hours duration, 
whether or not there is also fever or 
ileus 
1. Consider a diagnosis of chronic 
PVT in any patient with newly 
diagnosed portal hypertension 
2. If acute PVT is suspected, CT 
scan, before and after injection of 
vascular contrast agent, should be 
obtained for early confirmation of 
diagnosis. If CT scan is not rapidly 
available, obtain Doppler- 
sonography  
2. Obtain Doppler-sonography, then 
either CT scan or MRI before and 
after a vascular contrast agent to 
make a diagnosis of chronic PVT 
3. In patients with acute PVT and 
high fever and chills, septic 
pylephlebitis should be considered, 
whether or not an abdominal source 
of infection has been identified, and 
blood cultures should be routinely 
obtained 
3. Base the diagnosis on the absence 
of a visible normal portal vein and 
its replacement with serpiginous 
veins 
4. In acute PVT, the possibility of 
intestinal infarction should be 
considered from presentation until 
resolution of pain. The presence of 
ascites, thinning of the intestinal 
wall, lack of mucosal enhancement 
of the thickened intestinal wall,or 
the development of multiorgan 
failure indicate that intestinal 
infarction is likely and surgical 
exploration should be considered 
 
Table 5. PVT diagnose algorithm (DeLeve et al., 2009) 
8. Treatment 
In patients with PVT due to septic conditions (cholangitis, diverticulitis, appendicitis, 
cholecystitis, umbilical vein infection, pylephlebitis, liver abscesses etc) the prompt initiation 
of broad-spectrum antibiotic association therapy leads to an efficient repermebilisation of 
the portal vein within days. 
If patient is diagnosed in the recent phase of the PVT (hypoechoic aspect on the ultrasound 
examination together with blood flow deviation and flux acceleration on Doppler 
examination) anticoagulant therapy is indicated in order to prevent the total obstruction of 
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the portal vein and the cavernous transformation. Standard heparin or LMWH derivates are 
initially used followed by oral dicumarinic anticoagulants in order to obtain an INR 
between 2 and 2,5 with an efficient repermeabilisation in over 80% of cases in the next six 
months (Valla et al., 2002). As for the peripheral vein thrombosis, the oral anticoagulant 
therapy is considered to be mandatory for minimum three months and usually is indicated 
for at least six months. Chronic, indefinite oral anticoagulation is recommended in patients 
with identified hypercoagulability associated diseases or in presence of thrombus extension 
into the mesenteric vein.  
However, additional concern has been rise over vitamin K antagonists indication in cirrhotic 
patients due to plasmatic low protein C levels. As protein C is a vitamin K-dependent factor 
and treatment with vitamin K antagonist may further reduce the plasmatic levels of this 
anticoagulant protein, the increasing risk for venous thrombosis has been issued. Newly 
developed direct thrombin inhibitors and inhibitors of activated factor X (e.g. dabigatran, 
rivaroxaban, apixaban) are considered to be more attractive alternatives to vitamin K 
antagonists due to their null influence over protein C levels (Franchini & Mannucci, 2009). 
In addition to their oral administration they have the advantage of not requiring regular 
laboratory monitoring (such as INR) (Tripodi & Mannucci, 2011). 
Concern has been rise also over the safety of chronic anticoagulant therapy in patients with 
esophageal varices. The few clinical studies addressing this issue (Condat et al., 2001) 
revealed no significant increase in risk and severity of variceal bleeding.  
In initially acute phases, thrombolytic medication (e.g. streptokinase, tPA, alteplase) can be 
safely initiated especially in patients associating mesenteric ischemia due to thrombus 
extension in the upper mesenteric vein (Malkowski et al., 2003).  
In patients diagnosed with old age thrombus or cavernous transformation of the portal vein 
the anticoagulant treatment is not indicated due to the lack of efficiency and the associated 
risk of bleeding.  
The major complication of PVT is upper digestive bleeding originating from the eso-gastric 
varices, with a significant lower mortality rate in patients without liver cirrhosis (aprox. 5%) 
than in patients with cirrhosis (between 30 and 70%) (Jing-Tong et al., 2005). The endoscopic 
procedures (band ligation/sclerotherapy) are the first-line treatment indicated in these cases 
with multiple sessions until the occlusion of the varices. A special attention should be paid 
when indicating vasoconstrictive agents (e.g. glipresin, terlipresin) due to the possibility of 
inducind extended intestinal ischemia. Associated oral medication (nonselective beta-
blockers +/- long-acting nitrates) prevents the recurrent bleeding. In refractory cases of 
variceal bleeding and in gastric valices TIPS placement is considered. Malignant portal vein 
invasion/thrombosis can be safely managed with percutaneous stenting.  
More invasive surgical treatment (mesocaval/splenorenal shunts, eso-gastric 
devascularization) may be necessary in patients with uncontrolled bleeding.  
In children it has been recommended the mesenteric-to-left portal vein bypass with very 
good results in term of rebleeding prevention and improvement of cognitive function. 
Initially considered as contraindication for liver transplantation, the complete PVT is now 
considered to be just a relative contraindication but only in case the superior mesenteric vein 
is permeable. Partial PVT can be managed by thrombectomy or by-pass techniques. 
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Portal biliopathy is another potential complication developing in the evolution of PVT with 
cavernous transformation. It consists in multiple, successive stenosis involving the common 
bile duct and the hepatic duct as a result of extrinsic compression and/or ischemic fibrosis 
of the biliary tract. In symptomatic patients (cholangitis, cholecystitis, biliary stones in the 
CBD, secondary biliary cirrhosis) the portal biliopathy can be addressed with 
sphincterothomy, stone extraction, stricture dilatation and biliary stanting together with a 
porto-systemic shunt in order to reduce the external compression of the biliary tract.  
From the systemic conditions associated with portal cavernoma, the myeloproliferative 
syndrome is by far the most frequent one (37% of patients with non-cirrhotic non-malignant 
PVT) (Kiladjian et al., 2006). To prevent thrombotic complication in chronic 
myeloproliferative disorders, platelet-lowering agents are used to address the 
thrombocitemia-associated risk. Hydroxyurea, a ribonucleotide reductase inhibitor with 
myelosuppressive action, is the first line indication administered on a 500mg PO bid 
regimen. A platelet-specific lowering agent (Anagrelide) is available on a 0,5mg PO tid 
regimen for the patients with intoleration to hydroxyurea. For a more efficient 
myelosuppressive action Interferon-alpha is recommended on a 5MU SC tiw regimen. 
Despite their leukemogenic action, radiophosphorus (32P) and alkylating agents (e.g. 
chlorambucil) may be useful as backup regimens in case of recurrent disease (Tefferi et al., 
2001). The goal of platelet-lowering medication is to maintain the platelet level under 
400000/mm3 in the high-risk patients (Regev et al., 1997; Storen & Tefferi, 2001).  A more 
aggressive approach like bone marrow transplantation should be considered only in 
exceptional cases. 
9. Prognosis 
In the absence of liver cirrhosis and neoplasia the development of portal cavernoma is 
usually asymptomatic until the first variceal bleeding and has a better prognosis in 
comparison with variceal bleeding caused by cirrhosis (Janssen et al., 2001).  
Except the variceal bleeding, the natural history of portal cavernoma is unremarkable until 
the development of two other complications: intestinal ischemia (due to extension of the 
thrombus in the mesenteric vein) and portal biliopathy (common bile duct dilation with 
cholestatic syndrome). 
Although ET usually carries the best prognosis among the MPD, portal vein thrombosis was 
identified as a risk factor for poor survival, which appears to be the result of increased 
mortality from acute leukemic or myelofibrotic transformation and hepatic failure (Gangat 
et al., 2006). 
10. References 
Amitrano L, Guardascione MA, Brancaccio V, Margaglione  M, Manguso F, Iannaccone L, 
Grandone E, Balzano A. Risk factors and clinical presentation of portal vein 
thrombosis in patients with liver cirrhosis. J Hepatol, 2004;40:736-741 
Portal Vein Thrombosis with Cavernous  
Transformation in Myeloproliferative Disorders: Review Update 
 
81 
Bayraktar Y, Harmanci O. Etiology and consequences of thrombosis in abdominal vessels. 
World J Gastroenterol, 2006;12:1165-1174 
Bick RL. Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost, 
1992;18:353-372 
Brodmann S, Passweg JR, Gratwohl A. et al. Myeloproliferative disorders: complications, 
survival and causes of death. Ann Hematol, 2000;79:312–8 
Cai XY, Zhou W, Hong DF, et al. A latent form of essential thrombocythemia presenting as 
portal cavernoma. World J Gastroenterol, 2009;15(42):5368-70 
Cazals-Hatem D, Hillaire S, Rudler M et al. Obliterative portal venopathy: portal 
hypertension is not always present at diagnosis. J Hepatol, 2011;54(3):455-61 
Chawla Y, Duseja A, Dhiman RK. Review article: the modern management of portal vein 
thrombosis. Aliment PharmacolTher, 2009;30:881-89416  
Cohen J, Edelman RR, Chopra S. Portal vein thrombosis: a review. Am J Med, 1992;92:173-182 
Condat B, Valla D. Nonmalignant portal vein thrombosis in adults. Nat Clin Pract 
Gastroenterol Hepatol, 2006;3(9):505-15 
Condat B, Pessione F, Hillaire S, et al: Current outcome of portal vein thrombosis in adults: 
Risk and benefit of anti-coagulant therapy. Gastroenterology, 2001;120:490 
De Gaetano AM, Lafortune M, Patriquin H, et al. Cavernous transformation of the portal 
vein: patterns of intrahepatic and splanchnic collateral circulation detected with 
Doppler sonography. AJR Am J Roentgenol, 1995;165:1151-5 
de Suray N, Pranger D, Brenard R. Portal vein thrombosis as the first sign of a primary 
myeloproliferative disorder: diagnostic interest of the V617F JAK-2 mutation. A 
report of 2 cases. Acta Gastroenterol Belg, 2008;71(1):39-41 
DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology, 
2009;49(5):1729-64 
Diaz E, Nahon S, Charachon A et al.Thrombose portale recente regressive sous 
anticoagulants secondaire a un syndrome myeloprolifferatif latent, une mutation 
G20210A du gene de la prothrombine et un syndrome des antiphospholipides. 
Gastroenterol Clin Biol, 2001;25:549-551 
Dumortier J, Vaillant E, Boillot O, et al. Diagnosis and treatment of biliary obstruction 
caused by portal cavernoma. Endoscopy, 2003;35:446-50 
Fenaux P, Simon M, Caulier MT, et al. Clinical course of essential thrombocythemia in 147 
cases. Cancer, 1990;66(3):549-56 
Fimognari FL, Violi F. Portal vein thrombosis in liver cirrhosis. Intern Emerg Med, 
2008;3(3):213-8 
Franchini M, Mannucci PM. A new era of anticoagulants. Eur J Intern Med, 2009; 20:562-8 
Galati G, Gentilucci UV, Sansoni I, et al. A mocking finding: portal cavernoma mimicking 
neoplastic mass. First sign of myeloproliferative disorder in a patient with Janus 
kinase2 V617F mutation. Eur J Gastroenterol Hepatol, 2009;21(2):233-6 
Gangat N, Wolanskyj AP, Tefferi A. Abdominal vein thrombosis in essential 
thrombocythemia: prevalence, clinical correlates, and prognostic implications. Eur 
Jhaematol, 2006;77:327-333 
 
Portal Hypertension – Causes and Complications 
 
80
Portal biliopathy is another potential complication developing in the evolution of PVT with 
cavernous transformation. It consists in multiple, successive stenosis involving the common 
bile duct and the hepatic duct as a result of extrinsic compression and/or ischemic fibrosis 
of the biliary tract. In symptomatic patients (cholangitis, cholecystitis, biliary stones in the 
CBD, secondary biliary cirrhosis) the portal biliopathy can be addressed with 
sphincterothomy, stone extraction, stricture dilatation and biliary stanting together with a 
porto-systemic shunt in order to reduce the external compression of the biliary tract.  
From the systemic conditions associated with portal cavernoma, the myeloproliferative 
syndrome is by far the most frequent one (37% of patients with non-cirrhotic non-malignant 
PVT) (Kiladjian et al., 2006). To prevent thrombotic complication in chronic 
myeloproliferative disorders, platelet-lowering agents are used to address the 
thrombocitemia-associated risk. Hydroxyurea, a ribonucleotide reductase inhibitor with 
myelosuppressive action, is the first line indication administered on a 500mg PO bid 
regimen. A platelet-specific lowering agent (Anagrelide) is available on a 0,5mg PO tid 
regimen for the patients with intoleration to hydroxyurea. For a more efficient 
myelosuppressive action Interferon-alpha is recommended on a 5MU SC tiw regimen. 
Despite their leukemogenic action, radiophosphorus (32P) and alkylating agents (e.g. 
chlorambucil) may be useful as backup regimens in case of recurrent disease (Tefferi et al., 
2001). The goal of platelet-lowering medication is to maintain the platelet level under 
400000/mm3 in the high-risk patients (Regev et al., 1997; Storen & Tefferi, 2001).  A more 
aggressive approach like bone marrow transplantation should be considered only in 
exceptional cases. 
9. Prognosis 
In the absence of liver cirrhosis and neoplasia the development of portal cavernoma is 
usually asymptomatic until the first variceal bleeding and has a better prognosis in 
comparison with variceal bleeding caused by cirrhosis (Janssen et al., 2001).  
Except the variceal bleeding, the natural history of portal cavernoma is unremarkable until 
the development of two other complications: intestinal ischemia (due to extension of the 
thrombus in the mesenteric vein) and portal biliopathy (common bile duct dilation with 
cholestatic syndrome). 
Although ET usually carries the best prognosis among the MPD, portal vein thrombosis was 
identified as a risk factor for poor survival, which appears to be the result of increased 
mortality from acute leukemic or myelofibrotic transformation and hepatic failure (Gangat 
et al., 2006). 
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1. Introduction 
In cirrhotic patients the bleeding from esophageal varices is the most dangerous 
complication of portal hypertension and is attended with high rate of lethality. 
Endoscopic assessment of esophageal varices and the state of esophageal and stomach 
mucosa at the esophagogastroduodenoscopy presents high importance for the assessment 
of risk of their development (Coelho-Prabhu & Kamath, 2010). However, invasiveness as 
well as discomfort that are tolerated by patients during the given procedure, lead to the 
rejection from it and therefore they can’t be subjected to examination in a number of cases. 
Besides, the research might be impossible to carry out in case if the state of patient is 
grave (de Franchis et al., 2008). The investigation of hepatic venous pressure gradient, that 
reflects the portal hypertension intensity best of all haven`t been realized in the clinical 
practice up to now (Groszmann et al., 2006). Considering the above mentioned 
disadvantages of main methods, the development of additional prognostic criteria of the 
risk of esophageal varices bleeding remains the urgent problem of the internal medicine 
(Cárdenas & Ginès, 2009). 
Over the last years the greatest importance in the development of the given complication is 
placed to the endotoxemia as a result of the translocation of gram-negative bacteria from 
intestinal tube (Boursier et al., 2007). It was demonstrated that the latter presents the 
important part of the hyperdynamic circulatory status at the portal hypertension and also 
lies in the basis of hepatocellular insufficiency and brings about the haemostasis disorder in 
cirrhotic patients (Thalheimer et al., 2005). Besides, it was reported that bacteremia often 
accompanies esophageal varices bleeding (Lata et al., 2005), decreases the efficiency of the 
conservative or endoscopic therapy (Zhao et al., 2002) and bears the risk factor for recurrent 
bleeding (Brown et al., 2010). 
The aim of the research is to illustrate the appropriateness of the assessment of the bacterial 
endotoxins levels in the blood of cirrhotic patients as the method to predict the risk of 
esophageal varices bleeding. 
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2. Patients and methods 
The prospective incidence research has been carried out that covers 90 cirrhotic patients 
with portal hypertension between September 2008 and December 2010 at our clinic (The 
department of surgical diseases and urology, Chelyabinsk State Medical Academy, 
Chelyabinsk, Russia). Only patients with esophageal varices was included in the study. All 
patients underwent a detailed clinical evaluation, including blood tests, ultrasonography, 
esophagogastroduodenoscopy. Moreover the quality and quantity assessment of 
endotoxemia intensity was performed. 
2.1 Blood tests 
Hematological and biochemical work-up included measurement of hemoglobin, total 
leukocyte count, platelet count, serum concentrations of bilirubin (total and conjugated), 
protein, albumin, alanine aminotransferase and aspartate aminotrasferase. Furthermore the 
hemostatic factors of their peripheral blood, such as prothrombin time, International 
Normalized Ratio, activated partial thromboplastin time, activated recalcification time, 
soluble fibrin-monomer complexes, fibrinogen, Hageman factor dependent fibrinolysis, 
were examined. For each patient, a modified Child-Pugh score was calculated (Pugh et al., 
1973). All patients were tested for HBV-DNA, HBeAg, HBsAg, anti-HBcAg, antibodies to 
hepatitis C virus, antimitochondrial antibodies to determine the cause of liver cirrhosis. 
2.2 Ultrasound Doppler 
All patients underwent ultrasonography and the follow details were recorded: Maximum 
vertical span of the liver, nodularity of liver surface; spleen size (length of its longest axis); 
diametr of the portal and splenic veins; presence of portal-systemic collaterals; and presence 
of ascites. 
The portal vein was imaged longitudinally in the supine position, and the Doppler sample 
volume was set at the midpoint between the confluence of the splenic and superior 
mesenteric vein and the bifurcation of the portal vein at the hepatic hilus. When the sample 
point was adjusted to the center of the portal vein, the portal venous velocity was recorded 
in a quiet suspended expiration and was averaged over a few seconds. Portal venous flow 
was determined by the formula, cross-sectional area × mean velocity × 60 (Choi et al., 2003). 
The mean velocity of the splenic vein was determined using the same method as used for 
the portal vein. 
2.3 Endoscopic evaluation 
All patients underwent esophagogastroduodenoscopy for assessment of esophageal varices, 
the degree of which was defined according to the international classification offered by 
Japanese Research Society for Portal Hypertension (Japanese Research Society for Portal 
Hypertension, 1980): F0 – absent; F1 – straight; F2 – winding; F3 – nodule-beaded. 
2.4 Assessment of endotoxemia intensity 
To make the quality and quantity assessment of endotoxemia intensity their blood was 
collected into a sterile test tube without anticoagulants, it was placed into the thermostat for 
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30-40 minutes with the temperature of 37° C and then centrifugated during 15 minutes at 
3000 revolution per minute. The obtained serosity was used for analysis during 2 hours. In a 
number of case it was possible to apply cold singly and store it. 
Abacterial express-diagnostics of common endotoxin of gram-negative bacteria was 
conducted by the method of activated particles (MAP) with the test sets “MAP – Endotox 
spp.”, developed in Research center of cardiovascular surgery named after A.N. Bakulev, 
Russian Academy of Medical Sciences and Research and Production Company “Rokhat” 
(Bokeriia et al., 2007). The given method is based on immobilization of polymer chemical 
microspheres with a size of particle equal to 0,62 – 0,68 micron of monoclonal antibodies, 
subclass IqG 3 and IqG 2a, 0:111 B4 J5. The reaction accounting was maintained considering 
the degree of particle activation (DPA) in the diagnostic titer 1:8 on point-based system 
ranging from 1 to 4. 
The levels of endotoxemia is determined by means of turbidimetric test on the end point that 
serves as a variant of Limulus lysate amebocyte assay (LAL-assay), firstly described in 1968 by 
J. Levin and F.B. Bang (Levin J. & Bang F.B., 1968). Its basis is formed by the ability of Lymulus 
amebocyte lysate react with endotoxins (liposaccharides) of gram-negative bacteria in a 
specific way. The amount of bacterial endotoxin contained in the examined samples was 
determined according the pharmacopoeial techniques that were attached to the set of chemical 
reagents produced by the “LAL Center” (Moscow, Russia). The analysis was carried out on 
microtitration plates with the application of photoelectric colorimeter “Multi Scan”. The 
measurement were made at the length of wave equal to 405 millimicron. Calibration curve was 
built using three-four known concentrations of control standard endotoxin. 
2.5 Statistical analysis 
The statistical analysis of the data received was conducted with the help of program package 
“Statistica 5.5”. We calculated values M, their standard mistakes (m) and 95 % of confidence 
interval, and used non-parametric  Mann and Whitney test. Besides, we  applied Spirmen 
coefficient of rank correlation. The differences were considered to be accurate at P < 0,05. 
3. Results 
Ninety cirrhotic patients with portal hypertension were enrolled in this study, with a 
median age of 46,2 ± 20 years. There were 47 men and 43 women. Both the virus and alcohol 
were the aetiology of liver cirrhosis in 18 patients. Primary biliary cirrhosis was found in 3 
patients. It was not possible to establish the cause of disease in 51 cases. Hepatocellular 
insufficiency according to Child-Pugh score was grade A in 18 patients, grade B in 52 
patients, grade C in 20 patients. 
Esophagogastroduodenoscopy demonstrated esophageal varices of first degree (F1) in 17 
patients, of second degree (F2) in 52 patients, of third degree (F3) in 21 patients. Sixty-five 
had gastro-esophageal bleeding due to variceal rupture. Patients were divided into 3 
groups: first group (25 people) was presented by the patients without esophageal varices 
bleeding, the second group (20 people) consisted of those who had tolerated it in the 
medical background, the third group (45 people) – was made by patients in the urgent order 
with esophageal varices bleeding.  
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In the framework of both the quality and quantity assessment of endotoxemia there were 
the statistically significant differences obtained between the groups put in contrast (P < 
0,05). Thus, its intensity, determined by the method of particles activation turned out to be 
the most significant for the patients with esophageal varices bleeding, and appeared to be 
the minimal with people not suffering from such a complication (Table 1). 
 
Groups of patients 
Endotoxemia levels 
1 DPA 2 DPA 3 DPA 4 DPA 
I Without esophageal varices bleeding N = 20 N = 5 0 0 
II Esophageal varices bleeding in the medical history N = 5 N = 10 N = 5 0 
III Acute esophageal varices bleeding 0 N = 5 N = 11 N = 29 
Notice. Spirmen coefficient (R = 0,82; P < 0,05; N = 90). 
DPA - degree of particle activation. 
Table 1. Qualitative assessment of the endotoxemia intensity in cirrhotic patients with portal 
hypertension (MAP – Endotox test; DPA) 
The levels of bacterial endotoxins in the blood of patients that had arrived in the order of 
emergency varied between 4,1 to 59,1 ng/ml and was authentically higher (p<0,05) than of 
patients without or with the variceal bleeding in the medical background: from 0 to 0,8 
ng/ml and from 1,3 to 2,3 ng/ml, respectively (Table 2). 
 
Groups of patients 
Without esophageal 
varices bleeding 
Esophageal varices bleeding 
in the medical history 
Acute esophageal 
varices bleeding 
I II III 
0,5 ± 0,1 
N = 25 
1,9 ± 0,1 
N = 25 
P(I – II)* 
32,1 ± 3,0 
N = 45 
P(I - III)* 
P(II - III)* 
Notice: P()* - difference between contrast groups are statistically significant. 
U-criterion of Mann and Whitney applied; P < 0,05. 
LAL-assay - Limulus lysate amebocyte assay. 
Table 2. The bacterial endotoxins levels in the blood of cirrhotic patients with portal 
hypertension (ng/ml) (LAL-assay), M ± m 
With 13 patients without the previous record of variceal bleeding, the latter appeared in a 
period of 3-4 days later from the moment of planned hospitalization. In all cases there was 
the increased levels of bacterial endotoxins in the blood recorded as early as the very 
moment of admittance to hospital (8,3 ± 3,9 ng/ml), at the time of bleeding it increased to 
38,7 ± 4,6 ng/ml (p<0,05), and 5-7 days later after achieving the effective hemostasis it 
decreased to 3,2 ± 1,6 ng/ml (P < 0,05). 
Prognostic Significance of the Bacterial Endotoxins Levels  
in the Blood of Cirrhotic Patients in the Evaluation of the Risk of Esophageal Varices Bleeding 89 
Among the patients admitted with acute esophageal varices bleeding, 16 of them had its 
early recurrence in the upcoming 24 hours after the primary hemostasia. They all had a high 
levels of bacterial endotoxins in blood (36,2 ± 6,7 ng/ml) which having decreased down to 
6,8 ± 2,5 ng/ml (P < 0,05) against the background of conservative therapy, sharply rose to  
39,3 ± 6,3 ng/ml at the blooding recurrence. When the stable hemostasis had been achieved 
its values decreased down to 3,1 ± 1,1 ng/ml (P < 0,05). 
Presuming that the minimal concentration of bacterial endotoxins in the blood of those who 
suffer from the acute esophageal varices bleeding made 4,1 ng/ml and the maximal value 
among those who were admitted to hospital  routinely comprised 2,3 ng/ml, we had the 
opportunity to determine the intervals of values endotoxemia according to the degree of 
esophageal varices bleeding risk. Considering the fact that the levels of bacterial endotoxins 
in the blood of the selected patients (90 people) ranging from 0 to 4,0 ng/ml determed the 
low possibility of complication occurrence and the values above 4,1 ng/ml confirmed the  
high risk, the diagnostic criterion 4,0 ng/ml turned out to be the best one. The sensitivity 
and specificity was 90 % and 85 % respectively. 
From 45 patients that were admitted to hospitals with acute bleeding, only 2 patients had 
the esophageal varices of the first degree whereas 23 and 20 patients were found to suffer 
from the esophageal varices of the second and third degree correspondingly. On the 
opposite, among 45 patients that were hospitalized routinely the esophageal varices of the 
first degree was identified in 15 cases; of the second degree – found in 26 patients, and as for 
the third – only with 4 of them.  
At the quality assessment of endotoxemia in case of all the patients involved in research, 
there is the credible correlation (P < 0,05) between its parameters, the degree of esophageal 
varices and the bleeding occurrence. Thus, if in case of patients with acute bleeding with 
esophageal varices mainly of 2-3 degrees (43 people), the intensity of endotoxemia seemed 
significant, its intensity was insignificant among the patients with esophageal varices of 1-2 










F1 10 4 1 0 
F2 15 10 1 0 
F3 0 1 3 0 
Yes 
F1 0 1 1 0 
F2 0 4 10 9 
F3 0 0 0 20 
Notice. Spirmen coefficient (R = 0,87; P < 0,05; N = 90). 
MAP - method of activated particles. 
DPA - degree of particle activation. 
Table 3. The correlation between the intensity of endotoxemia in cirrhotic patients, the 
degree of esophageal varices and the availability of acute bleeding from them (MAP – 
Endotox test; DPA) 
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In order to carry out the correlation analysis of bacterial endotoxins levels in the blood, the 
degree of esophageal varices and the acute bleeding occurrence the patients were divided 
into four subgroups. The patients with esophageal varices of the first degree without acute 
bleeding made subgroup A. Since the intensity of endotoxemia in the patients with 
esophageal varices of the second and the third degree, admitted without the mentioned 
complication was similar and a number of the latter minor we combined into one subgroup 
B. For this very reason the patients were combined suffering from esophageal varices of the 
first and second degree, hospitalized with acute bleeding (subgroup C). Those who were 
admitted in the emergency order with the same diagnosis as well as the esophageal varices 
of the third degree made subgroup D. 
The data received corresponded to the quality values and were statistically accurate (P < 
0,05). There was also the direct correlation dependence observed between the levels of 
bacterial endotoxins in the blood, the degree of esophageal varices and the availability of 
acute bleeding from them. Thus, the endotoxemia was least pronounced in the patients of 
subgroup A: ranging from 0 to 0,8 ng/ml and mostly identified in subgroup D: from 29,4 to 
59,1 ng/ml. In subgroups B and C: from 0,9 to 2,3 ng/ml and from 9,8 to 19,9 ng/ml, 
correspondingly (Table 4). 
 
Groups of patients 
Without acute esophageal varices bleeding With acute esophageal varices bleeding 
Subgroup А Subgroup B Subgroup C Subgroup D 
0,03 ± 0,01 
N = 15 
1,2 ± 0,8 
N = 30 
P(A-B)* 
14,9 ± 5,0 
N = 25 
P(A-C)*; P(B-C)* 
34,3 ± 4,7 
N = 20 
P(A-D)*; P(B-D)*; 
P(C-D)* 
Notice: P()* - difference between the contrast subgroups are statistically significant. U-criterion of Mann 
and Whitney applied; P < 0,05. 
LAL-assay - Limulus lysate amebocyte assay. 
Table 4. The correlation between the bacterial endotoxins levels in the blood of cirrhotic 
patients, the degree of esophageal varices and the availability of acute bleeding from them 
(ng/ml) (LAL-assay), M ± m 
4. Discussion 
In cirrhotic patients the bleeding from esophageal varices is a serious and  potentially life-
threatening complication of portal hypertension. The risk of bleeding can be reduced nearly 
by half by appropriate prophylactic therapy (de Franchis, R. & Baveno V Faculty, 2010), 
which has prompted the identification of noninvasive indicators of esophageal varices, 
aimed to decrease the need for screening endoscopy, which is currently recommended in all 
cirrhotic patients at the time of diagnosis. Low platelet count, splenomegaly, a portal vein 
diametr on ultrasound ≥ 13 mm, a high Child-Pugh score, low ptothrombin activity, the 
presence of spider angiomas, and a low platelet to spleen ratio have been the parameters 
most frequently associated with presence varices and the risk of bleeding from them 
(Berzigotti A. et al., 2008). Endotoxaemia is frequently found in cirrhotic patients, even in 
the absence of any signs of sepsis. Thus higher endotoxins concentrations are found in  
peripheral blood of cirrhotics than in normal subjects with a statistically significant gradient 
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between portal and peripheral blood, highlighting the role of the bowel as the source of 
endotoxins. Both peripheral and portal levels of endotoxaemia are correlated with the 
severity of liver disease which is a more important predictor of high plasma endotoxins 
concentrations than portosystemic shunting or portal hypertension (Lin R.S. et al., 1995). 
Further, plasma levels of the bacterial endotoxins in cirrhotic patients were significantly 
positively associated with hepatic venous pressure gradient, wedge hepatic venous 
pressure, and hepatic sinusoid resistance (Lee K.C., 2010). 
We evaluated of the bacterial endotoxins levels in the blood of cirrhotic patients as the 
method to predict the risk of esophageal varices bleeding. Our study detected that the 
highest manifestation of endotoxemia in cirrhotic patients is observed in case of acute 
bleeding from the esophageal varices. With the patients that had bleeding in the medical 
background, its values exceed the values of those who hadn`t this complication.  
While the bacterial endotoxins levels in the blood of cirrhotic patients ranging from 0 to 4,0 
ng/ml determines the low possibility of bleeding occurrence, the values exceeding 4,1 
ng/ml demonstrate its high risk probability. Accordingly, diagnostics criterion of 4,0 ng/ml 
appears to be the most adequate and relevant one. The sensitivity and specificity was 90 % 
and 85 % respectively. 
Moreover we found that the intensity of endotoxemia with cirrhotic patients adequately 
correlate with the degree of esophageal varices and the bleeding occurrence in them.  
5. Conclusion 
Notwithstanding the fact that the main predictor of the risk of esophageal varices bleeding 
in cirrhotic patients is endoscopic assessment of their intensity according to data of 
esophagogastroduodenoscopy, in case if its fulfillment appears to be impossible (if a patient 
rejects the research being made, if the condition of a patient is grave and so on) the detection 
of the bacterial endotoxins serum levels can serve as the alternative prognostic index. 
Further validation of the results will be achieved through long-term follow-up of the 
patients and a larger number of studied subjects. 
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1. Introduction 
Liver microcirculation means that the blood circulation is sinusoids as a center, from the end 
branch of portal vein and hepatic artery through sinusoids to central vein in the liver. Liver 
microcirculation has two characteristics. One character is there are two import systems from 
portal vein and hepatic artery. Another is sinusoids with unique structure. All blood vessels 
which diameters are less 300m are part of microcirculation system. These vessels are able 
to regulate the blood flow and distribution.1 
Sinusoids are a capillary bed which is major place for regulation of blood and exchange of 
material in the liver. Sinusoids are constituted by microvasculature, sinusoid endothelial 
cells（SEC）, Kupffer cells （KC）and hepatic stellate cells（HSC）. 2 SEC and HSC are 
considered as cellular factors for regulation of sinusoids blood flow. HSC is located in 
perisinusoids with functions include storing Vitamin A, and controlling the diameter and 
blood flow of sinusoids by its pseudopods around sinusoids.3 SEC, KC and HSC all have 
contractility because they contain fiber, microvasculature and contractile protein.2  
The liver complex functions, which are biological synthesis, metabolism, detoxify and host 
defense, are tightly dependent perfect liver microcirculation.4 It is showed that failure of liver 
microcirculation is a general pathological alteration in chronic hepatitis and liver cirrhosis 
because changed construction of microvasculature, capillarization of sinusoid (the collagen is 
filled in perisinusoids) and compression of fibrous tissue. Generally, stenosis of sinusoid will 
lead to increase of resistence, decrease of blood flow rate and flow volume, and formation of 
portal hypertension. It is indicated that after hepatitis B virus infection, platelets were recruited 
to the liver, and their activation correlated with severely reduced sinusoidal microcirculation, 
delayed virus elimination and increased immunopathological liver cell damage.5 
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In normal condition, liver microcirculation is regulated by 3 ways. (1) SEC is a regulator of 
blood flow in the liver. The liver injury will lead to injury of SEC, reduction of fenestrae in 
SEC, straitens of sinusoid within accumulation of erythrocytes and formation of 
microthrombus. Injury and necrosis of SEC are major causes of disorder of liver 
microcirculation. (2) KC can also regulate the liver blood flow by its pseudopod inner of 
sinusoid. Actived KC may lead stenosis of sinusoid due to conglutination of leukocytes.6 (3) 
HSC is able to directly regulate contraction of sinusoids in normal liver. Active HSC has 
stronger character of contraction with increased concentration of Ca2+. HSC is just located in 
the site of sinusoid contraction. Propotional relationship has been proved between 
contraction of HSC and activation of HSC both in vivo and in vitro.7,8  Many chemical 
compounds are as inductors to induce contraction of HSC. They are included Endothelin-1 
(ET-1), Angiotensin II and vasopressin. ET-1 is concerned a strongest cytokine to induce 
contraction of HSC. Perfusion of ET-1 through portal vein leads to contraction of sinusoids. 
However, the compounds of NO, CO and adrenal medullar hormone have the functions to 
against ET-1-stimulated contraction of HSC. Contraction of active HSC (myofibroblast cell), 
which locates in fibrous septum in cirrhotic liver, can change construction of hepatic lobule 
and lead to increase resistens of microcirculation in the liver.  
Once failure of microcirculation in the liver, some symptoms and signs of patient are similar 
“blood stasis” in Traditional Chinese Medicine. Those are twinge in inside right flank or rib, 
hepatomegaly or splenomegaly, dim complexion, accompanied with spider nevi and liver 
palms, deep-red tongue, ecchymosis, taut or thready pulse. Some Chinese herb medicine, 
which is able to promote blood circulation to remove blood stasis, can prevent esophageal 
variceal bleeding on cirrhotic patients with portal hypertension, improve liver 
microcirculation and decrease portal hypertension through treating cirrhotic rats in vivo and 
inhibit contraction of active HSC in vitro in resent 10 years.9 
Fuzheng Huayu Capsule (FZHYC), a traditional Chinese medicine recipe, has demonstrated 
the effect of anti-fibrosis and reduced portal vein pressure in patients with chronic hepatitis 
B.10 Fuzheng means supporting the healthy energy. Huayu means dispersing blood stasis. 
The recipe is composed by 6 herbs those are Dan Shen (Radix Salviae Miltiorrhizae), Chong 
Cao (Paecilomyces hepiali Chen & Dai), Tao Ren (Semen Persicae), Jiao Gu Lan (Gynostemma 
pentaphyllum), Song Hua Fen (Pinus armandii Franch) and Wu Wei Zi (Fructus Schisandrae 
Chinensis). FZHYC has been used in numerous studies in China and has been found to have 
a satisfactory prophylaxis effect on the chronic liver injury and hepatic fibrosis in rats and 
humans. In addition, it enhances hepatic fibrolysis.11 
2. The clinical research 
2.1 Aims 
To elucidate the role of FZHYC in the prevention of esophageal variceal bleeding on 
cirrhotic patients with portal hypertension.  
2.2 Methods 
In a multi-center randomized and placebo-controlled trial, 146 cirrhotic patients, whose age 
range was between 18 and 70 years old, with esophageal varices were enrolled. According 
to the degree of esophageal and gastric varices, patients were stratified as 2 levels: small 
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level, and moderate and severe level. The randomization code was generated by SAS 
software for each subject. For patients with small varices, the trial was double blinded. The 
patients were randomly assigned to 2 groups: Patients were treated with FZHYC in FZHYC 
group or received placebo in control group. For patients with moderate and severe varices, 
the trial was single blind. They were divided into 3 groups: FZHYC group in which patients 
were treated with FZHYC, propranolol group in which patients were treated with 
Propranolol and combination group in which patients received both FZHYC and 
propranolol. The dose of FZHYC was 15 capsules (0.3g per capsule) per day and orally 
administrated at 3 times. The placebo was composed of stir-fried wheat powder with an 
identical-appearance in the aspects of dosage, color of the contents and packaging. The 
clinical intervention period lasts 2 years and the follow up would stop once the end points 
occur. The primary end point was esophageal or gastric variceal bleeding. 
2.3 Results  
2.3.1 In patients with small varices level 
A total of 6 patients reached the primary end point of esophageal variceal bleeding: 1 of 29 
patients in the Fuzheng Huayu group and 5 of 27 patients in the control group. The actuarial 
probability of remaining free of esophageal variceal bleeding was a significant different 
between 2 groups (96.3% vs. 77.01%, P=0.0422) (Fig. 1). Some patients with small varices 
were willing to be re-examined by endoscopy after treatment and small varices was 
dispared in several patients. There was a significant difference of esophageal varices degree 
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Fig. 1. Actuarial probability of remaining free of esophageal variceal bleeding in cirrhotic 
patients with small varices level. The patients were treated with Fuzheng Huayu Capsule in 
FZHYC group or placebo in control group for 24 months. Actuarial probability of remaining 
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Fig. 1. Actuarial probability of remaining free of esophageal variceal bleeding in cirrhotic 
patients with small varices level. The patients were treated with Fuzheng Huayu Capsule in 
FZHYC group or placebo in control group for 24 months. Actuarial probability of remaining 
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Groups n No varices（n） No changes（n） Enlarged varices（n） 
FZHYC * 15 8 5 2 
control  9 1 3 5 
Note: compared with control group,*: P=0.014 
Table 1. Difference of developing small varices in FZHYC group and in controls after 24 
months 
 
Fig. 2. Alteration of small varices by endoscopy examination at pre and post treatment of 
FZHYC. Arrow shows the small varices in a cirrhotic patient at pre treatmtnt (left). The 
small varices, however, was disappeared in same patient at post treatmtnt (right). 
2.3.2 In patients with moderate and severe varices level 
5 patients in FZHYC group (n=30), 8 patients in Propranolol group (n=30) and 3 patients in 
the combination group (n=30) had esophageal variceal bleeding during their follow-up. 
Compared to the Propranolol group (56.99%), there were significant differences in the 
actuarial probability of remaining free of esophageal variceal bleeding in FZHYC group 
(76.13%, P＝0.0131) and the combination group (87.55%, P＝0.0086). Remaining free of 
variceal bleeding has a higher trend in combination group, but there was no significant 
difference between combination group and FZHYC group (P＝0.3876) (Fig.3).  
2.4 Summary 
FZHYC could effectively reduce the risk of esophageal variceal bleeding for cirrhotic 
patients with varices; especially the combination of the capsule and Propranolol delivered a 
better effect. The capsule could reduce the varices size in patients with small ones. 
3. The experiment in vivo 
For studying the mechanism of Fuzheng Huayu Capsule on prevention of esophageal 
variceal bleeding, we performed several experiments. Radix Salviae Miltiorrhizae is a major 
herb medicine in Fuzheng Huayu Recipe. Salvianolic-acid B (SA-B), which was extracted 
from Radix Salviae Miltiorrhizae, has been demonstrated to inhibit proliferation and functions 
of HSC in vitro 12and anti-fibrosis in vivo.13 We did lot of work to deal with how Fuzheng 
Huayu Recipe and SA-B relieves portal hypertension. 
post treatment pre treatment 
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Fig. 3. Actuarial probability of remaining free of esophageal variceal bleeding in cirrhotic 
patients with moderate and severe varices level The patients were treated with Fuzheng 
Huayu Capsule in FZHYC group, Propranolol in Propranolol group, or hoth in combination 
group for 24 months. Actuarial probability of remaining free of esophageal variceal bleeding 
was higher in combination group and FZHYC group than in Propranolol group. Compared 
with Propranolol group, the difference was significant in combination group (P<0.01) and in 
FZHYC group (P<0.05). Although the probability was higher in combination group than in 
FZHYC group, but the difference was not significant. 
3.1 Experiment 1: Chinese herb medicine can decrease portal vein pressure in 
cirrhotic rats 
3.1.1 Aims 
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Groups n No varices（n） No changes（n） Enlarged varices（n） 
FZHYC * 15 8 5 2 
control  9 1 3 5 
Note: compared with control group,*: P=0.014 
Table 1. Difference of developing small varices in FZHYC group and in controls after 24 
months 
 
Fig. 2. Alteration of small varices by endoscopy examination at pre and post treatment of 
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Fig. 3. Actuarial probability of remaining free of esophageal variceal bleeding in cirrhotic 
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Huayu Capsule in FZHYC group, Propranolol in Propranolol group, or hoth in combination 
group for 24 months. Actuarial probability of remaining free of esophageal variceal bleeding 
was higher in combination group and FZHYC group than in Propranolol group. Compared 
with Propranolol group, the difference was significant in combination group (P<0.01) and in 
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group (n=13), Fuzheng Huayu (FZHY) group (n=15) and the SA-B group (n=16), once liver 
cirrhosis was confirmed. The rats in the FZHY group were gavaged with extractor of 
Fuzheng Huayu Recipe. The content of extractor equals 36.9g crude drug per 100ml. The 
rats in the SA-B group were gavaged with SA-B solution (125mg per 100ml). 
Simultaneously, the rats in control group and normal group were gavaged with water. All 
dose of gavage was 1ml/100g body weight, once per day, for 3 weeks.         
3.1.2.3 Measurement of portal vein pressure 
The rats were anesthetized with 2% sodium pentobarbital (2ml/kg body weight) in the end 
of experiment. One PE-10 tube filling with heparin was inserted from superior mesenteric 
vein into portal vein and then connected with pressotransducer to measure pressure. 
Enterocoelia was exposed totally after mesurement. If ascites was found, dry cotton ball was 
used to blot liquid and then it was weighted for measurement of ascites. Serum separated 
from blood which was taken in the vena cava was used for liver function detection. The 
sample of liver tissue, which was 1.0cm0.8cm0.3cm, was fixed by formalin, embedded by 
paraffin, and cutted for 4µm thick for HE and collagen staining. Moreover, 100mg liver 
tissue was used to detect hydroxyproline (Hyp). 
3.1.3 Result 
3.1.3.1 Investigating death and ascites in the rats  
During making hepatic cirrhosis model, there were no dead rats in week 4 but the death 
started in week 5. Until the end of week 7, there was still no death in normal group but there 
were 4 dead rats in control group, 2 dead rats both in FZHY group and in SA-B group, 
respectively. The reason that leads to death was liver failure. The number of the rats with 
ascites was most in control group than in other groups. The difference was significantly. 
(Tab. 2) 
 
Groups n Death（n） Ascites（n） 
normal 14 0 0 









Note: compared with control group, *: P<0.05 
Table 2. The situation of death and ascites in cirrhotic rats in each group 
3.1.3.2 Observation of Pathology of liver in rats  
3.1.3.2.1 Inflammation was reduced by Chinese herb medicine in the liver of cirrhotic rats 
The structure of liver lobule was clear, hepatocytes arranged as cords radially from central 
vein to the periphery and a few connective tissue was observed in the portal area in normal 
group. At the end of treatment, pathological alteration was observed in the liver that was 
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large bleeding area, a lot of swell or necrotic hepatocytes, a lot of infiltrating inflammatory 
cells including lymphocytes and mononuclears, distorted sinusoids and obviously widened 
portal areas in controls. They were varying decreased that was degeneration or necrosis of 
hepatocytes, and intrahepatic hemorrhage both in FZHY group and in SA-B group 
compared with controls. (Fig. 4) 
3.1.3.2.2 Hepatic fibrosis was reversed by Chinese herb medicine 
A little collagen fibers located only in portal areas or surrounded central veins in normal rat 
liver. Increased fibrous tissue formed thick interval that invaded into the hepatic lobules and 
moved round to form pseudolobules with different size in controls’liver. The fibrous 
intervals were thinner both in FZHY group and SA-B group than in controls. It means that 
hepatic fibrosis was reversed by FZHY recipe and SA-B. (Fig. 5) 
3.1.3.2.3 The liver function of cirrhotic rats can be improved by Chinese herb medicine 
Compared with normal rats, it was significantly increased in controls that are the activity of 
serum ALT and AST, serum level of TBiL（P<0.01 and P<0.05）but meanwhile the 
concentration of serum Alb were significantly decreased（P<0.05）. However, they were 
obviously lower both in FZHY group and SA-B group than in controls that are the activity 
of serum ALT and AST（P<0.01）, and serum level of TBiL（P<0.05）. The concentration of 
serum Alb were back to normal level with significantly difference compared with controls 






Fig. 4. Fuzheng Huayu Recipe and SA-B could relieve inflammation and structure damage 
in the liver tissue of DMN model rats A: normal group, B: control group, C: FZHY group 
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Fig. 5. Fuzheng Huayu Recipe and SA-B could relieve collagen fiber deposition in the liver 
tissue of DMN model rats A: normal group, B: control group, C: FZHY group, and D: SA-B 
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Fig. 6. Fuzheng Huayu Recipe and SA-B could decrease the avtivity of serum ALT and AST, 
and serum level of TBiL, but increase serum concentration of Alb in DMN model rats  
normal group, n=14; control group, n=9; FZHY group, n=13; SA-B group, n=14. 
3.1.3.2.4 The concentration of Hyp in the liver tissue of cirrhotic rats was decreased by 
Chinese herb medicine 
Compared with normal group, concentration of Hyp in the liver tissue was significantly 
increased at the end of experiment in controls (P<0.01). The concentration of Hyp, however, 
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Fig. 7. Fuzheng Huayu Recipe and SA-B could decrease concentration of Hyp in the liver 
tissue of DMN model rats A. normal group, n=12; control group, n=9; FZHY group, n=12. B. 
normal group, n=13; control group, n=9; SA-B group, n=12. 
3.1.3.2.5 Portal vein pressure of the cirrhotic rats was declined and the tissue 
concentration of ET-1 was dropped by Chinese herb medicine 
The portal vein pressure of control rats was significantly increased in the end of 
experiment compared with normal rats (P<0.01). The increased range was up to 8mmHg. 
The portal pressure，however, was significantly lower in the rats treated with FZHY 
Recipe or SA-B than controls (P<0.05). (Fig. 8) The hepatic tissue concentration of ET-1 
was obviously higher in controls than in normal group (P<0.01). But concentration of ET-1 
was remarkably declined in FZHY group and SA-B group compared with controls 
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Fig. 8. Fuzheng Huayu Recipe and SA-B could decrease portal vein pressure in DMN model 




Fig. 9. Fuzheng Huayu Recipe and SA-B could decrease content of ET-1 in the liver tissue of 
DMN model rats normal group, n=14; control group, n=9; FZHY group, n=13; SA-B group, 
n=14. 
3.1.4 Summary 
The elevation of portal vein pressure is positively correlated with the increase of ET-1 
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can dramatically decrease the cirrhosis-induced elevation of portal vein pressure and 
concentration of ET-1 in the liver tissue through their effect on anti-fibrosis in the liver. 
3.2 Experiment 2: Chinese herb medicine can relieve capillarization of sinusoid in 
cirrhotic rats 
3.2.1 Aims 
To investigate the effects of FZHY Recipe on capillarization of hepatic sinusoids. 
3.2.2 Methods 
32 Sprague-Dawley male rats, weighing about 150g, were randomly divided into normal 
group (n=7) and model group (n=25). The modeling mathod was the same as Experiment 1 
for making cirrhosis. The cirrhotic rats were more randomly divided into control group 
(n=11), and FZHY group (n=14). The drug, dose and method of administration for each 
group were the same as Experiment 1, too. But the duration of treatment was for 4 weeks. 
Rat’s blood, under etherization condition, was collected from inferior vena cava, and was 
separated to serum. The sample of liver (1.0cm×0.8cm×0.3cm) was immediately taken and 
fixed in neutral formalin, embedded in paraffin, sectioned at 5 m thick. The sections of 
liver were stained with HE, Masson and immunohistochemistry. Three rats were randomly 
selected from each group respectively for observation of hepatic microstructure. The each 
liver sample was cut to a 1 mm3 cube, fixed with 2.5% glutaraldehyde and 1% osmium 
tetroxide for 2h, embedded with araldite 618, and cut to ultrathin sections. The sections were 
observed by the electron microscope (H-600). 100mg liver tissue was used to detect Hyp. 
3.2.3 Results 
3.2.3.1 Fuzheng Huayu Recipe had the potent effect against hepatic fibrosis of the model 
rat 
It was observed that hemorrhage, necrosis and extensive connective tissue hyperplasia in 
the liver tissues of model rats. The fiber septa reached out its branches towards the liver 
lobule. (Fig. 10 and Tab. 3) The level of hydroxyproline was significantly increased. 
Compared with controls, liver inflammation, necrosis of hepatocytes and hepatic fibrosis 
was reduced in FZHY group. The concentration of liver hydroxyproline was significantly 
lower in FZHY group than in controls (P<0.05). (Tab. 4) 
 
Groups n 
Hyperplasia degree of collagenous fibers 
0 + ++ +++ ++++ 
normal 7 7 0 0 0 0 
controls 11 0 1 1 4 5 
FZHY * 14 0 0 8 4 2 
Note: compared with controls, *: U=4.06, P<0.01 
Table 3. Hyperplasia degree of collagenous fibers in each group 
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Fig. 10. Fuzheng Huayu Recipe inhibited hepatic fibrosis The liver sections were stained 
with Masson and showed hepatic fibrosis. A: Fibrous septa (arrows indicated) and 
pseudolobule (arrow’s head indicated) have formed in controls. B: Fibrous septa (arrow 
indicated) is less and pseudolobule is absent in FZHY group (100×). 
 
Groups n Hyp(μg/g liver wet weight) 
normal 7 112.37±11.93 
controls 11 292.83±36.78* 
FZHY 14 215.03±75.46# 
Note: compared with normal, *: P<0.05; compared with controls, #: P<0.05 
Table 4. Liver Hydroxyproline level in liver tissues ( x ±s) 
3.2.3.2 Fuzheng Huayu Recipe could effectively inhibit sinusoid capillarization in fibrotic 
rats 
It was observed that the structure of sinusoids is clearly and the phenotype of SEC is thin by 
microscopy in normal group. There were many fenestrae in SEC cytoplasm and no 
basement membrane covered on SEC in perisinusoid side. In controls, the sinusoids were 
twisted and narrow, the fenestrae in SEC were reduced or disappeared, and basement 
membrane was observed. (Fig.11)Factor Ⅷ related antigen (Ⅷ R·Ag), -smooth muscle actin 
(-SMA) and laminin (LM), the important indexes for hepatic sinusoid capillarization, were 
positive staining in liver tissure. But collagen type Ⅳ (Col Ⅳ), which is a composition of 
functional membrane but not a composition of basement membrane, expressed majorly in 
fibrous septa and HSC but less and discontinuously in perisinusoids in controls. Compared 
with controls, however, the narrow sinusoids were reduced and some sinusoids returned to 
normal phenotype, basement membrane looked discontinuous thiner, and the positive 
degree of Ⅷ R·Ag, -SMA and LM were lower and their positive area was significantly 
smaller by image analysis in the liver of FZHY group than in that of controls (P<0.05). Col Ⅳ 
expressed still continuously in perisinusoids in FZHY group. It indicated that the normal 
structure of sinusoids was most kept and it meansed that the alteration of hepatic sinusoid 
capillarization was reversed. (Fig.12) 
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Fig. 11. Fuzheng Huayu Recipe could inhibit sinusoid capillarization by observation of 
electron micrographs S: sinusoid; C: collagen. A: Hepatic sinusoid appeare as a typical 
capillary surrounded by continuous basement membrane. (arrow’s heads indicated) in the 
liver of fibrotic rat. The perisinusoid is stenosis (arrows indicated) and microvilli of 
hepatocyte are almost absent in the space (15000×). B: Sinusoid capillarization is not formed 
in the liver of rat treated with Fuzheng Huayu Recipe. The fenestrae are observed (arrow’s 
heads indicated) in cytoplasm of SEC. A mass of microvilli of hepatocyte stretchs into 
perisinusoid is exist (arrow indicated) but basement membrane is absent (10000×).   
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Fig. 11. Fuzheng Huayu Recipe could inhibit sinusoid capillarization by observation of 
electron micrographs S: sinusoid; C: collagen. A: Hepatic sinusoid appeare as a typical 
capillary surrounded by continuous basement membrane. (arrow’s heads indicated) in the 
liver of fibrotic rat. The perisinusoid is stenosis (arrows indicated) and microvilli of 
hepatocyte are almost absent in the space (15000×). B: Sinusoid capillarization is not formed 
in the liver of rat treated with Fuzheng Huayu Recipe. The fenestrae are observed (arrow’s 
heads indicated) in cytoplasm of SEC. A mass of microvilli of hepatocyte stretchs into 
perisinusoid is exist (arrow indicated) but basement membrane is absent (10000×).   
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Fig. 12. Fuzheng Huayu Recipe could alter the express of indexes for hepatic sinusoid 
capillarization by immunohistochemistry staining in fibrotic liver of rats Arrows show the 
positive area. A: Ⅷ R·Ag is around the vessels with strong staining in controls. B: The positive 
area of Ⅷ R·Ag is decreased in FZHY group. C: Col Ⅳ expresses majorly in fibrous septa and 
HSC but less and discontinuously in perisinusoids in controls. D: Col Ⅳ expresses almost 
continuously in perisinusoids in FZHY group. E: The express of LM is observed on the wall of 
vessels and sinusoids in the liver of controls. F: The express of LM is only observed on the wall 
of vessels in the liver of FZHY group. G: -SMA expresses strongly in perisinusoids, HSC and 
fibous septa in controls. H: -SMA expresses dramaticlly less in FZHY group (100×). 
3.2.4 Summary 
Fuzheng Huayu Recipe had the potent effect on against liver fibrosis. The one of 
mechanisms of the recipe perhaps is associated with inhibition of hepatic sinusoid 
capillarization. 
3.3 Experiment 3: SA-B could decrease portal vein pressure in rats induced by ET-1 
3.3.1 Aims 
To establish a rat model of portal hypertension induced by ET-1 and investigate the effect of 
SA-B on decreasing portal vein pressure in the model. 
3.3.2 Methods 
3.3.2.1 To establish portal hypertension model of rats induced by ET-1 
48 Sprague-Dawley male rats were randomly divided into four groups: the NS solution 
group, the ET-1 low-dose group (0.3g/kg body weight), the ET-1 medium-dose group 
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(1.0g/kg body weight) and the ET-1 high-dose group (3.0g/kg body weight). Rats were 
injected with 200l NS solution into rat via femoral vein by a pump with a rate of 80μl/min 
in NS solution group. As the same method, rats were injected with 200ml ET-1 solution with 
the dose of 0.3g/kg body weight, 1.0g/kg body weight or 3.0g/kg body weight 
respectively in 3 ET-1 groups. Then, monitored the changes of carotid pressure and portal 
vein pressure in each group at 2min, 4min, 6min, 8min, 10min, 15min, 20min, 25min and 
30min after injection. 
3.3.2.2 To treat rats with drugs in portal hypertension models 
20 Sprague-Dawley male rats with about 330g body weight were randomly divided into 
four groups: normal group, SA-B group, BQ-123 (ETAR antagonist) group and BQ-788 (ETBR 
antagonist) group (n=5 in each group). In normal group, BQ-123 group and BQ-788 group, 
rats were gavaged with water at a dose of 1ml/100g body weight and rats in SA-B group 
were gavaged with SA-B solution (containing 125mg/100ml) at the same dose. The gavage 
was performed twice per day for 5 days. The experiment started at 1 hour after the final 
gavage. First, via rat’s femoral vein, rats was injected with BQ-123 (12.5µg/kg body weight) 
in BQ-123 group and with BQ-788 (15µg/kg body weight) in BQ-788 group. 30min later, rats 
were injected with a dose (3µg/kg body weight) of ET-1 solution by a pump with rate of 
80μl/min in each group. Then, the portal vein pressure was measured before and after 
injection of ET-1. 
3.3.2.3 To measure carotid pressure, heart rate and portal vein pressure 
A piece of PE-50 tube, which full with heparin solution, was inserted into the left carotid 
artery of the rat. Following that, connect the tube to a pressure transducer in order to 
measure carotid pressure and heart rate. Then a piece of PE-10 tube, which full with heparin 
solution, was inserted from superior mesenteric vein to the middle of portal vein.  Connect 
the tube to a pressure transducer for measurement of portal vein pressure. 
3.3.3 Results 
3.3.3.1 A kind of model of rat with portal hypertension was successfully established by 
injection of ET-1  
There was no obvious effect of solution volume on carotid pressure and portal vein pressure 
after injection of NS solution. ET-1 solution with equal volume of NS solution was injected 
into the rats in low- and medium-dose groups. The carotid pressure was not noticeable rise 
or fall, only minor fluctuations within 20 min after injection. The carotid pressure, however, 
was increased slightly after injection of ET-1 in high-dose group but the alteration was not 
significant (Fig.13). Portal vein pressure was increased in short time after injection of ET-1 
although the alteration was not same in three different dose groups. The alteration of 
pressure was most remarkable in high-dose group than in others. After reaching to peak 
level, portal vein pressure was stable for 4min, 4min and 10min in low-, medium- and high-
dose groups, respectively (Fig.14 and Tab. 5). The results indicated that the increase of portal 
vein pressure was solely caused by the injection of ET-1 and without related with the 
volume of solution in this kind of animal model. This inducing method would not cause a 
significant increase of systemic blood pressure. Compared with the existing portal vein 
perfusion model, this kind of portal hypertension model is more similar to the "living" state. 
It was also avoided that increase of portal vein pressure caused by sudden increase of partial 
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(1.0g/kg body weight) and the ET-1 high-dose group (3.0g/kg body weight). Rats were 
injected with 200l NS solution into rat via femoral vein by a pump with a rate of 80μl/min 
in NS solution group. As the same method, rats were injected with 200ml ET-1 solution with 
the dose of 0.3g/kg body weight, 1.0g/kg body weight or 3.0g/kg body weight 
respectively in 3 ET-1 groups. Then, monitored the changes of carotid pressure and portal 
vein pressure in each group at 2min, 4min, 6min, 8min, 10min, 15min, 20min, 25min and 
30min after injection. 
3.3.2.2 To treat rats with drugs in portal hypertension models 
20 Sprague-Dawley male rats with about 330g body weight were randomly divided into 
four groups: normal group, SA-B group, BQ-123 (ETAR antagonist) group and BQ-788 (ETBR 
antagonist) group (n=5 in each group). In normal group, BQ-123 group and BQ-788 group, 
rats were gavaged with water at a dose of 1ml/100g body weight and rats in SA-B group 
were gavaged with SA-B solution (containing 125mg/100ml) at the same dose. The gavage 
was performed twice per day for 5 days. The experiment started at 1 hour after the final 
gavage. First, via rat’s femoral vein, rats was injected with BQ-123 (12.5µg/kg body weight) 
in BQ-123 group and with BQ-788 (15µg/kg body weight) in BQ-788 group. 30min later, rats 
were injected with a dose (3µg/kg body weight) of ET-1 solution by a pump with rate of 
80μl/min in each group. Then, the portal vein pressure was measured before and after 
injection of ET-1. 
3.3.2.3 To measure carotid pressure, heart rate and portal vein pressure 
A piece of PE-50 tube, which full with heparin solution, was inserted into the left carotid 
artery of the rat. Following that, connect the tube to a pressure transducer in order to 
measure carotid pressure and heart rate. Then a piece of PE-10 tube, which full with heparin 
solution, was inserted from superior mesenteric vein to the middle of portal vein.  Connect 
the tube to a pressure transducer for measurement of portal vein pressure. 
3.3.3 Results 
3.3.3.1 A kind of model of rat with portal hypertension was successfully established by 
injection of ET-1  
There was no obvious effect of solution volume on carotid pressure and portal vein pressure 
after injection of NS solution. ET-1 solution with equal volume of NS solution was injected 
into the rats in low- and medium-dose groups. The carotid pressure was not noticeable rise 
or fall, only minor fluctuations within 20 min after injection. The carotid pressure, however, 
was increased slightly after injection of ET-1 in high-dose group but the alteration was not 
significant (Fig.13). Portal vein pressure was increased in short time after injection of ET-1 
although the alteration was not same in three different dose groups. The alteration of 
pressure was most remarkable in high-dose group than in others. After reaching to peak 
level, portal vein pressure was stable for 4min, 4min and 10min in low-, medium- and high-
dose groups, respectively (Fig.14 and Tab. 5). The results indicated that the increase of portal 
vein pressure was solely caused by the injection of ET-1 and without related with the 
volume of solution in this kind of animal model. This inducing method would not cause a 
significant increase of systemic blood pressure. Compared with the existing portal vein 
perfusion model, this kind of portal hypertension model is more similar to the "living" state. 
It was also avoided that increase of portal vein pressure caused by sudden increase of partial 
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blood volume by quickly direct injection of ET-1 in portal vein. This kind of model would 
better reflect the true effect of ET-1 compared with other kind of model. Therefore, this kind of 
model could use not only for investigation of efficacy and mechanism of drug, but also 
provided an ideal experimental subject for screening drugs to treat portal hypertension. 
 
                                                NS group                                                                     low-dose group 
 
                                           medium-dose group                                                        high-dose group 
Fig. 13. Effect of ET-1 with different doses on rat carotid pressures After detecting carotic 
pressure for 5min, NS solution or ET-1 with same volume but different doses were 
constantly injected and carotic pressure was detected for 30min. The pressure was not 
increased during detected time in NS group, and low- and medium-dose groups. But the 
carotid pressure was increased slightly in high-dose group. 
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                                        medium-dose group                                                          high-dose group 
Fig. 14. Effect of ET-1 with different doses on rat portal vein pressure After detecting portal 
vein pressure for 5min, NS solution and ET-1 with same volume but different doses were 
constantly injected and portal vein pressure was detected for 30min. There was no obvious 
effect of NS solution on portal vein pressure. The pressure was increased at 5min when 
starting injection of ET-1 and kept high level for 4min, 4min and 10min in low-, medium- 
and high-dose groups after the pressure reaching to a peak level at 9 min, respectively. 
 
Groups n Initial pressure Highest pressure Increased range 
  (mmHg) (mmHg) (mmHg) 
NS 8 6.6±0.3 6.5±0.4 -0.1±0.2 
low-dose 10 6.1±0.8 7.5±0.8** 1.3±0.3 
medium-dose 10 6.3±0.5 8.1±0.6** 1.8±0.5## 
high-dose 9 6.0±0.6 8.5±0.9** 2.5±0.5##☆☆ 
Note: compared with the initial pressure in the interior-group, **: P<0.01; compared with NS group, 
: P<0.001; compared with low-dose group, ##: P<0.01; compared with medium-dose group, ☆☆: 
P<0.01 
Table 5. Effect of ET-1 with different doses on portal vein pressure of rats (X±S) 
 
Groups n Initial pressure Highest pressure Increased range 
  (mmHg) (mmHg) (mmHg) 
control 5 6.1±0.7 8.6±1.1*** 2.5±0.4 
SA-B 5 6.1±0.7 7.8±1.6** 1.6±0.5## 
BQ-123 5 5.9±1.1 7.1±1.0 1.2±0.2### 
BQ-788 5 5.9±0.9 6.9±1.1 0.98±0.5### 
Note: compared with initial pressure interior-group, **: P<0.01, ***: P<0.001; compared with the 
controls, ##: P<0.01, ###: P<0.001 
Table 6. Effect of SA-B, BQ-123 or BQ-788 on reducining portal vein pressure of rats induced 
by ET-1 (X±S) 
3.3.3.2 SA-B could inhibit the rise of portal vein pressure in rats induced by ET-1 
Portal vein pressur significantly increased after ET-1 solution (3μg/kg body weight) was 
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blood volume by quickly direct injection of ET-1 in portal vein. This kind of model would 
better reflect the true effect of ET-1 compared with other kind of model. Therefore, this kind of 
model could use not only for investigation of efficacy and mechanism of drug, but also 
provided an ideal experimental subject for screening drugs to treat portal hypertension. 
 
                                                NS group                                                                     low-dose group 
 
                                           medium-dose group                                                        high-dose group 
Fig. 13. Effect of ET-1 with different doses on rat carotid pressures After detecting carotic 
pressure for 5min, NS solution or ET-1 with same volume but different doses were 
constantly injected and carotic pressure was detected for 30min. The pressure was not 
increased during detected time in NS group, and low- and medium-dose groups. But the 
carotid pressure was increased slightly in high-dose group. 
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                                        medium-dose group                                                          high-dose group 
Fig. 14. Effect of ET-1 with different doses on rat portal vein pressure After detecting portal 
vein pressure for 5min, NS solution and ET-1 with same volume but different doses were 
constantly injected and portal vein pressure was detected for 30min. There was no obvious 
effect of NS solution on portal vein pressure. The pressure was increased at 5min when 
starting injection of ET-1 and kept high level for 4min, 4min and 10min in low-, medium- 
and high-dose groups after the pressure reaching to a peak level at 9 min, respectively. 
 
Groups n Initial pressure Highest pressure Increased range 
  (mmHg) (mmHg) (mmHg) 
NS 8 6.6±0.3 6.5±0.4 -0.1±0.2 
low-dose 10 6.1±0.8 7.5±0.8** 1.3±0.3 
medium-dose 10 6.3±0.5 8.1±0.6** 1.8±0.5## 
high-dose 9 6.0±0.6 8.5±0.9** 2.5±0.5##☆☆ 
Note: compared with the initial pressure in the interior-group, **: P<0.01; compared with NS group, 
: P<0.001; compared with low-dose group, ##: P<0.01; compared with medium-dose group, ☆☆: 
P<0.01 
Table 5. Effect of ET-1 with different doses on portal vein pressure of rats (X±S) 
 
Groups n Initial pressure Highest pressure Increased range 
  (mmHg) (mmHg) (mmHg) 
control 5 6.1±0.7 8.6±1.1*** 2.5±0.4 
SA-B 5 6.1±0.7 7.8±1.6** 1.6±0.5## 
BQ-123 5 5.9±1.1 7.1±1.0 1.2±0.2### 
BQ-788 5 5.9±0.9 6.9±1.1 0.98±0.5### 
Note: compared with initial pressure interior-group, **: P<0.01, ***: P<0.001; compared with the 
controls, ##: P<0.01, ###: P<0.001 
Table 6. Effect of SA-B, BQ-123 or BQ-788 on reducining portal vein pressure of rats induced 
by ET-1 (X±S) 
3.3.3.2 SA-B could inhibit the rise of portal vein pressure in rats induced by ET-1 
Portal vein pressur significantly increased after ET-1 solution (3μg/kg body weight) was 
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which were pretreated with SA-B solution by gavage or with BQ-123 or BQ-788 by injection, 
was also increased after ET-1 injection, however, the ranget-increased was obviously less 
than that in controls (P<0.01, P<0.001) (Tab.6). Furthermore, the stable time, when portal 
vein pressure kept high level after reaching peak level, was short in SA-B group. It was just 





Fig. 15. SA-B could inhibit portal vein pressure of rats induced by ET-1 Portal vein pressure 
began increase at 5min when starting injection of ET-1. The peak level of pressure was at 
9min in SA-B group. Then the pressure kept high level until to at 15min.  In controls, 
however, the pressure continuously increased until to highest peak level at 15min and 
began to decrease. The pressure level was still hinger (a little bit higher than a peak level in 
SA-B group) until to at 25min. 
 
Groups n Carotid artery pressure Heart rate 
  (mmHg) (Beats/min) 
control 3 130.9±13.2 439±21 
SA-B 5 145.6±10.1 439±21 
Table 7. Compare of the carotid artery pressure and heart rate in SA-B group and controls 
3.3.3.3 SA-B did not affect on carotid pressure and heart rate in normal rat 
Rats were pretreated with SA-B solution by gavage for 5d, but the carotid pressure and 
heart rate were no significant different between in SA-B group and controls. (Tab.7) 
3.3.4 Summary 
A kind of rat model of portal hypertension is successfully established by injection of ET-1. 
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3.4 Experiment 4: SA-B can decrease portal vein pressure in mice induced by ET-1 
3.4.1 Aims 
To establish portal hypertension model of mice induced by ET-1 and investigate the effect of 
SA-B on decreasing portal vein pressure in this kind of model. 
3.4.2 Methods 
3.4.2.1 To establish a kind of portal hypertension model mice induced by ET-1 
36 male Kunming mices, 30±5g body weight, were randomly divided into three groups: 
control group (n=12), SA-B group (n=12) and blocker group (n=12). Mice were gavaged with 
SA-B (1mg/ml) in SA-B group and gavaged with water in control group and blocker group. 
The volume of gvage was 0.5 ml per mouse once a day for 3days.  Mice were injected with 
BQ-123（2g/kg body weight）by tail vein at 0.5h before start of below experiment in 
blocker group. 
Mice were injected with ET-1（1.6g/kg body weight）at constant velocity by tail vein. 6 
mice were randomly taken out from each group to measure blood flow volume in liver 
microcirculation using a laser-Doppler flow instrument before and after injection of ET-1. 
Other 6 mice in each group were measured the blood flow rate in liver microcirculation by 
an inverted fluorescence microscope with microscopic live video technology before and 
after injection of ET-1.  
3.4.2.2 To measure the average blood flow volume in the perfusion of liver 
microcirculation 
Each mouse was injected with 2% pentobarbital sodium solution at a dose of 2ml/kg body 
weight for anesthesia. After opening abdomen the liver was put on a detector connected 
with a laser-Doppler flow instrument to record the blood flow volum in the perfusion of 
liver microcirculation for 5min. After a pause, ET-1 was injected by a syringe pump at a 
constant rate of 80l/ min through tail vein. Then, the blood flow volum was recorded again 
for 5min.  The average blood flow volume was calculated from the stable datas during the 
former 5min record and late 5min record, respectively.  
3.4.2.3 To measure the blood flow rate in liver microcirculation 
Each mouse was injected with 2% pentobarbital sodium  solution at a dose of 2ml/kg 
body weight for anesthesia. After opening abdomen the liver was put on a piece of glass 
plate which was on an inverted fluorescence microscope. After 0.05ml pre-labeled 
erythrocytes with FITC was injected into the inferior vena cava, a suitable site was 
focused to observe the liver microcirculation. Some FITC-RBCs were observed to be 
moving quickly in microvasculature or sinusoids and recorded with digital video. ET-
1(1.6g /kg body weight) was injected by a syringe pump at a constant rate of 80l/ min 
through tail vein of mouse then moving FITC-RBCs were immediately recorded again 
with digital video. The moving range of FITC-RBCs in record was calculated by the 
analytic software to compare the differences of blood flow rate in liver microcirculation in 
3 groups. 
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3.4 Experiment 4: SA-B can decrease portal vein pressure in mice induced by ET-1 
3.4.1 Aims 
To establish portal hypertension model of mice induced by ET-1 and investigate the effect of 
SA-B on decreasing portal vein pressure in this kind of model. 
3.4.2 Methods 
3.4.2.1 To establish a kind of portal hypertension model mice induced by ET-1 
36 male Kunming mices, 30±5g body weight, were randomly divided into three groups: 
control group (n=12), SA-B group (n=12) and blocker group (n=12). Mice were gavaged with 
SA-B (1mg/ml) in SA-B group and gavaged with water in control group and blocker group. 
The volume of gvage was 0.5 ml per mouse once a day for 3days.  Mice were injected with 
BQ-123（2g/kg body weight）by tail vein at 0.5h before start of below experiment in 
blocker group. 
Mice were injected with ET-1（1.6g/kg body weight）at constant velocity by tail vein. 6 
mice were randomly taken out from each group to measure blood flow volume in liver 
microcirculation using a laser-Doppler flow instrument before and after injection of ET-1. 
Other 6 mice in each group were measured the blood flow rate in liver microcirculation by 
an inverted fluorescence microscope with microscopic live video technology before and 
after injection of ET-1.  
3.4.2.2 To measure the average blood flow volume in the perfusion of liver 
microcirculation 
Each mouse was injected with 2% pentobarbital sodium solution at a dose of 2ml/kg body 
weight for anesthesia. After opening abdomen the liver was put on a detector connected 
with a laser-Doppler flow instrument to record the blood flow volum in the perfusion of 
liver microcirculation for 5min. After a pause, ET-1 was injected by a syringe pump at a 
constant rate of 80l/ min through tail vein. Then, the blood flow volum was recorded again 
for 5min.  The average blood flow volume was calculated from the stable datas during the 
former 5min record and late 5min record, respectively.  
3.4.2.3 To measure the blood flow rate in liver microcirculation 
Each mouse was injected with 2% pentobarbital sodium  solution at a dose of 2ml/kg 
body weight for anesthesia. After opening abdomen the liver was put on a piece of glass 
plate which was on an inverted fluorescence microscope. After 0.05ml pre-labeled 
erythrocytes with FITC was injected into the inferior vena cava, a suitable site was 
focused to observe the liver microcirculation. Some FITC-RBCs were observed to be 
moving quickly in microvasculature or sinusoids and recorded with digital video. ET-
1(1.6g /kg body weight) was injected by a syringe pump at a constant rate of 80l/ min 
through tail vein of mouse then moving FITC-RBCs were immediately recorded again 
with digital video. The moving range of FITC-RBCs in record was calculated by the 
analytic software to compare the differences of blood flow rate in liver microcirculation in 
3 groups. 
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3.4.3 Results 
3.4.3.1 SA-B reduced average blood flow volume in liver microcirculation 
The blood flow volume in liver microcirculation was decreased in 3 groups after injection of 
ET-1. The reduced range was smaller in SA-B group and in block group than in controls 
(P<0.01).  (Tab. 8) 
3.4.3.2 SA-B reduced average blood flow rate in liver microcirculation 
The blood flow rate in liver microcirculation was significantly decreased after injection of 
ET-1 (P<0.01). But the reduced range was smaller in SA-B group and in blocker group than 
in controls (P<0.05 and P<0.01). (Tab. 9) 
 
Average blood flow volume in liver microcirculation（BPU） 
Groups n Before ET-1 injection 
After ET-1 
injection Reduced range 
control 6 1186.83±41.14 1060.50±18.33 126.33±27.51 
SA-B 6 1269.50±59.90 1189.33±40.33 80.17±20.30 ** 
blocker 6 202.00±36.54 1131.00±23.67 71.00±12.82 ** 
Note: compared with the controls, **: P<0.01 
Table 8. SA-B and BQ-123 could inhibit reduction of average blood flow volume in mice 
induced by ET-1 (X ± S) 
 
Blood flow rate in liver microcirculation（mm/s） 
Groups n Before ET-1 injection 
After ET-1 
injection Reduced range 
Control 6 0.60±0.01 0.36±0.02☆☆ 0.23±0.02 
SA-B 6 0.62±0.04 0.39±0.01☆☆ 0.18±0.04 * 
blocker 6 0.60±0.05 0.43±0.01☆☆ 0.17±0.05 ** 
Note: compared with initial blood flow rate,☆☆: P<0.01; compared with controls, *: P<0.05，**: P<0.01   
Table 9. SA-B and BQ-123 could inhibit reduction of the liver blood flow rate in mice 
induced by ET-1 (X ± S). 
3.4.4 Summary 
The average blood flow volume and blood flow rate in mice liver microcirculation were 
reduced by extraneous ET-1. SA-B could inhibit the effect of ET-1 to improve liver 
microcirculation.  
4. The experiment in vitro 
It is believed that recipe of herb medicine is not suitable for research of mechanism in vitro. 
For more studying the mechanism of Fuzheng Huayu Recipe on reducing portal 
hypertension, we can only select SA-B as investigated subject in vitro. 
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4.1 Aims 
To investigate the effects of SA-B on inhibiting contraction of human HSC induced by ET-1. 
4.2 Methods 
4.2.1 To observe contraction of HSC 
Human HSC was isolated from the normal section of transplant patients’liver by enzymatic 
digestion and density-gradient centrifugation with Nycodenz solution.14. Passaged HSC was 
planted on the collagen gel which was pre-poured into 12-wells plates. After cells had 
adhered, HSC was divided into 5 groups: 1) serum-free group in which HSC was cultured 
with serum-free M199; 2) ET group in which HSC was treated with ET-1(10 -8 mol/L); 3) 
low-dose group in which HSC was treated with ET-1 and 10-7mol/L SA-B; 4) medium-dose 
group in which HSC was treated with ET-1 and 10-6mol/L SA-B; 5) high-dose group in 
which HSC was treated with ET-1 and 10-5mol/L SA-B. The edge of the gel was scraped out 
wall of the well by a syringe needle after adding drugs. The diameter of gel was observed at 
2h, 4h, 6h, and 12 h during HSC culture and a gel image analysis system was used to 
calculate the area of gel. The area of gel can indicate the contractibility of HSC. The 
experiment was repeated for 3 times. 
4.2.2 To detect the concentration of free calcium ([Ca2+]i) in HSC 
HSC was planted in 6-wells plates. Flu-3/AM was added into media with final 
concentration of 5μmol/L. Then HSC was in a incubator with 37℃, 5%CO2-95% humid air 
and dark for 30min. HSC was washed twice with serum-free M199 for moving the dye and 
divided into 5 groups as above. HSC in each group was observed under a laser confocal 
microscope before and after adding relevant drugs. The observation conditions were Kr/Ar 
laser, excitation wavelength 488nm, emission wavelength 505-530nm. The experiment was 
repeated 2 times.    
4.3 Results  
4.3.1 SA-B inhibited contraction of HSC induced by ET-1 
Area of gel was significantly bigger in low-dose group (2209.02±177.96μm2), medium-dose 
group (2164.95±111.84μm2) and high-dose group (2374.73±218.38μm2) than in ET group 
(156.23±102.16m2). The statistical difference was dramatically (P<0.01). But there was no 
obviously difference among in 3 SA-B treatment groups. (Fig. 16) The morphological 
changes of HSC showed dose-dependent after incubation with SA-B. The phenotype of HSC 
in low-dose group was similar to that in ET group. The phenotype of HSC in high-dose 
group was similar to that in serum-free group. The phenotype of HSC in medium-dose 
group was between the low- and high-dose groups. (Fig. 17)  
4.3.2 SA-B suppressed the intracellular concentration of [Ca2+]i in HSC induced by ET-1 
Compared with ET group in which fluorescence of HSC was very strong, [Ca2+]i 
fluorescence image appeared the opposite phenomenon in 3 SA-B treatment groups. Only a 
few cells appeared slightly enhanced fluorescent and the intracellular concentration of 
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3.4.3 Results 
3.4.3.1 SA-B reduced average blood flow volume in liver microcirculation 
The blood flow volume in liver microcirculation was decreased in 3 groups after injection of 
ET-1. The reduced range was smaller in SA-B group and in block group than in controls 
(P<0.01).  (Tab. 8) 
3.4.3.2 SA-B reduced average blood flow rate in liver microcirculation 
The blood flow rate in liver microcirculation was significantly decreased after injection of 
ET-1 (P<0.01). But the reduced range was smaller in SA-B group and in blocker group than 
in controls (P<0.05 and P<0.01). (Tab. 9) 
 
Average blood flow volume in liver microcirculation（BPU） 
Groups n Before ET-1 injection 
After ET-1 
injection Reduced range 
control 6 1186.83±41.14 1060.50±18.33 126.33±27.51 
SA-B 6 1269.50±59.90 1189.33±40.33 80.17±20.30 ** 
blocker 6 202.00±36.54 1131.00±23.67 71.00±12.82 ** 
Note: compared with the controls, **: P<0.01 
Table 8. SA-B and BQ-123 could inhibit reduction of average blood flow volume in mice 
induced by ET-1 (X ± S) 
 
Blood flow rate in liver microcirculation（mm/s） 
Groups n Before ET-1 injection 
After ET-1 
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SA-B 6 0.62±0.04 0.39±0.01☆☆ 0.18±0.04 * 
blocker 6 0.60±0.05 0.43±0.01☆☆ 0.17±0.05 ** 
Note: compared with initial blood flow rate,☆☆: P<0.01; compared with controls, *: P<0.05，**: P<0.01   
Table 9. SA-B and BQ-123 could inhibit reduction of the liver blood flow rate in mice 
induced by ET-1 (X ± S). 
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[Ca2+]i was obviously lower in 3 SA-B treatment groups than in ET group. The intracellular 
concentration of [Ca2+]i was weak and only two relative low-lying peaks were in low-dose 
group within 120sec. The alteration of intracellular concentration of [Ca2+]i was smaller in 
medium-dose group and high-dose group during observation. (Fig.18). The results 
indicated that one of mechanisms of SA-B on inhibiting contraction of HSC may be related 





Fig. 16. SA-B could inhibit contraction of human HSC a: serum-free group; b: ET group; c: 
low-dose group; d: medium-dose group; e: high-dose group. Human HSC was cultured on 
collangen gel. Actived HSC are able to contract to lead to area of gel becoming small. In 
serum-free group, contraction capacity of HSC was weak so that the area of gel was nearly 
invariant. Active HSC induced by ET-1 contracted strongly. The area of gel was significantly 
smaller in ET group than in serum-free groups. SA-B could inhibit contraction of HSC 
induced by ET-1. The area of gel was bigger in 3 SA-B treatment groups than in ET group. 
Groups 
★★  ★★ ★★ 
☆☆ 
★★ VS model group       P<0.01 
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Fig. 17. The morphological changes of HSC in each group a: serum-free group; b: ET group; 
c: low-dose group; d: medium-dose group; e: high-dose group. HSC grew exuberantly on 
gel and the pseudopodium of HSC was a lot, thin and long in serum-free group. After 
induced by ET-1 for 12h, however, HSC became obviously small with contraction. The 
quantity and the pseudopodium of HSC was decreased in ET group. The phenotype of HSC 
in low-dose group was similar to that in ET group. The phenotype of HSC in high-dose 
group was similar to that in serum-free group. The phenotype of HSC in medium-dose 
group was between the low- and high-dose groups (By OLYMPUS I × 50 / I × 70 inverted 
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Fig. 18. SA-B suppressed the intracellular concentration of [Ca2+]i in HSC Fluorescent of Flu-
3/AM which represents the intracellular concentration of [Ca2+]i was observed. The 
expression of fluorescent in HSC was very stronger in ET group than in serum-free group. 
But the expression of fluoresent in HSC was dose-dependent in 3 SA-B treatment groups. 
The higher the dose of SA-B was, the weaker expression of fluorescent was (By Zeiss510 
laser confocal microscope, German, 200×). 
            Groups: 
                    serum-free   ET 
 
                       low-dose    medium-dose 
 
                    high-dose 
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5. Conclusion  
The Chinese medicine, Fuzheng Huayu Recipe, is able to reduce portal hypertension in liver 
cirrhosis both in clinic and in vivo. The effect of Fuzheng Huayu Recipe is related with 
reversing hepatic fibrosis and capillarization, and decreasing concentration of ET-1 in the 
liver tissue. SA-B is an extracted component of Fuzheng Huayu Recipe. Several studies 
showed that the effect in SA-B was similar to Fuzheng Huayu Recipe on reversing hepatic 
fibrosis and decreasing concentration of ET-1 in the liver tissue. SA-B inhibited contraction 
of HSC through suppressing the intracellular concentration of [Ca2+]i. Based on above 
effects, intrahepatic vessel resistance was reduced which leaded to improve liver 
microcirculation. It has distinctively character that Chinese herb medicine is used to treat 
hepatic portal hypertension which is caused by failure of liver microcirculation in chronic 
liver diseases.  
6. Acknowledgements 
This work was supported by grants from National Natural Science Foundation of China 
30672489; Leading Academic Discipline Project of Shanghai Municipal Education 
Commission J50307; E-Institute of TCM Internal Medicine, Shanghai Municipal Education 
Commission E03008; Innovation Research Team in Universities, Shanghai Municipal 
Education Commission; and Leading Academic Discipline Project of Hepatology, SATCM 
(2011sh). Translation assistance from Lu Chao, Wang Meifeng, Zhang Jing, Wu Mei and Pan 
Yuanwei is gratefully acknowledged. 
7. Reference 
McCuskey RS. The hepatic microvascular system in health and its response to toxicants. 
Anat Rec (Hoboken). 2008,291(6):661-71. 
Wu Zhiyong. Regulation of liver microcirculation and portal hypertension. J. 
Hepatopancreatobiliary Surgery. 2000,12(1):53-54. 
Pinzani M, Milani S, Defranco R, et al. Endothelin 1 is overexpressed in human cirrhotic 
liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 
1996,110:534-548. 
Vollmar B, Menger. The hepatic microcirculation: mechanistic contributions and therapeutic 
targets in liver injury and repair. Physiol Rev. 2009,89(4):1269-339. 
Spengler U. Hepatic microcirculation: a critical but neglected factor for the outcome of viral 
hepatitis. J Hepatol. 2009,50(3):631-3. 
Nishida J, McCuskey RS, McDonnell D. Protective Role of NO in Hepatic Microcirculatory 
Dysfunction during Endotoxemia. Am J Physiol. 1994,267(6 Pt 1):G1135-41. 
Ramadori G. The stellate cell of the liver. Virchows Arch B Cell Pathol 1991, 61:147-158. 
Pinzani M. Hepatic stellate (ITO) cells: expanding roles for a liver-specific pericyte. J 
Hepatol 1995, 22: 700-706. 
ZHANG Jie, XU Lieming, ZHANG Wenwei. Study of Effect and Mechanism of Salvianolic-
acid B Salt on Inhibiting the Contraction of Human Hepatic Stellate Cells Induced 
by Endothelin-1. Chinese J Integrative Medicine. 2009,29(1):60-64. 
 
Portal Hypertension – Causes and Complications 118 
 
 
    
                         
 
Fig. 18. SA-B suppressed the intracellular concentration of [Ca2+]i in HSC Fluorescent of Flu-
3/AM which represents the intracellular concentration of [Ca2+]i was observed. The 
expression of fluorescent in HSC was very stronger in ET group than in serum-free group. 
But the expression of fluoresent in HSC was dose-dependent in 3 SA-B treatment groups. 
The higher the dose of SA-B was, the weaker expression of fluorescent was (By Zeiss510 
laser confocal microscope, German, 200×). 
            Groups: 
                    serum-free   ET 
 
                       low-dose    medium-dose 
 
                    high-dose 
Traditional Chinese Medicine  
Can Improve Liver Microcirculation and Reduce Portal Hypertension in Liver Cirrhosis 119 
5. Conclusion  
The Chinese medicine, Fuzheng Huayu Recipe, is able to reduce portal hypertension in liver 
cirrhosis both in clinic and in vivo. The effect of Fuzheng Huayu Recipe is related with 
reversing hepatic fibrosis and capillarization, and decreasing concentration of ET-1 in the 
liver tissue. SA-B is an extracted component of Fuzheng Huayu Recipe. Several studies 
showed that the effect in SA-B was similar to Fuzheng Huayu Recipe on reversing hepatic 
fibrosis and decreasing concentration of ET-1 in the liver tissue. SA-B inhibited contraction 
of HSC through suppressing the intracellular concentration of [Ca2+]i. Based on above 
effects, intrahepatic vessel resistance was reduced which leaded to improve liver 
microcirculation. It has distinctively character that Chinese herb medicine is used to treat 
hepatic portal hypertension which is caused by failure of liver microcirculation in chronic 
liver diseases.  
6. Acknowledgements 
This work was supported by grants from National Natural Science Foundation of China 
30672489; Leading Academic Discipline Project of Shanghai Municipal Education 
Commission J50307; E-Institute of TCM Internal Medicine, Shanghai Municipal Education 
Commission E03008; Innovation Research Team in Universities, Shanghai Municipal 
Education Commission; and Leading Academic Discipline Project of Hepatology, SATCM 
(2011sh). Translation assistance from Lu Chao, Wang Meifeng, Zhang Jing, Wu Mei and Pan 
Yuanwei is gratefully acknowledged. 
7. Reference 
McCuskey RS. The hepatic microvascular system in health and its response to toxicants. 
Anat Rec (Hoboken). 2008,291(6):661-71. 
Wu Zhiyong. Regulation of liver microcirculation and portal hypertension. J. 
Hepatopancreatobiliary Surgery. 2000,12(1):53-54. 
Pinzani M, Milani S, Defranco R, et al. Endothelin 1 is overexpressed in human cirrhotic 
liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 
1996,110:534-548. 
Vollmar B, Menger. The hepatic microcirculation: mechanistic contributions and therapeutic 
targets in liver injury and repair. Physiol Rev. 2009,89(4):1269-339. 
Spengler U. Hepatic microcirculation: a critical but neglected factor for the outcome of viral 
hepatitis. J Hepatol. 2009,50(3):631-3. 
Nishida J, McCuskey RS, McDonnell D. Protective Role of NO in Hepatic Microcirculatory 
Dysfunction during Endotoxemia. Am J Physiol. 1994,267(6 Pt 1):G1135-41. 
Ramadori G. The stellate cell of the liver. Virchows Arch B Cell Pathol 1991, 61:147-158. 
Pinzani M. Hepatic stellate (ITO) cells: expanding roles for a liver-specific pericyte. J 
Hepatol 1995, 22: 700-706. 
ZHANG Jie, XU Lieming, ZHANG Wenwei. Study of Effect and Mechanism of Salvianolic-
acid B Salt on Inhibiting the Contraction of Human Hepatic Stellate Cells Induced 
by Endothelin-1. Chinese J Integrative Medicine. 2009,29(1):60-64. 
 
Portal Hypertension – Causes and Complications 120 
She Weimin, Hu Dechang, Zhou Zhaohui, Gu Weiguang and Wang Jiyao. Clinical study of 
Ganping Capsule to treat fibrotic patients with chronic hepatitis B. Chinese 
Hepatol. 2002,7(4):254-255. 
Xu Lieming, Liu Ping, Liu Cheng, Gu Hongtu, Xue Huiming, Lv Gang and Li Fenghua. 
Action of Fuzheng Huayu 319 decoction on liver fibrosis in chronic hepatitis B  
Chinese J Hepatol. 1997,5(4):207-209. 
Xu Lieming, Liu Cheng and Liu Ping. Effect of lithospermate B on proliferation and shape of 
rat hepatic Fat-storing cells and production of extracellular matrix in vitro.    
Chinese J Hepatol. 1996,4(2):86-89. 
Liu Ping, Zhu Dayuan, Hu Yiyang, Jiang Fuxiang, Liu Cheng, Wang Baode, Xu Lieming, 
Jiang Shanhao, Liu Chenghai and Zhang Zhiqing. Study of Salvianolic-acid B on 
anti-fibrosis in chronic hepatitis B. Bulletin of Medical Research 2003,32(2):16-17. 
L Xu, A Y Hui, E Albanis, M J Arthur, S M O’Byrne, WS Blaner, P Mukherjee, S L 
Friedman, F J Eng. Human Hepatic Stellate Cell Lines, LX-1 and LX-2: New Tools 
for Analysis of Hepatic Fibrosis. Gut  2005;54:142-151. 
7 
Role of Manganese  
as Mediator of Central Nervous System: 
Alteration in Experimental Portal Hypertension 
Juan Pablo Prestifilippo1,2, Silvina Tallis2,  
Amalia Delfante2, Pablo Souto2,  
Juan Carlos Perazzo2 and Gabriela Beatriz Acosta1,2 
1Institute of Pharmacological Research (ININFA),  
National Research Council of Argentina (CONICET) 
 and Department of Pathophysiology,  
School of Pharmacy and Biochemistry,  
University of Buenos Aires, Buenos Aires,  
2Laboratory of Portal Hypertension,  
School of Pharmacy and Biochemistry & Hepatic Encephalopathy,  
University of Buenos Aires, Buenos Aires,  
Argentina 
1. Introduction 
Portal hypertension (PH) is a major syndrome that frequently accompany chronic liver 
diseases such as cirrhosis. Prehepatic PH develops a splanchnic hyperdynamic circulation 
and hyperemia with increased splanchnic resistance and production of collateral vessels that 
drive splanchnic blood flow to systemic circulation (Chojkier & Groszmann, 1981). Several 
substances have been proposed as mediators of this hypodynamic circulatory state 
including prostacyclins, nitric oxide and endotoxins (Bosch et al., 1992; Reiner & 
Groszmann, 1999; Palma et al., 2005). PH is found in patients with cirrhosis, and in portal 
vein thrombosis. It is characterized by an increase in splanchnic blood flow and pressure, 
among others caused by abdominal blood flow resistance, secondary to important liver 
parenchyma alterations (fibrosis or cirrhosis). 
Recent studies have demonstrated that experimental PH in rats is also a sub-clinic model of 
Minimal Hepatic Encephalopathy (MHE) (Butterworth et al., 2009), since rats with PH 
develop hyperammonemia, electrophysiology alterations, blood-brain barrier (BBB) 
breakdown, hippocampal mitochondrial dysfunction and changes in frontal cortex and 
hippocamus on glutamate uptake (Scorticati et al., 2004; Lores-Arnaiz et al., 2005; Eizayaga 
et al., 2006; Acosta et al., 2009; Bustamante et al., 2011). 
Chronic hepatic encephalopathy (HE) is a complex neuropsychiatric syndrome associated 
with liver dysfunction, such as cirrhosis. The pathophysiology of HE is poorly understood 
and there are few high-quality diagnostic tests and markers. As a result, its treatment has 
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improved only slightly over the last several decades (Zafirova & O’Connor, 2010). The 
current classificaton of HE is: Type A HE associated with acute liver failure, Type B with 
portosystemic bypass without intrinsic liver disease and Type C with cirrhosis (Merino et 
al., 2011; Ferenci et al., 2002). In chronic liver dysfunction, such as cirrhosis, it occurs more 
insidiously causing a range of neuropsychiatric disturbances which include psychomotor 
dysfunction, impaired memory, increased reaction time, sensory abnormalities and poor 
concentration (Albrecht, 1998; Scorticati et al., 2005; Albrecht et al., 2007). In its severest 
forms, patients may develop confusion, stupor, coma and death (Ferenci et al., 2002). 
Hyperammonemia is a well-known toxic substance for the central nervous system (CNS), 
especially when levels exceed the antitoxic capacity of the brain cells. Arterial blood 
ammonia concentrations are frequently elevated in patients with portal-systemic 
encephalopathy and studies in experimental animal models of chronic liver failure reveal 
blood and brain  ammonia concentrations approaching the millimolar range (normal range 
0.05-0.10 mM) (Butterworth, 1991; Therrien et al., 1991).  
The CNS is an important target for manganese (Mn), an essential element that is normally 
excreted via the hepatobiliary route (Papavasiliou et al., 1966; Teeguarden et. al., 2007). 
Manganese has a key role in the normal functioning of several enzymes including 
mitochondrial superoxide dismutase, glutamine synthetase, and phosphoenolpyruvate 
carboxykinase (Bentle et al., 1976; Stallings et al., 1991). The metal was first considered to be 
neurotoxic more than 150 years ago, when workers employed in grinding black oxide of Mn 
developed an unsteady gait and muscle weakness (Couper, 1837). Since that time, many 
cases of Mn neurotoxicity (manganism), a neurologic disease characterized by psychological 
and neurologic abnormalities, have been reported, particularly in miners, smelters, welders, 
and workers involved in the alloy industry (Mena et al., 1967; Eamara et al., 1971). 
As manganese acts as a cofactor for many enzymes and therefore, it plays important 
biological functions (Keen et al., 1984). Nevertheless, high concentration of Mn exerts toxic 
effects in the brain (Yamada et al., 1986) and the accumulation of Mn in the basal ganglia 
produces an irreversible neurological syndrome similar to Parkinson's disease. Typically, 
patients exhibit extrapyramidal changes that include hypokinesia, rigidity and tremor 
(Cotzias, 1958; Mena, 1974). High levels of this metal can cause alterations in development 
as well as reproductive dysfunction (Grey & Laskey, 1980; Laskey et al., 1982). Manganese 
deficiencies produce impairment of growth and reproduction in rats of both sexes (Boyer et 
al., 1942; Smith et al., 1944; Prestifilippo et al., 2008). Manganese exists as divalent and 
trivalent forms in the plasma (Nandedkav et al., 1973; Scheuhammer and Cherian, 1985) and 
both may be transported into the brain across the BBB and reach the blood–cerebral spinal 
fluid (CSF) and accumulates in the brain (Aschner 1992; 1999). 
Importantly, these not only occurs in animal models but in human since the patients with 
chronic liver failure have been shown to exhibit increased serum and brain levels of Mn and 
display many of the clinical and pathological features associated with manganese toxicity 
(Krieger et al., 1995; Spahr et al., 1996; Hauser et al., 1994; 1996; Sassine et al., 2002). 
Excessive deposition of Mn in brain has also been demonstrated in a rat model of cirrhosis 
(Rose et al., 1999). This elevation is believed to be due to decrease elimination of manganese 
via biliary excretion (Papavasiliou et al., 1966; Teeguarden et al., 2007), and to increase 
systemic availability due to portal-systemic shunting associated with chronic liver disease 
(Spahr et al., 1996;  Rose et al., 1999). 
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1.1 Study of the effect of manganese in plasma and hypothalamus levels in portal 
hypertensive rats 
Different studies indicated that participation of manganese in HE (Hauser et al., 1994; 
Matsuda et al., 1994; Krieger et al., 1995; Pomier-Layrargues et al., 1995; Siger-Zajde et al., 
2002). Therefore we determinate manganese concentration on plasma and the effects of this 
metal in hypothalamus in PH rats. 
1.2 Investigate the action of manganese of manganese on amino acids and nitric 
oxide levels 
Amino acids play an important role in the maintenance of homeostasis on the brain. 
Considering that manganese may also have a role in the pathogenesis of chronic HE (Hauser 
et al., 1994; Matsuda et al., 1994; Krieger et al., 1995; Poimier-Layrargues et al., 1995). The 
second point was to analyze the effects of manganese on amino acids levels in 
hypothalamus using the same animal model.  
The third point to consider in this work was whether changes produced by manganese in 
PH may be due to the mechanism of nitric oxide pathway.  
2. Materials and methods 
2.1 Animals and surgical procedures  
Adult male Wistar rats (240–260 g of body weight) were kept under controlled conditions 
of light (12 h light/dark cycle: 8 a.m. to 8 p.m.). They were housed under constant 
temperature and a 12-hour light-dark cycle and kept in an acclimatized animal room (21-
23 ºC) with ad libitum access to dry food and tap water. Special care for perfect air renewal 
was taken. 
All animal procedures were performed in accordance with our institutional guidelines after 
obtaining the permission of the Laboratory Animal Committee and with the U.S. National 
Institute of Health Guide for the Care and Use of Laboratory Animals (NIH publication N8 
80-23/96).  
Prehepatic PH in rats was induced by a calibrated stenosis of the portal vein according to 
Chojkier & Groszmann (1981). Rats were lightly anesthetized with ether and then a midline 
abdominal incision was made. The portal vein was located and isolated from surrounding 
tissues. A ligature of 3.0 silk sutures was placed around the vein, and snugly tied to a 20-
gauge blunt-end needle placed alongside the portal vein. The needle was subsequently 
removed to yield a calibrated stenosis of the portal vein, after which the abdominal incision 
was sutured. Operations were performed at 2 p.m. to obey circadian rhythm. Fourteen days 
after portal vein ligation, animals exhibit an increase in portal pressure. Sham-operated rats 
underwent the same experimental procedure, except that the portal vein was isolated but 
not stenosed. Animals were placed in individual cages and allowed to recover from surgery. 
Rats were sacrificed by decapitation at two weeks after surgery.  
All efforts were made to minimize suffering of animals and to reduce the number of animals 
used.  
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2.2 Portal pressure measurement 
Fourteen days after the corresponding operation, the rats were anesthetized with 
intraperitoneal sodium pentobarbital (40 mg/kg). Portal pressure was measured through a 
needle placed in the splenic pulp, and maintained in place by cyanoacrylate gel. The needle 
was cannulated to a polyethylene catheter (50) filled with a heparinized saline solution (25 
U/mL), and connected to a Statham Gould P23ID pressure transducer (Statham, Hato Rey, 
Puerto Rico), coupled to a Grass 79D polygraph (Grass Instruments, Quincy, MA, USA). 
2.3 Determination of plasma ammonia 
Blood samples were obtained by abdominal aortic artery puncture for the determination of 
biochemical parameters. Ammoniac Enzymatic UV kits (Biomerieux-France) were used to 
determine plasma ammonia concentration. 
 
 Sham operated PH 
Portal pressure (mmHg) 7.3±1.4 13.5±1.3* 
Plasma Ammonia(μm/L) 26±4 82±17 ** 
Table 1. Determination of portal pressure and plasma ammonia levels 
Portal pressure was 7.3 ± 1.4 mm Hg in the sham-operated group versus  PH group vs 13.5 ± 
1.3 mm Hg by an enhanced 184% (* p<0.05). In other hand,  plasma ammonium levels was 
26 ± 4 μm/L in the sham-operated group versus PH group was 82 ± 17 μm/L, by an increase 
of 315% (** p <0.01). 
2.4 Determination of manganese levels and in Hypothalamus  
For the determination of manganese levels in tissue, brains were rapidly dissected and the 
hypothalamus was removed. Tissue blocks were snap frozen in liquid nitrogen and saved at 
-80 ºC and blood was digested by digestion in oxidizing acid, both were analysis by 
inductively coupled plasma mass spectrometry as described (Melnyk et al., 2003). The 
method was considered in Sham operated when the duplicates were ± 15% of the expected 
value and blank values were < 0.001 ppb. 
 
Fig. 1. Manganese analyses. A significant increase of manganese (*p < 0.05) was observed in 
plasma levels in PH groups compared with the respective Sham operated. 
Sham operated 
 




Fig. 2. Effects of Manganese on hypothalamus. The stenosis of the portal vein produced an 
accumulation of Manganese in the brain by 14 days after surgery versus sham operated  
resulting an increase in Manganese levels in hypothalamus *(p <0.05).  
2.5 In vivo studies 
The rats were anesthetized (ketamian/xilasiana) and implanted a cannula into the lateral 
cerebral ventricle, using a stereotaxic instrument and coordinates from the atlas. The correct 
localization of the cannula in the ventricle was confirmed at the end of the experiment. The 
experiments were performed a week after the implantation of the cannula. The day of 
experiment, conscious, freely moving rats were divided into two groups of 10 animals each. 
The rats were microinjected intracerebroventricularly (i.c.v.) during 1 min with 5 μl of sterile 
saline (control group) or 10 μg of MnCl2/5 μl sterile saline. After decapitation, the brains 
were rapidly dissected and the hypothalamus was removed. All incubations were carried 
out in a Dubnoff shaker (50 cycles per min; 95% O2/5% CO2) at 37°C. The hypothalami 
(seven to eight for each group) were preincubated individually in glass tubes in 500μl of 
Krebs-Ringer bicarbonate-buffered medium (NaCl 124.40 mM, KCl 4.98 mM, NaHCO3 24.88 
mM, CaCl2 1.50 mM, MgCl2 1.42 mM, KH2PO4 1.25mM containing 0.1% glucose, pH: 7.4). 
After this preincubation (15 min) the medium was discarded and replaced with fresh 
medium alone or containing the substances to be tested. The incubation continued for 30 
min. At the end of the incubation period the media were removed and the tissues were 
homogenized and submitted to appropriate extraction procedure and stored at −20 °C until 
the respective assays were conducted. 
2.6 NOS enzimatic activity determination 
Determination of NOS activity was performed by a modification (Canteros et al., 1995) of 
the 14C-arginine method of Bredt & Snyder (1989). After the incubation period (30 min) 
the hypothalamus  were immediately homogenized in 0.5 ml of N-(2-hydroxyethyl)-
piperazine-N-2-ethanesulfonic acid (HEPES) (20mM, pH: 7.4) with addition of CaCl2 
(1.25mM) and DL-dithiothreitol (DTT, 1mM). The reaction was started by adding NADPH 
(nicotinamide adenine dinucleotide phosphate, reduced) (120M) and 200.000 dpm of 14C-
arginine (360 mCi/mmol) to the homogenates. The tubes were incubated for 15 min at 
Sham operated 
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37ºC in a Dubnoff metabolic shaker (50 cycles per min and 95%O2;5%CO2 atmosphere). At 
the end of this incubation period, the tubes were immediately centrifuged at 10.000 g for 
10 min at 4ºC. The supernatants were immediately applied to individual columns 
containing 1 ml of Dowex AG 50 W-X8 200 mesh sodium form, and washed with 2.0 ml of 
double distilled water. All collected fluid from each column was counted for 14C-citrulline 
activity in a scintillation counter. NOS converts arginine into equimolar quantities of 
citrulline and NO, the data were expressed as pmol of NO produced per hypothalamus 
per min. 
  
Fig. 3. Determination of NOS activity. Results show that Manganese increased NOS activity 
(**p<0.01) evaluated by the conversion of 14C-arginine into 14C-citrulline compared with the 
control group.  
2.7 Quantification of GABA, aspartate and glutamate 
The method described by Durkin et al. (1988) allowed the isolation of -aminobutiric acid 
(GABA), aspartate and glutamate. Aliquots of 50 μl of homogenates were mixed with 400 μl 
of O-phthalaldehyde, 50 μl of 2-mercaptoethanol in 50 μl of ethanol, and 400 μl of 0.5 M 
sodium borate, pH 9 (reaction mixture). After 30 min at room temperature, 50 μl of the 
reaction mixture were injected into the HPLC column. The O-phthalaldehyde derivates 
were then separated on a reverse-phase column and eluted with a buffer of 
acetonitrile/sodium acetate 1:9 (v/v), pH 4 at a flow rate of 1.6 ml/min. The concentrations 
of amino acids were extrapolated from curves made with known amounts of standard 
amino acids. 
Different functions of the CNS are mediated by the action of diverse amino acids 
neurotransmitters such as aspartate, glutamate and GABA. Therefore, with the purpose of 
determining whether manganese could affect their secretions, evaluating the release and the 
content of aspartate, glutamate and GABA from the hypothalamus obtained after i.c.v. 
injection of manganese determined by high-performance liquid chromatography (HPLC). 
GABA release by 2 folds (* p< 0.05) compared with the respective control group. The others 
neurotransmitters not shown significative differences. 
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 Aspartate Glutamate GABA 
 Release Content Release Content Release Content 
Control 192 ± 11 1505± 171 157±10 309± 39 78 ± 7 84 ± 24 
Manganese 206± 11 1679± 63 163± 9 271±  47 106± 7 * 115 ±21 
Table 2. Release and concentration of different amino acids such as aspartate, glutamate and 
GABA following the injection of manganese. 
2.8 Drugs, chemicals and radiolabeled compounds  
Manganese chloride (MnCl2) was purchased from Anedra (San Fernando, Buenos Aires, Argentina). 
HEPES, DTT, NADPH, Glutamate, Aspartate and GABA were purchased from Sigma Aldrich (St 
Louis, MO , USA). Dowex AG 50 W-X8 200-400 mesh sodium form was obtained from Bio-Rad 
(Hercules, CA), and the 14C-arginine-monohydrochloride 360 mCi/mmol was from Amersham 
Pharmacia (Buckinghamshire, HP, UK). All other chemical materials used in this work were from 
analytical grade.  
2.9 Statistical analysis 
Experiments were repeated at least twice employing seven to eight animals per group in 
each experiment. All data are expressed as the mean ± SEM. Comparisons between groups 
were performed by using a one-way ANOVA followed by the Student-Newman-Keuls 
multiple comparison tests for unequal replicates. Student's t-test was used when comparing 
two groups. Differences with p values < 0.05 were considered significant. 
3. Conclusions 
Experimental prehepatic PH produces a hyperdynamic redistribution of splanchnic 
circulation and minimal liver damage. Ammonia was considerate the major responsible of 
the alterations in CNS included cytotoxic brain edema characterized by swelling of 
astrocyte. However the ammonia is not the only toxic and as Shawcross & Jalan (2005) 
demonstrated the participation of other relevant metabolic molecules such as manganese. 
In the present work we showed for the first time that rats with experimental prehepatic PH 
presented increase of manganese level in plasma and hyphotalamus. The manganese is 
transported to the liver after absorption from the gut and the liver may be important as a 
deposit for manganese, with hepatic manganese later delivered to the brain (Takeda, 1998). 
Rats with PH show a redistribution of splanchnic circulation and increase the different toxic 
in blood including ammonia and manganese as shown in this work. Even more, patients 
with abnormal deposit of manganese in the basal ganglia has been estimated by magnetic 
resonance imaging was associated with the elevated levels of manganese in the blood 
(Krieger et al., 1995; Siger-Zajdel et al., 2002).  
This metal is able to enter the brain through the cerebral vasculature and the spinal fluid. 
The mechanism by which Mn crosses the BBB is not yet well understood, but involves 
binding of the metal to transport systems such as transferrin (Aschner & Aschner, 1992; 
1999). Also, as Mn levels rise in blood, the influx into the spinal fluid rises and entry across 
the choroid plexus becomes more important (Murphy et al., 1991). Importantly, Mn 
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circulation and minimal liver damage. Ammonia was considerate the major responsible of 
the alterations in CNS included cytotoxic brain edema characterized by swelling of 
astrocyte. However the ammonia is not the only toxic and as Shawcross & Jalan (2005) 
demonstrated the participation of other relevant metabolic molecules such as manganese. 
In the present work we showed for the first time that rats with experimental prehepatic PH 
presented increase of manganese level in plasma and hyphotalamus. The manganese is 
transported to the liver after absorption from the gut and the liver may be important as a 
deposit for manganese, with hepatic manganese later delivered to the brain (Takeda, 1998). 
Rats with PH show a redistribution of splanchnic circulation and increase the different toxic 
in blood including ammonia and manganese as shown in this work. Even more, patients 
with abnormal deposit of manganese in the basal ganglia has been estimated by magnetic 
resonance imaging was associated with the elevated levels of manganese in the blood 
(Krieger et al., 1995; Siger-Zajdel et al., 2002).  
This metal is able to enter the brain through the cerebral vasculature and the spinal fluid. 
The mechanism by which Mn crosses the BBB is not yet well understood, but involves 
binding of the metal to transport systems such as transferrin (Aschner & Aschner, 1992; 
1999). Also, as Mn levels rise in blood, the influx into the spinal fluid rises and entry across 
the choroid plexus becomes more important (Murphy et al., 1991). Importantly, Mn 
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accumulates in the hypothalamus (Deskin et al., 1980; Pine et al., 2005) and is known to be 
taken up by both neurons and glial cells (Tholey et al., 1990) and, hence, suggesting a 
potential role in neuronal/glial communications within the developing hypothalamus.  
We investigated the participation of hypothalamus NO production and we found that the 
rats with administer this metal increased the activity of NOS. So we can deduce that  nitric 
oxide  has been involved in  this  pathophysiological brain processes 
This metal is able to enter the brain through the cerebral vasculature and the spinal fluid. 
The mechanism by which manganese crosses the BBB is not yet well understood, but 
involves binding of the metal to transport systems such as transferrin (Aschner & Aschner, 
1992; 1999). On the other hand, has been observed a decrease of GABA concentration 
opposite to the chronic exhibition to manganese in certain regions of the CNS as the globo 
pallidum, but not in substance nigra or hippocampus (Bonilla et al., 1994; Zwingmann et al., 
2003). This effect on GABA levels produces to itself across the direct action of the manganese 
on the expression of glutamic decarboxylase, enzyme that regulates GABA synthesis 
(Tomas-Camardiel et al., 2002). 
When the Mn is  accumulated in the synapsis it produces a consistent neuropathy with an 
excitocitotoxic effect, suggesting that the mechanism of glutamate is involved in the 
development of the pathology described by the manganese. These findings suggest that the 
manganese induce an increase in nitric oxide synthase production probably correlated to 
GABAergic and glutamatergic hypothalamic neurons that form a part of a network neuronal 
autoregulation. 
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1. Introduction 
Hemocytopenia is very common in patients with cirrhotic portal hypertension. These patients 
experience complications of monolineage or multi-lineage peripheral cytopenias. However, 
the range of variation of these cytopenias is unclear, and the question of whether they affect all 
patients remains uncertain. In general, it is believed that such cytopenias are caused by 
hypersplenism; however, this may not always be the case as numerous factors that cause 
hemocytopenia exist, and hypersplenism is only one of them. Patients with hypersplenism 
experience hemocytopenia, but not all cytopenias are caused by hypersplenism.  
Can cytopenias be graded? How do cytopenias affect prognosis? According to the 
observation of clinical cases, cytopenias may, in fact, influence prognosis. These questions 
will be discussed in this chapter, which integrates clinical data from 366 cases investigated 
by the author.  
2. Changes of peripheral blood cells 
It has been accepted that “all patients with splenomegaly due to cirrhotic portal hypertension 
will manifest cytopenias in peripheral blood [1]; however, certain limitations were noticed in 
the traditional opinion by the author after studying clinical data from 366 cases.  
This study included 250 male patients and 116 female patients (a total of 366 patients), and 
the ratio of males to females was 2.2:1. The patients’ ages ranged from 5 to 79 years, with an 
average of 43 years. All the patients had hepatic cirrhosis and an enlarged spleen. The 
average spleen size was 224mm×159mm×95mm, as measured by B ultrasound or CT scan. 
Upper gastrointestinal imaging and gastroscopy revealed that there were medium-to-severe 
varices in the distal esophagus and gastric fundus (Figure 1). Seventy-four patients (20.2%) 
were hospitalized for gastrointestinal hemorrhage, and 248 (67.8%) patients had previously 
experienced hemorrhaging.Thirty-six patients (9.8%) had a normal blood cell count and 330 
patients had peripheral cytopenias, in which mono-lineage cytopenias accounted for 30% 
(99/330), bi-lineage cytopenias accounted for 35.8% (118/330) and tri-lineage cytopenias 
accounted for 34.2% (113/330).The range of variation of hemocytopenia is listed in Table 1. 
Two-hundred ninety-seven cases underwent bone marrow aspiration, in which 155 cases 
(52.2%) showed moderate proliferation. The remaining cases were normal.  
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Fig. 1. severe varices in the distal esophagus and gastric fundus. 
 
Item N % WBC (×109/L) RBC (×1012/L) PLT (×109/L) 





WBC+PLT 30 9.1 2.76±0.71 (median 2.73) ---- 
56.9±21.2 
(median 53.8) 
RBC+PLT 48 14.5 ---- 2.83±0.20 (median2.63) 
67.2±21.3 
(median 62.5) 
WBC+RBC 40 12.1 2.85±0.76 (median 2.68) 
3.11±0.30 
(median 2.96) ----- 
PLT 27 8.2 ---- ---- 66.2±23.3 (median 61.7) 
WBC 14 4.2 2.98±0.65 (median 2.82) ----- ----- 
RBC 58 17.6 ---- 2.71±0.50 (median 2.56) ---- 
Note: The difference in WBC was significant between Group 1 and Group 2, 4 and 6 (P＜0.05), and not 
significant between Group 2 and Group 4 and 6 (P＞0.05); The difference in RBC was significant 
between Group 1 and Group 7, between Group 3 and Group 4, and between Group 4 and Group 7 
(P＜0.05), not significant between Group 1 and Group 3 and 4 (P＞0.05), and not significant between 
Group 3 and Group 7 (P＞0.05); And the difference in PLT was not significant when the 4 groups were 
compared (P＞0.05, F=1.61). 
Table 1. Hemocyte decrease (mean±SEM) in 330 cases ( x ±s)  
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3. Causes of hemocytopenia in peripheral blood 
There are numerous causes for cytopenias in patients with hepatocirrhotic portal 
hypertension, including the toxic effects of hepatic viruses and alcohol on the bone marrow, 
hypofunctioning of the liver [2], splenomegaly, hypersplenism, gastrointestinal bleeding, and 
hematopoietic dysfunction caused by malnutrition. In most cases, cytopenias are caused by 
multiple factors.  
3.1 Toxic effects of hepatic virus 
Hepatic viruses can directly suppress the differentiation and proliferation of hemopoietic 
stem cells and progenitor cells [3]. (2) Hepatic virus can cause disorders of cellular immunity 
and humoral immunity in vivo, to compromise the body’s capacity to eliminate the viruses. 
The constant presence of viruses damages the hemopoietic functioning of the bone marrow 
[4]. (3) Viruses can impair the activity of bone marrow stromal cells to reduce the secretion of 
cytokines and to affect the proliferation of hemopoietic cells. (4) During pathogenesis caused 
by cytokines, the increase in the γ- interferon level and decrease in the interleukin-6 and 
erythropoietin levels, can affect the proliferation of hemopoietic cells [5]. The hepatitis B 
virus (HBV) and hepatitis C virus (HCV) can suppress the bone marrow, and affect the 
growth of all karyocytes in the bone marrow. This may lead to hypoplastic anemia, and 
patients must undergo a bone marrow transplant to survive.  
The liver and bone marrow are target tissues of HBV. This virus can kill or injure 
hemopoietic cells directly, causing myelosuppression, and leading to leukopenia and 
reduction in the detoxification ability of the liver. This renders the body more sensitive to 
certain medicines, toxins and environmental pollutants, and cause hypofunctioning of bone 
marrow hematopoiesis. Leukopenia further damages immunity to cause the active 
replication of HBV, forming a vicious cycle. Currently, antiviral therapy is the first choice 
for chronic hepatitis B patients; however, antiviral medications also lead to 
myelosuppression. Therefore, monitoring leukocytes in the peripheral blood is conducive to 
the regulation of antiviral therapy. If the leukocyte count is lower than 2×109/L, antiviral 
therapy should be discontinued. Both HBV and HCV can induce suppression of the 
precursor cells of the bone marrow, and affect the lymph cells, causing lymphopenia and 
hypofunctioning of the bone marrow.  
3.2 Toxic effects of alcohol 
In the 1980s, studies of patients with alcoholic liver disease reported that neutrophil 
granulocytes demonstrated retarded growth and delayed release in the bone marrow. Later 
studies showed increased apoptosis of neutrophil granulocytes. Patients with end-stage 
cirrhosis complicated with neutropenia underwent Granulocyte-Macrophage Colony 
Stimulating Factor (GM-CSF) therapy for 7 days, and the leukocyte count increased more 
than 100%. However, the increased leukocytes could not be destroyed in the spleen, for no 
leukocyte fragments were found in the spleen. Ethanol can suppress or stimulate cellular 
proliferation, but in most cases, it suppresses cellular growth and increases cytotoxic effects. 
Its mechanism includes retarded cellular proliferation and induced apoptosis and necrosis [6-
8]. A foreign study reported [9] that long-term alcoholism could cause abnormalities in the 
bone marrow and peripheral blood. In that study, 91% patients manifested changes in the 
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peripheral blood including granulopenia, thrombopenia, etc., and changes in bone marrow 
included highly-differentiated hemopoietic tissue and myelofibrosis. Long-term alcohol 
consumption can reduce the absorption of folic acid and vitamin B12, which impairs the 
synthesis of erythrocytes. Djordjevic et al [10] believed both that hepatic viruses and 
alcoholism were able to cause cytopenias.  
3.3 Hypofunctioning of liver 
Hypofunctioning of the liver reduces degradation of toxic metabolites by liver cells; in this 
case, the liver cannot detoxify the toxins that suppress the bone marrow, thus affecting 
hemopoietic function. The incidence of liver disease combined with thrombopenia is 15% - 
70%. It is usually at mild or moderate level, and its severity is a prognostic indicator. In liver 
diseases, thrombopenia is closely related to hepatocirrhosis, anti-platelet autoantibodies [11], 
bone marrow suppression caused by HBV and HCV, and toxic effects from excessive 
alcohol consumption [12]. The discovery of thrombopoietin (TPO) in 1994 ushered in a new 
era in the study of cirrhotic thrombopenia. TPO is almost exclusively produced in liver cells; 
a small proportion of TPO is produced in the kidneys, bone marrow stromal cells and 
muscle. The production of TPO depends on the function and amount of liver cells. In 
cirrhosis, functional liver cells become less able to decrease the secretion of TPO. A study by 
Wolber et al. [13], of cirrhotic patients developing from the compensation to decompensation 
stage, demonstrated that the expression or serum level of TPO changed from an increase to 
a decrease, and that the platelet count decreased gradually. The decrease in liver function, to 
some extent, was related to hemocytopenia and bone marrow dysfunction. Forbes et al. [14] 
suggested that hepatic exogenous myofibroblasts played an important role in hepatic 
fibrosis. In hepatic fibrosis, bone marrow stem cells differentiate into hepatic endothelial 
parenchymal cells but not into myofibroblasts. This indicates that the change in hemopoietic 
function and inner environment of the bone marrow might be somehow related to or 
interactive with the occurrence and development of hepatic fibrosis or even hepatic 
cirrhosis. These observations suggest that changes in the bone marrow of cirrhotic patients 
do not result from one single factor but a combination of multiple factors, with a 
complicated regulation mechanism. The changes in bone marrow might be directly or 
indirectly related to the severity of hepatic cirrhosis and changes in liver or spleen function. 
Their relationship and the detailed mechanism remain to be further explored. Solving this 
puzzle will be of significant importance to clinical practice.  
3.4 Splenomegaly and hypersplenism 
Hypersplenism is secondary to splenomegaly. Two mechanisms for splenomegaly caused 
by liver diseases exist. The first mechanism is expansionary splenomegaly, including 
congestive splenomegaly caused by increased venous pressure and hyperemic 
splenomegaly caused by increased splenic arterial flow; the former is the main cause. The 
second mechanism is hypertrophic splenomegaly, including: (1) Hepatic virus antigen and 
exogenous antigens unprocessed by the liver due to a shunting procedure, can stimulate the 
spleen and lead to hypertrophy of the immune tissue in the spleen (splenic corpuscle, 
periarterial lymphatic sheath, marginal zone). (2) In hepatic cirrhosis, increased necrotic 
cells and hypofunctioning of the hepatic reticuloendothelial system promote compensatory 
hypertrophy and lead to hyperfunctioning of the splenic reticuloendothelial system. (3) 
Increased intrasplenic pressure, stasis of blood circulation, change in the metabolic 
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environment and other factors can cause fibroplastic proliferation. Generally speaking, 
intrasplenic immune tissues show obvious hypertrophy during hepatitis, and middle or end 
stage cirrhotic patients mainly manifest splenic sinus dilation, hypertrophy of 
reticuloendothelial system and fibrous tissues.  
Currently, there are several hypotheses concerning the mechanism of cytopenia: (1) The 
hypothesis of intrasplenic trapping[15]: After the formation of splenomegaly, blood volume 
in the spleen increases, and a great number of leukocytes, erythrocytes and platelets are 
trapped in the spleen. The ratio of trapped hemocytes compared with that in the normal 
spleen is 5.5- to 20-fold, resulting in hemocytopenia in the peripheral blood. (2) The 
hypothesis of cytophagy: There are a large number of mononuclear-macrophages in the 
spleen. Under pathological circumstances, mononuclear-macrophages demonstrate 
hyperfunctioning in cytophagy and destruction of hemocytes, especially erythrocytes [16]. 
Recently, a study using erythrocyte creatine (EC), the life-span sensitive marker of 
erythrocytes, revealed that the EC level was significantly increased in patients with 
splenomegaly due to post-necrotic cirrhosis compared with patients with hepatic cirrhosis 
with normal spleens (P<0.05). In addition, the same was observed compared with the 
normal control group but without a significant difference [17]. This suggested that 
splenomegaly accelerated the destruction of erythrocytes and the determination of the EC 
value could be used to evaluate the severity of cirrhotic splenomegaly [18]. (3) The spleen can 
produce excessive “splenic hormones” to suppress the hemopoietic function of the bone 
marrow, and accelerate the destruction of and trap produced hemocytes to prevent them 
from entering into blood circulation [19]. (4) The hypothesis of autoimmunity: The spleen is a 
large lymph organ that produces antibodies. Antigens unprocessed by the liver enter the 
marginal zones of splenic lymph follicles (splenic nodule) and activate the pro-lymphocytes 
and plasma cells to generate antibodies. These antibodies can destroy hemocytes causing 
hemocytopenia in the peripheral blood.  
3.5 Gastrointestinal bleeding 
Gastroesophageal fundus varices bleeding is a common complication for patients with 
cirrhotic portal hypertension. Gastrointestinal bleeding of any cause can directly lead to a 
decreased amount of hemocytes in the effective circulatory blood volume.  
Chronic gastrointestinal bleeding can result in iron, folic acid and vitamin B12 deficiencies, 
and insufficient material for the synthesis of erythrocytes. Massive loss of erythrocytes can 
lead to anemia in patients. A Cr51 labeled-erythrocyte test demonstrated that only 20% of 
patients with cirrhosis complicated with anemia had increased erythrocytes in their spleens.  
3.6 Malnutrition 
Portal hypertensive gastropathy can cause malabsorption of hematopoietic growth factors 
and non-visible loss of nutrients necessary for hematopoiesis. Additionally, the lack of iron, 
folic acid and vitamin B12 results in insufficient materials for the synthesis of erythrocytes, 
leading to decreased hematopoiesis.  
The significance of exploring the causes of hemocytopenia in the peripheral blood in the 
patients with cirrhotic portal hypertension lies in its guidance for treatment and evaluation 
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for therapeutic effects. If hemocytopenia is caused by splenomegaly or hypersplenism, 
whether monolineage or multi-lineage, the decreased hemocytes will rise significantly after 
a splenectomy (P<0.01). The most sensitive is hemocyte is the platelet, which will increase 
half an hour after the operation, and reach the highest level in 2 weeks; afterwards it will 
decrease gradually and remain at a normal level. Leukocytes and erythrocytes would 
increase following the platelets. Hemocytopenia in the peripheral blood caused by non-
splenic factors does not lead to a definite increase in hemocytes after splenectomy.  
4. Hemocytopenia in peripheral blood and its prognosis  
The postoperative prognosis was classified as cured, improved or dead. There were few 
cases without any changes. In this analysis, cured meant meeting the following criteria: the 
disappearance of ascites, abdominal distension and hemorrhage, blood cell count increase 
and recovery, improvement in liver function, no severe postoperative complications, and 
meeting the criteria for being discharged from the hospital. On the other hand, dead meant 
that the patients died during hospitalization, or that the patients in critical condition died 
one week after early discharge from the hospital, as requested by the relatives. All others 
were considered improved. Comparison of the therapeutic effect between each mono-
lineage cytopenia group is shown in Table 2. Comparison of the therapeutic effect between 
mono-lineage cytopenia and bi-lineage and comparisons of the therapeutic effect between 
the mono-lineage cytopenia and bi-lineage cytopenias, the mono-lineage cytopenia and 
multi-lineage cytopenias are shown in Table3 and Table 4, respectively. 
 
Group Grade Case number 









2-3 10 6(60) 4 (40) 0 




<2 4 3 (75) 0 1 (25) 
χ2=10.908 
P=0.028<0.05 2-3 20 16 (80) 2 (10) 2 (10) 




<30 3 1 (33.3) 2 (66.7) 0 
χ2=2.220, 
P=0.695 30-50 1 1 (100) 0 0 





<30 78 32 (41) 39 (50) 7(9) 
χ2=4.236, 
P=0.375 
30-70 52 28 (53.8) 20 (38.5) 4 (7.7) 
>70 236 122 (51.7) 89 (37.7) 25 (10.6) 
Note: Among the four mono-lineage peripheral cytopenia groups, only the RBC group demonstrated a 
significant difference in intra-group comparison (p<0.05); comparison among the four groups revealed 
no significant difference (P>0.05).  
Table 2. Comparison of the therapeutic effect between each mono-lineage peripheral 
cytopenia group 
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Table 2 shows that only the RBC group demonstrated a significant difference (P＜0.05) in 
the intra-group comparison among the mono-lineage cytopenia groups. According to Table 
3 and Table4, there were significant differences (P＜0.05) in the therapeutic effects between 
mono-lineage cytopenias and multi-lineage cytopenias, indicating that the more severe the 
cytopenia, the worse the therapeutic results appeared to be. 
For the multi-lineage cytopenias(Table5), a multiple linear regression analysis was applied, 
and results revealed that thrombocytopenia was the major factor (P＜0.005) influencing the 
therapeutic effect, while leukopenia, erythropenia and decreased hemoglobin showed no 
statistical significance, and should not be considered. Erythropenia showed significant 
differences in the intra-group comparison of mono-lineage cytopenias, but no difference 
compared to other mono-lineage cytopenia groups. This was possibly due to the small 
sample size in the mono-lineage cytopenia groups. Leukopenia showed no significant 
difference in the univariate analysis or the multivariate analysis, and had no influence on 
the therapeutic results. For example, 2 patients recovered and were discharged from the 
hospital though their leukocyte count was lower than 1×109/L; this may have been because 
they had no serious postoperative infection. Theoretically, anemia is related to the 
prognosis, but in this research it showed no statistical significance in the univariate analysis 
or the multivariate analysis; the reason for this may have been because the blood 
transfusions before and during operation had a favorable effect on the blood condition. 
Although thrombocytopenia had no statistical significance in the univariate analysis, in the 
multiple linear regression analysis it was indicated to be the most important influential 
factor with the increase in case load.  
 
Item Total case number 
Therapeutic effect χ2, P value Cured (%) Improved (%) Dead (%) 
Mono-lineage 
cytopenia 99 60 (60.6%) 33 (33.3%) 6 (6.1%) χ2=7.446,  
P=0.024 Bi-lineage 
cytopenia 118 51 (43.2%) 51 (43.2%) 16 (13.6%) 
Table 3. Comparison of the therapeutic effect between the mono-lineage cytopenia and bi-
lineage cytopenia 
 
Item Total case number 
Therapeutic effect χ2, P value Cured (%) Improved (%) Dead (%) 
Mono-lineage 
cytopenia 99 60 (60.6) 33 (33.3) 6 (6.1) χ2=7.819, 
P=0.02 Multi-lineage 
cytopenia 231 102 (44.2) 102 (44.2) 27 (11.6) 
Table 4. Comparison of the therapeutic effect between the mono-lineage cytopenia and tri-
lineage cytopenia 
Thrombocytopenia is a significant and common complication in posthepatitic cirrhotic 
portal hypertension[20-21]; it is related to not only retention of blood cell in the spleen, blood 
cell aggregation and enhanced phagocytosis of macrophages[22], but also HBV infection, and 
compensation and regulation of marrow[23]. Djordevic et al[10]. proposed that extreme 
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that the patients died during hospitalization, or that the patients in critical condition died 
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Table 2 shows that only the RBC group demonstrated a significant difference (P＜0.05) in 
the intra-group comparison among the mono-lineage cytopenia groups. According to Table 
3 and Table4, there were significant differences (P＜0.05) in the therapeutic effects between 
mono-lineage cytopenias and multi-lineage cytopenias, indicating that the more severe the 
cytopenia, the worse the therapeutic results appeared to be. 
For the multi-lineage cytopenias(Table5), a multiple linear regression analysis was applied, 
and results revealed that thrombocytopenia was the major factor (P＜0.005) influencing the 
therapeutic effect, while leukopenia, erythropenia and decreased hemoglobin showed no 
statistical significance, and should not be considered. Erythropenia showed significant 
differences in the intra-group comparison of mono-lineage cytopenias, but no difference 
compared to other mono-lineage cytopenia groups. This was possibly due to the small 
sample size in the mono-lineage cytopenia groups. Leukopenia showed no significant 
difference in the univariate analysis or the multivariate analysis, and had no influence on 
the therapeutic results. For example, 2 patients recovered and were discharged from the 
hospital though their leukocyte count was lower than 1×109/L; this may have been because 
they had no serious postoperative infection. Theoretically, anemia is related to the 
prognosis, but in this research it showed no statistical significance in the univariate analysis 
or the multivariate analysis; the reason for this may have been because the blood 
transfusions before and during operation had a favorable effect on the blood condition. 
Although thrombocytopenia had no statistical significance in the univariate analysis, in the 
multiple linear regression analysis it was indicated to be the most important influential 
factor with the increase in case load.  
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Therapeutic effect χ2, P value Cured (%) Improved (%) Dead (%) 
Mono-lineage 
cytopenia 99 60 (60.6%) 33 (33.3%) 6 (6.1%) χ2=7.446,  
P=0.024 Bi-lineage 
cytopenia 118 51 (43.2%) 51 (43.2%) 16 (13.6%) 
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cytopenia 99 60 (60.6) 33 (33.3) 6 (6.1) χ2=7.819, 
P=0.02 Multi-lineage 
cytopenia 231 102 (44.2) 102 (44.2) 27 (11.6) 
Table 4. Comparison of the therapeutic effect between the mono-lineage cytopenia and tri-
lineage cytopenia 
Thrombocytopenia is a significant and common complication in posthepatitic cirrhotic 
portal hypertension[20-21]; it is related to not only retention of blood cell in the spleen, blood 
cell aggregation and enhanced phagocytosis of macrophages[22], but also HBV infection, and 
compensation and regulation of marrow[23]. Djordevic et al[10]. proposed that extreme 
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thrombocytopenia was life-threatening. A PLT count of < 30×109/L can cause variceal 
hemorrhaging in the distal esophagus and gastric fundus, and intraoperative and 
postoperative massive wound hemorrhaging, which can be life-threatening. Therefore, PLT 
transfusions should be performed before an operation to increase the PLT count to 50×109/L to 
ensure the safety of the patient. Cui et al[24]. reported that PLT transfusions combined with 
plasma fibrinogen transfusions led to better results. In some cases, after transfusion of 12-24 
units of PLT, the PLT count did not increase obviously, or decreased to the previous lowest 
count after 1-2 days. These types of patients are suitable for splenectomy[25]. Mastuura et 
al.[26]suggested that the excessive postoperative PLT count was also a life-threatening factor, so 
the condition of the patient should be closely monitored[27-28] when there is excessive platelet 
count, appropriate treatment should be administrated immediately.  
 
Item T value P value 
PLT 2.827 .005 
RBC -.439 .661 
WBC 1.516 .130 
HB 0.628 0.531 
Constant 1.395 .000 
Note: Regression equation Ŷ =1.395+0.151 PLT 
Table 5. Multiple linear regression analysis of blood cells in 366 cases 
5. Grading of hemocytopenia 
In 1907, Chauffard proposed the term ‘hypersplenism’ for the first time[29]. After further 
research, in 1949, Doan[30] proposed the criteria for hypersplenism: 1. enlarged spleen 2. 
mono-lineage or multi-lineage cytopenias 3. normal or proliferative bone marrow 4. 
disappearance of the pathological changes in the blood components after splenectomy. 
While these four criteria are indispensable for the diagnosis of hypersplenism, peripheral 
cytopenia and an increase and recovery in blood cell count after a splenectomy are the major 
criteria for assessing hypersplenism due to cirrhotic portal hypertension. This is because 
splenomegaly in itself is a necessary criterion for the cirrhotic portal hypertension. 
It is of vital significance to formulate a grading method, like the Child-Pugh Classification 
for liver function, to evaluate hypersplenism. However, grading of hypersplenism is 
extremely difficult for many reasons. 1) Some patients show decreased monolineage 
cytopenias and others show bi-lineage cytopenias. Even patients with pancytopenia barely 
meet the grading criteria. 2) There are many causes of hemocytopenia, but no examination 
can ascertain whether it is caused by splenomegaly or hypersplenism. A definite diagnosis 
would be made only when hemocytes returned to a normal level after splenectomy.  
Although grading of hypersplenism is difficult, hemocytopenia could be graded. According 
to a multiple linear regression, thrombopenia is the major factor influencing the effect of 
surgery. The 330 cases of cytopenia scores were mainly based on thrombocytopenia 
combined with erythropenia, as well as clinical experience (leukopenia). Scoring was as 
follows: PLT＞50<100×109/L was scored as 1 point, 30-50×109/L was scored as 2 points, 
<30×109/L was scored as 3 points; RBC 3-4×1012/L was scored as 0 points, and 
RBC<3×1012/L was scored as 1 point; WBC 2-4×109/L was scored as 0 points, and 
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WBC<2×109/L was scored as 1 point. Except for 36 cases with normal blood cell counts and 
69 cases with 0 points, the influences of scores on postoperative prognoses in 261 cases are 
shown in Table 6 (totally 105 cases). There were significant differences between the 3 groups 
(P＜0.05). Therefore, peripheral cytopenias were graded as mild (<2), medium (2-3) or 
severe (>3) (Table 7). 
Thus, only cytopenias can be graded. In the present study, the cases were scored and 
graded based on the accumulated scores. The scoring criteria used in this study were: 
1.Analytical results of multiple linear regression: F value obtained from multiple linear 
regression equation was 7.993 (P＜0.005), indicating that multiple linear regression was 
applicable. The equation Ŷ=1.395+0.151PLT indicated that thrombocytopenia was the 
major influential factor for postoperative prognosis. Therefore, according to the severity 
of the thrombocytopenia, 1 to 3 points was scored. 2. Intra-group comparison of 
erythropenia showed a significant difference (P＜0.05), so an RBC count ≤3×1012/L was 
scored as 1 point. 3. According to clinical experience, leukopenia can cause severe 
infection and lead to undesirable effects. A WBC of count ≤2×109/L was scored as 1 point, 
though leukopenia showed no statistical significance in either the univariate analysis or 
multivariate analysis. A total score of ＜2 points indicated mild cytopenia, 2-3 points 
indicated medium cytopenia and ＞3 points indicated severe cytopenia. If cytopenias are 
caused by hypersplenism, this grading standard could also be used for grading 
hypersplenism or as a reference. 
 
Item Total case number 
Therapeutic effect 
χ2, P value 
Cured (%) Improved (%) Death (%) 
1 point 136 80 (58.8%) 43(31.6%) 13 (9.6%) 
χ2=10.163 
P=0.034 2-3 points 95 41 (43.2%) 44 (46.3%) 10 (10.5%) 
4-5 points 30 10 (33.3%) 15 (50%) 5 (16.7%) 
Table 6. Comparison of the influence of different scores on the therapeutic effect 
 

























Total score ＜2 2-3 ＞3 
Table 7. Grading of peripheral cytopenias (hypersplenism) 
Cytopenia grading could facilitate clinical practice in various aspects, including assessing 
the disease condition, representation and academic communication, communication with 
patients and their relatives to resolve or avoid medical disputes, choosing a suitable 
treatment plan (for example, splenectomy is suitable for severe cytopenia or hypersplenism) 
and taking preventive methods before an operation16 to increase the curative rate.  
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units of PLT, the PLT count did not increase obviously, or decreased to the previous lowest 
count after 1-2 days. These types of patients are suitable for splenectomy[25]. Mastuura et 
al.[26]suggested that the excessive postoperative PLT count was also a life-threatening factor, so 
the condition of the patient should be closely monitored[27-28] when there is excessive platelet 
count, appropriate treatment should be administrated immediately.  
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It is of vital significance to formulate a grading method, like the Child-Pugh Classification 
for liver function, to evaluate hypersplenism. However, grading of hypersplenism is 
extremely difficult for many reasons. 1) Some patients show decreased monolineage 
cytopenias and others show bi-lineage cytopenias. Even patients with pancytopenia barely 
meet the grading criteria. 2) There are many causes of hemocytopenia, but no examination 
can ascertain whether it is caused by splenomegaly or hypersplenism. A definite diagnosis 
would be made only when hemocytes returned to a normal level after splenectomy.  
Although grading of hypersplenism is difficult, hemocytopenia could be graded. According 
to a multiple linear regression, thrombopenia is the major factor influencing the effect of 
surgery. The 330 cases of cytopenia scores were mainly based on thrombocytopenia 
combined with erythropenia, as well as clinical experience (leukopenia). Scoring was as 
follows: PLT＞50<100×109/L was scored as 1 point, 30-50×109/L was scored as 2 points, 
<30×109/L was scored as 3 points; RBC 3-4×1012/L was scored as 0 points, and 
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WBC<2×109/L was scored as 1 point. Except for 36 cases with normal blood cell counts and 
69 cases with 0 points, the influences of scores on postoperative prognoses in 261 cases are 
shown in Table 6 (totally 105 cases). There were significant differences between the 3 groups 
(P＜0.05). Therefore, peripheral cytopenias were graded as mild (<2), medium (2-3) or 
severe (>3) (Table 7). 
Thus, only cytopenias can be graded. In the present study, the cases were scored and 
graded based on the accumulated scores. The scoring criteria used in this study were: 
1.Analytical results of multiple linear regression: F value obtained from multiple linear 
regression equation was 7.993 (P＜0.005), indicating that multiple linear regression was 
applicable. The equation Ŷ=1.395+0.151PLT indicated that thrombocytopenia was the 
major influential factor for postoperative prognosis. Therefore, according to the severity 
of the thrombocytopenia, 1 to 3 points was scored. 2. Intra-group comparison of 
erythropenia showed a significant difference (P＜0.05), so an RBC count ≤3×1012/L was 
scored as 1 point. 3. According to clinical experience, leukopenia can cause severe 
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χ2=10.163 
P=0.034 2-3 points 95 41 (43.2%) 44 (46.3%) 10 (10.5%) 
4-5 points 30 10 (33.3%) 15 (50%) 5 (16.7%) 
Table 6. Comparison of the influence of different scores on the therapeutic effect 
 

























Total score ＜2 2-3 ＞3 
Table 7. Grading of peripheral cytopenias (hypersplenism) 
Cytopenia grading could facilitate clinical practice in various aspects, including assessing 
the disease condition, representation and academic communication, communication with 
patients and their relatives to resolve or avoid medical disputes, choosing a suitable 
treatment plan (for example, splenectomy is suitable for severe cytopenia or hypersplenism) 
and taking preventive methods before an operation16 to increase the curative rate.  
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6. Treatment  
As to the patients with splenomegaly due to cirrhotic portal hypertension complicated with 
hemocytopenia in the peripheral blood, treatment should aim at both the causes and clinical 
symptoms, that is, the principle of treating the branch and the root simultaneously.  
6.1 Treatment of causes of disease 
 Antiviral treatment: Patients with severe viral infection should take antiviral medicine 
for an extended time, and should be constantly monitored to protect liver function.  
 Avoid drinking alcohol: Patients with alcoholic cirrhosis and post-hepatic cirrhosis 
should avoid drinking alcohol; otherwise, disease conditions may deteriorate. In 
addition, medications that affect liver function should be avoided.  
 Correcting malnutrition: Patients with obvious emaciation and malabsorption should 
replenish nutrients, such as iron, folic acid and vitamin B12 to avoid a shortage of 
materials for the synthesis of erythrocytes. Additionally, patients should undergo blood 
transfusions to treat anemia and increase the hemochrome level.  
6.2 Treatment of symptoms 
Different treatments should be applied according to the severity of the disease. Patients with 
mild hemocytopenia should be under close observation; for patients with moderate 
hemocytopenia, blood components or whole blood transfusions should be applied as well as 
hemocyte boosting medications. In severe cases, a splenectomy in the patients with 
splenomegaly should be considered. Theoretically, splenic arterial embolization can also 
achieve the same effect as a splenectomy, but this procedure tends to cause splenic 
infarction, splenic necrosis, splenic abscess and high fever. This method should only be 
attempted by experienced physicians.  
In recent years, autologous stem cell transplantation has achieved good results in the 
treatment of cirrhotic portal hypertension complicated with hemocytopenia in the 
peripheral blood [17], but more research is needed to further its application in clinics.  
6.3 Treatment of both the branch and root: Treating the causes and the clinical 
symptoms  
1. Gastrointestinal bleeding: Gastrointestinal bleeding is not only a cause of 
hemocytopenia in peripheral blood, but also a complication of cytopenia. It is of vital 
importance to treat gastrointestinal bleeding; treatment measures include blood 
transfusion, fluid infusion, intravenous injection of antacid, administration of 
somatostatin (sandostatin and stilamin), endoscopic loop ligation of bleeding areas, 
sclerotherapy, and so on. Lecleire et al. [31] demonstrated that the success rate of 
endoscopic treatment could reach 80%. Intervention embolization can also be applied. 
Selective embolization can stop the bleeding in most cases. In recent years, with the 
improvement of coaxial catheter and embolization material, super-selective 
angiography and transcatheter embolization (SATE) is regarded as a safe and effective 
method to treat gastrointestinal hemorrhage[32]. It should be the first choice for patients 
suffering from post-operational massive hemorrhage, especially for the elderly or the 
sick. If the intervention fails, surgery should be performed.  
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If massive hemorrhage cannot be stopped using the measures mentioned above, emergency 
surgery should be performed, including pericardial devascularization and/or placement of 
a transjugular intrahepatic portal systemic shunt.  
2. Liver transplantation: Schuppan et al. [33] concluded that liver transplantation was an 
effective method to treat cirrhotic portal hypertension, as it not only corrected liver 
problems, but also cured portal hypertension, and was likely an effective way to treat 
hemocytopenia. After transplantation, the TPO level increases immediately. In 2 or 3 
days, the TPO level can be 5-10 times the level it was before the surgery. In about 6 
days, the platelet count returns to the normal range, and anemia is corrected. Therefore, 
liver transplantation can treat both the branch and root simultaneously.  
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